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Amorphous solid dispersions (ASDs) can improve the oral bioavailability of poorly water-
soluble drugs.  However, the physical instability of the amorphous form, denoted by the 
propensity to recrystallize, is a major barrier to the use of ASDs.  The overarching goal of 
this thesis was to understand the mechanisms by which two major classes of additives – 
antiplasticizers (various polymers) and plasticizers (mainly glycerol) – affect the physical 
stability of amorphous formulations, in the dry solid form, as well as in aqueous solution.  
In the first project, we investigated the impact of the strength of drug–polymer 
interactions, on the dissolution performance of ASDs. With ketoconazole and three 
polymers as model compounds, we observed that the interactions that stabilize amorphous 
drugs in the solid state, can also be relevant and important in sustaining the level of 
supersaturation in aqueous solution.  The second project explored the use of analytical 
ultracentrifugation as a novel technique for characterizing drug–polymer interactions in 
aqueous buffers.  It was possible to quantify the “free” versus “bound” fractions of drug 
in aqueous solution, and to semi-quantitatively assess the impact of interactions on the 
dissolution performance of ASDs.  The third and fourth projects evaluated the effects of 
glycerol on the molecular mobility and physical stability of amorphous itraconazole (ITZ), 
in the “solid” state.  It is well-known that small molecule plasticizers, such as water or 
glycerol, increase the molecular mobility and accelerate the crystallization of amorphous 
drugs.  In the case of amorphized ITZ, however, glycerol at low concentrations did not 
cause physical instability.  Rather, the smectic state (one of the intermediate liquid-
crystalline phases of ITZ) was selectively stabilized.   The mechanism by which glycerol 
stabilized the smectic state was investigated with high resolution techniques (synchrotron 
diffractometry, differential and adiabatic scanning calorimetry, and spectroscopy).  The 
results revealed that additives with fast dynamics, can drive weak first-order (or second-
order) intermediate liquid-crystalline phase transitions, to strong first-order transitions, by 
a possible coupling of the additive concentration to the order parameter.  We also 
demonstrated that the stabilized smectic state can perform the dual role of maintaining 




TABLE OF CONTENTS 
LIST OF FIGURES ...................................................................................................................................... X 
LIST OF TABLES ..................................................................................................................................... XVI 
1 INTRODUCTION ............................................................................................................................ 1 
1.1 BACKGROUND AND MOTIVATION ......................................................................................................... 2 
1.2 THEORETICAL BACKGROUND AND LITERATURE REVIEW ..................................................................... 6 
1.2.1 Pharmaceutical solid forms: crystalline and amorphous ................................................... 6 
1.2.2 Pharmaceutical solid forms: mesomorphic forms (liquid crystals) .................................... 8 
1.2.3 Phase transitions in rod-like liquid crystals ..................................................................... 11 
1.2.4 Potential benefits of pharmaceutical liquid crystals ......................................................... 17 
1.2.5 Molecular mobility............................................................................................................ 18 
1.2.6 Polymeric additives .......................................................................................................... 19 
1.2.7 Plasticizers........................................................................................................................ 23 
1.2.8 Dissolution of amorphous solid dispersions ..................................................................... 25 
1.2.9 Characterizing drug–polymer interactions in aqueous solution....................................... 27 
1.3 CHAPTER DESCRIPTIONS AND HYPOTHESES ....................................................................................... 30 
1.3.1 Chapter 2 .......................................................................................................................... 30 
1.3.2 Chapter 3 .......................................................................................................................... 31 
1.3.3 Chapters 4 and 5 ............................................................................................................... 32 
2 THE INFLUENCE OF THE STRENGTH OF DRUG–POLYMER INTERACTIONS ON THE 
DISSOLUTION PERFORMANCE OF AMORPHOUS SOLID DISPERSIONS .................... 34 
2.1 OVERVIEW ......................................................................................................................................... 35 
2.2 INTRODUCTION .................................................................................................................................. 36 
2.3 EXPERIMENTAL SECTION .................................................................................................................... 40 
vi 
 
2.3.1 Materials ........................................................................................................................... 40 
2.3.2 Preparation of amorphous systems ................................................................................... 41 
2.3.3 In vitro powder dissolution testing ................................................................................... 41 
2.3.4 Synchrotron X-ray diffractometry ..................................................................................... 43 
2.3.5 Solution NMR ................................................................................................................... 43 
2.3.6 Isothermal titration calorimetry (ITC) .............................................................................. 46 
2.4 RESULTS AND DISCUSSION ................................................................................................................. 48 
2.4.1 Powder dissolution ........................................................................................................... 49 
2.4.2 Crystallization in aqueous buffer ...................................................................................... 57 
2.4.3 Drug–polymer interactions in solution ............................................................................. 60 
2.4.4 Possible mechanisms of interaction in aqueous solution .................................................. 72 
2.5 SIGNIFICANCE .................................................................................................................................... 74 
2.6 CONCLUSIONS .................................................................................................................................... 75 
2.7 ACKNOWLEDGEMENTS ....................................................................................................................... 75 
2.8 SUPPLEMENTARY INFORMATION ........................................................................................................ 77 
3 ANALYTICAL ULTRACENTRIFUGATION FOR THE CHARACTERIZATION OF 
DRUG–POLYMER INTERACTIONS IN AQUEOUS SOLUTION ......................................... 86 
3.1 OVERVIEW ......................................................................................................................................... 87 
3.2 INTROUDUCTION ................................................................................................................................ 88 
3.3 EXPERIMENTAL SECTION .................................................................................................................... 92 
3.3.1 Selection of model systems ................................................................................................ 92 
3.3.2 Materials ........................................................................................................................... 93 
3.3.3 Preparation of amorphous solid dispersions .................................................................... 95 
3.3.4 Preparation of buffers and solutions ................................................................................ 95 
3.3.5 UV-Vis spectroscopy ......................................................................................................... 96 
3.3.6 Analytical ultracentrifugation........................................................................................... 96 
vii 
 
3.3.7 Isothermal titration calorimetry (ITC) .............................................................................. 98 
3.3.8 Powder in vitro dissolution ............................................................................................... 99 
3.4 RESULTS AND DISCUSSION ............................................................................................................... 100 
3.4.1 Wavelength selection for analytical ultracentrifugation................................................. 100 
3.4.2 Sedimentation profiles of neat drugs and polymers ........................................................ 102 
3.4.3 Sedimentation profiles of drug–polymer mixtures .......................................................... 106 
3.4.4 General inference from AUC results .............................................................................. 109 
3.4.5 Isothermal titration calorimetry (ITC) ............................................................................ 110 
3.4.6 Dissolution of amorphous solid dispersions ................................................................... 113 
3.4.7 Possible effects of interaction strength on supersaturation ............................................ 114 
3.5 CONCLUSIONS .................................................................................................................................. 118 
3.6 ACKNOWLEDGEMENTS ..................................................................................................................... 119 
3.7 SUPPORTING INFORMATION.............................................................................................................. 120 
4 EFFECT OF GLYCEROL ON THE ORDER OF THE MESOPHASE TRANSITIONS OF 
SUPERCOOLED ITRACONAZOLE. ....................................................................................... 129 
4.1 OVERVIEW ....................................................................................................................................... 130 
4.2 INTRODUCTION ................................................................................................................................ 131 
4.3 EXPERIMENTAL METHODS ................................................................................................................ 135 
4.3.1 Materials ......................................................................................................................... 135 
4.3.2 Sample preparation ........................................................................................................ 135 
4.3.3 Differential scanning calorimetry (DSC) ........................................................................ 136 
4.3.4 Adiabatic scanning calorimetry (ASC) ........................................................................... 137 
4.4 BRIEF THEORY OF ADIABATIC SCANNING CALORIMETRY ................................................................. 137 
4.5 RESULTS AND DISCUSSION ............................................................................................................... 139 
4.5.1 General information on itraconazole ............................................................................. 139 
4.5.2 Effect of glycerol on the mesophase transitions.............................................................. 140 
viii 
 
4.5.3 Effect of glycerol on the glass transition temperature .................................................... 142 
4.5.4 The order of the transitions ............................................................................................ 146 
4.5.5 ASC results for neat itraconazole ................................................................................... 148 
4.5.6 ASC results for the ITZ-glycerol mixtures ...................................................................... 150 
4.5.7 Critical exponent analysis of the N-SmA transition ........................................................ 152 
4.5.8 Implications of the critical behavior ............................................................................... 156 
4.6 SIGNIFICANCE .................................................................................................................................. 157 
4.7 CONCLUSIONS .................................................................................................................................. 158 
4.8 ACKNOWLEDGEMENTS ..................................................................................................................... 159 
5 STABILIZATION OF THE SMECTIC PHASE OF ITRACONAZOLE: IMPLICATIONS ON 
CRYSTALLIZATION PROPENSITY AND DISSOLUTION PERFORMANCE. ............... 160 
5.1 OVERVIEW ....................................................................................................................................... 161 
5.2 INTRODUCTION ................................................................................................................................ 163 
5.3 EXPERIMENTAL METHODS ................................................................................................................ 167 
5.3.1 Materials ......................................................................................................................... 167 
5.3.2 Sample Preparation ........................................................................................................ 167 
5.3.3 Differential Scanning Calorimetry (DSC) ...................................................................... 168 
5.3.4 Variable Temperature Synchrotron X-ray diffractometry .............................................. 169 
5.3.5 Dielectric Spectroscopy .................................................................................................. 170 
5.3.6 Infrared Spectroscopy ..................................................................................................... 172 
5.3.7 Nuclear Magnetic Resonance Spectroscopy ................................................................... 172 
5.3.8 Powder Dissolution ........................................................................................................ 173 
5.4 RESULTS AND DISCUSSION ............................................................................................................... 174 
5.4.1 Calorimetric investigations............................................................................................. 174 
5.4.2 Structural Analysis by Synchrotron X-Ray Diffractometry ............................................. 176 
5.4.3 Drug-plasticizer interactions .......................................................................................... 189 
ix 
 
5.4.4 Molecular Mobility ......................................................................................................... 192 
5.4.5 Most probable molecular packing model ....................................................................... 196 
5.4.6 Effect of smectic layer stabilization on the crystallization tendency below 𝑻𝒈 .............. 197 
5.4.7 Effect of smectic layer stabilization on dissolution performance ................................... 199 
5.5 SIGNIFICANCE .................................................................................................................................. 201 
5.6 CONCLUSIONS .................................................................................................................................. 202 
5.7 ACKNOWLEDGEMENTS ..................................................................................................................... 203 
5.8 SUPPORTING INFORMATION.............................................................................................................. 204 
6 CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE RESEARCH .................... 210 




LIST OF FIGURES 
Figure 1.1.  Schematic depicting the variation in enthalpy as a function of temperature. 6 
Figure 1.2.  The spring and parachute concept, to describe achieving high apparent 
solubility for poorly-soluble drugs. .................................................................................. 25 
Figure 2.1.  Structures of the model drug (KTZ) and polymers (PAA, PVP and PHEMA).
 .......................................................................................................................................... 40 
Figure 2.2.  Dissolution profiles of crystalline KTZ, amorphous KTZ, and ASDs 
formulated with (a) PAA and (b) PVP at polymer contents ranging between 4 and 40% 
w/w ................................................................................................................................... 50 
Figure 2.3.  Comparison of dissolution profiles of ASDs formulated at different polymer 
contents. ............................................................................................................................ 53 
Figure 2.4.  Dissolution profiles of crystalline KTZ, amorphous KTZ, and physical 
mixtures formulated with (a) PAA and (b) PVP, at polymer contents ranging between 4 
and 40% w/w .................................................................................................................... 55 
Figure 2.5.  Dissolution enhancement factors, obtained from dissolution profiles of 
amorphous solid dispersions (ASDs) and physical mixtures (PMs) ................................ 57 
Figure 2.6.  (a-c) Synchrotron X-ray diffraction patterns of powder samples, wetted with 
dissolution medium (phosphate buffer, pH 7.4 at ~25 °C) and monitored as a function of 
time. .................................................................................................................................. 59 
Figure 2.7.  One-dimensional 1H NMR spectra KTZ alone, and with polymers in D2O at 
pH 2.5. .............................................................................................................................. 62 
Figure 2.8.  2D 1H1H NOESY plot of KTZ alone in D2O at pH 2.5. .............................. 64 
Figure 2.9.  2D 1H1H NOESY plot of a mixture of KTZ and PAA in D2O. ................... 65 
xi 
 
Figure 2.10.  2D 1H1H NOESY plot of a mixture of KTZ and PVP in D2O at pH 2.5. .. 66 
Figure 2.11.  Normalized diffusion coefficients of the neat drug (KTZ alone), neat 
polymers (PAA or PVP alone), and the drug or polymer in the drug–polymer mixtures.
 .......................................................................................................................................... 68 
Figure 2.12.  Isothermal titration calorimetry power compensation signals, obtained from 
sequential injections ......................................................................................................... 70 
Figure 2.13.  Isothermal titration calorimetry results. ..................................................... 71 
Figure 3.1.   Structures and average molecular weights (𝑀𝑤) of the drugs and polymers.
 .......................................................................................................................................... 94 
Figure 3.2. UV absorbance spectra of neat drugs, neat polymers, and (drug + polymer) 
mixtures. ......................................................................................................................... 102 
Figure 3.3.  Sedimentation profiles of the neat drugs and neat polymers. .................... 105 
Figure 3.4.  Sedimentation profiles of drug–polymer mixtures. ................................... 108 
Figure 3.5. ITC raw data measured during the stepwise injection of KTZ (20 mg/mL) into 
(a) 5 mg/mL PAA (b) 5 mg/mL Soluplus. ..................................................................... 112 
Figure 3.6.  In vitro powder dissolution profiles of amorphous solid dispersions, each at 
33 %w/w drug loading. .................................................................................................. 117 
Figure 4.1. DSC heating curves of itraconazole-glycerol binary mixtures of different 
compositions. .................................................................................................................. 144 
Figure 4.2.  Phase diagram generated from the DSC results ......................................... 145 
Figure 4.3. Experimental glass transition temperatures (𝑇𝑔) of itraconazole-glycerol 
binary mixtures ............................................................................................................... 145 
xii 
 
Figure 4.4. (a) ASC data for neat itraconazole, covering the N-SmA and the I-N 
transitions. ...................................................................................................................... 149 
Figure 4.5.  ASC results for ITZ-glycerol mixtures from the smectic A to the isotropic 
phase. .............................................................................................................................. 151 
Figure 4.6.  Adiabatic scanning calorimetry results above and below the N-SmA 
transition of neat itraconazole. ....................................................................................... 154 
Figure 4.7.  Adiabatic scanning calorimetry results for the N-SmA transition of neat 
itraconazole. Double logarithmic plot of the difference (𝐶 − 𝐶𝑝) expressed in J/gK, as a 
function of the reduced temperature difference │𝜏│. .................................................... 155 
Figure 5.1.  Structures of the model compounds. .......................................................... 166 
Figure 5.2.  DSC curves obtained from the second heating of (a) Neat ITZ, (b) ITZ + 2% 
glycerol and (c) ITZ + 5% glycerol. ............................................................................... 174 
Figure 5.3.  1D synchrotron powder diffraction patterns of unaligned samples, at ambient 
temperature (𝑇 ≈ 30 °C). ................................................................................................ 178 
Figure 5.4.  Temperature dependence of the integrated intensity (peak area) of the 𝑞 ≈ 0.2 
Å−1 peak for (a) neat itraconazole, (b) ITZ + 1% glycerol. ............................................ 181 
Figure 5.5.  Temperature dependence of the integrated intensities (peak areas) of the three 
low angle Bragg peaks (𝑞 ≈ 0.2, 0.4, 0.6 Å-1) of the itraconazole sample containing 5% 
glycerol. .......................................................................................................................... 182 
Figure 5.6.  Integrated intensity (peak area, 𝐼) of the 𝑞 ≈ 0.2 Å−1 peak as a function of 
temperature during cooling, for neat ITZ (labelled as ITZ crystalline) and itraconazole 
formulations with different glycerol contents. ............................................................... 183 
Figure 5.7.  (a) Translational order parameter Σ, calculated from equation (5.4), as a 
function of reduced temperature, for ITZ samples with different glycerol contents. .... 184 
xiii 
 
Figure 5.8.  Temperature dependence of the (a) average lateral separation (𝑑 =  2𝜋/𝑞) 
and (b) average bulk correlation length (𝑑 =  2𝜋/𝑓𝑤ℎ𝑚), of the wide-angle peak (sub 
peak at 𝑞~1.3 Å-1) of ITZ with different glycerol contents. ........................................... 189 
Figure 5.9.  FTIR spectrum of neat ITZ, overlaid with spectra of ITZ-glycerol mixtures.
 ........................................................................................................................................ 191 
Figure 5.10.  Overlay of 15N solid-state NMR spectra. ................................................. 191 
Figure 5.11.  Panels a-c show the dielectric loss ( ″) vs frequency (𝑓) data, measured at 
multiple temperatures above the glass transition temperature, on unaligned samples. (a) 
Neat ITZ (b) ITZ + 2% glycerol, and (c) ITZ + 5% glycerol......................................... 193 
Figure 5.12.  Temperature-dependence of α relaxation times for unaligned samples of 
itraconazole, containing different concentrations of glycerol. ....................................... 195 
Figure 5.13.  Synchrotron XRD patterns obtained after each sample had been stored for 
2 years, at the different temperatures indicated. ............................................................. 199 
Figure 5.14.  In vitro dissolution profiles of powder samples in 0.1 N HCl, at 37 °C. . 201 
 
SUPPLEMENTARY FIGURES 
Figure S2.1.  (a) Solubility of ketoconazole as a function of pH. (b) Microspecies 
distribution of ketoconazole at different aqueous solution pH values. ............................ 77 
Figure S2.2.  Dissolution profiles of crystalline KTZ, amorphous KTZ, and (a) ASDs or 
(b) Physical Mixtures, formulated with PHEMA, at polymer contents ranging between 4 
and 40% w/w .................................................................................................................... 78 
Figure S2.3.  (a) Maximum dissolved drug concentration (𝐶𝑚𝑎𝑥) values, (b) cumulative 
percent drug dissolved*, obtained from dissolution profiles of amorphous solid 
dispersions (ASDs) and physical mixtures (PMs) ............................................................ 79 
xiv 
 
Figure S2.4. 2D 1H1H NOESY spectra of (a) neat PAA and (b) neat PVP. .................... 81 
Figure S2.5 (a, c-f). Representative 2D DOSY plots of the neat drug (KTZ), the neat 
polymers (PAA or PVP), and the drug+polymer mixtures. ............................................. 82 
Figure S3.1.  Sedimentation velocity analytical ultracentrifugation raw data for neat 
polyacrylic acid.  Top: Experimental data.  Bottom: residuals of the fit........................ 121 
Figure S3.2.  Sedimentation velocity analytical ultracentrifugation raw data for neat 
Soluplus®. Top: Experimental data.  Bottom: residuals of the fit. ................................ 122 
Figure S3.3. Sedimentation velocity analytical ultracentrifugation raw data for neat 
hydroxypropylmethylcellulose acetate succinate (HPMCAS). Top: Experimental data.  
Bottom: residuals of the fit. ............................................................................................ 123 
Figure S3.4. Sedimentation velocity analytical ultracentrifugation raw data for neat 
carbamazepine. Top: Experimental data.  Bottom: residuals of the fit. ......................... 124 
Figure S3.5. Sedimentation velocity analytical ultracentrifugation raw data for neat 
ketoconazole. Top: Experimental data.  Bottom: residuals of the fit. ............................ 125 
Figure S3.6.  Sedimentation velocity analytical ultracentrifugation raw data for 
ketoconazole in polyacrylic acid. Top: Experimental data.  Bottom: residuals of the fit.
 ........................................................................................................................................ 126 
Figure S3.7.  Sedimentation velocity analytical ultracentrifugation raw data for 
ketoconazole in Soluplus®. Top: Experimental data.  Bottom: residuals of the fit. ...... 127 
Figure S3.8.  Sedimentation velocity analytical ultracentrifugation raw data for 
carbamazepine in HPMCAS. Top: Experimental data.  Bottom: residuals of the fit. .... 128 
Figure S5.1.  Representative 2D synchrotron diffraction image of an ITZ + 5% glycerol 
sample, collected at ~30°C. ............................................................................................ 204 
xv 
 
Figure S5.2.  Representative fit, showing the deconvolution of the diffuse wide-angle 
peak (𝑞 from 0.7 to 2.3 Å-1) of itraconazole containing glycerol (5% w/w), into two sub-
peaks. .............................................................................................................................. 205 
Figure S5.3.  Temperature dependence of the area of the 𝑞 ≈ 0.2 Å−1 peak for (a) ITZ+2% 
glycerol, (b) ITZ+5% glycerol, and (c) ITZ+10% glycerol. .......................................... 207 
Figure S5.4.  Overlay of one-dimensional 13C NMR spectra for neat ITZ (blue) and ITZ 
+ 20% glycerol (red)....................................................................................................... 208 
Figure S5.5  Synchrotron XRD patterns of neat amorphous itraconazole (rapidly 
quenched from the melt), held isothermally at 45 °C for various storage durations, 𝑡. . 208 
Figure S5.6  Synchrotron XRD patterns of ITZ+5% glycerol samples, held isothermally 





LIST OF TABLES 
Table 1.1.  Variation of enthalpy (𝐻) and specific heat capacity (𝐶𝑝) with temperature 
for liquid crystalline phase transitions. ............................................................................. 14 
Table 1.2.  Polymers used in ASDs. ................................................................................ 20 
Table 3.1. Solvents and solution concentrations used in the AUC experiments. ............ 96 
Table 3.2.  Peak positions and peak areas for the neat drugs, the neat polymers and the 
drug–polymer mixtures. ................................................................................................. 109 
Table 3.3. Dissolution test results (±standard deviation, n=3). ..................................... 117 
Table 4.1. Transition temperatures (𝑇, °C) and associated enthalpies (∆𝐻, J/g) determined 
from the reversible heat flow signals of modulated DSC reheating scans ..................... 146 
Table 4.2.  Adiabatic scanning calorimetry results for itraconazole with different glycerol 
contents. .......................................................................................................................... 150 
Table 5.1.  Values of the parameters 𝐼0, 𝛽 and 𝑇𝑐 obtained from fits of equation (5.5) to 
the peak areas for the itraconazole samples with different glycerol contents. ............... 185 
 
SUPPLEMENTARY TABLES 
Table S2.1.  NMR peak assignments for KTZ in D2O, acidified to pH 2.5. Based on 
structure numbering scheme of Figure 2.1. ..................................................................... 80 
Table S2.2.  Diffusion coefficients of neat KTZ, PAA and PVP (lines 1 to 3), and the drug 










1.1 BACKGROUND AND MOTIVATION 
Advances in combinatorial chemistry and high throughput screening methods, have led to 
an explosion in the number of chemical compounds that are potential drug candidates1,2.  
With every lead molecule identified, efforts are intensified to market the drug as a solid 
oral dosage form (e.g. as tablets or capsules) because of convenience to patients, safety, 
high compliance rates and low manufacturing costs.  When given orally, the solid drug 
must first dissolve in the aqueous environment of the gastro-intestinal (GI) tract, before 
being absorbed into the bloodstream3.  Aqueous solubility and GI membrane permeability, 
therefore, form the basis for the Biopharmaceutics Classification System (BCS)3.  There 
are four main BCS classes, with each class having an almost equal number of drugs that 
are currently marketed4.  In the research and development pipeline, however, only 5-10% 
of compounds have high solubility and high permeability (BCS class I compounds).  The 
majority (60-70%) have poor solubility but adequate permeability (BCS class II)4.  
Research into strategies that could overcome the solubility challenge, is therefore a key 
focus in the pharmaceutical sciences5.   
 
There are several approaches to enhance the aqueous solubility of poorly-soluble drugs: 
particle size reduction (e.g. micronization and nanosizing), formation of salts (for drugs 
with ionizable functional groups), formation of co-crystals (for drugs with hydrogen bond 
donor or acceptor groups), use of solubilizing carriers (e.g. lipids as self-emulsifying 
delivery systems; cyclodextrins or surfactants as complexation agents) and 
3 
 
amorphization4,6–9.  Of these approaches, amorphous systems have gained much attention 
over the last few decades as a result of extensive fundamental research, advances in large-
scale manufacturing methods such as hot-melt extrusion technology, and the experience 
gained through launch of commercial products.10,11  
 
Amorphous materials lack the long-range lattice periodicity of the corresponding 
crystalline compounds. The disordered molecules can therefore readily interact with the 
(mainly aqueous) GI fluid, without the need to overcome the crystal lattice energy barrier, 
leading to high apparent aqueous solubility.  However, the high energetic state is also a 
thermodynamic driving force for crystallization both in the dry, solid state as well as in 
aqueous solution.  To overcome this challenge, the drug is dispersed (as an amorphous 
solid dispersion) in a carrier that can prevent or retard drug crystallization.  An amorphous 
solid dispersion (ASD) can thus be defined as a  molecular-level mixture of  a drug with 
one or more inert carriers, to form a homogeneous phase4,5,12.  With amorphous 
formulations, solubility increases as high as a thousand-fold relative to the crystalline drug 
solubility, have been reported13,14.   
 
The two key characteristics of any successfully designed ASD are (i) physical stability 
during processing and storage, and (ii) optimal dissolution performance15.  Academic and 
industrial research in the early years focused on understanding the factors that affect the 
physical stability of ASDs under “dry” conditions16.  Both thermodynamic (e.g. heat of 
fusion, configurational entropy, surface energy)17,18 and kinetic (e.g. diffusivity and 
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molecular mobility)19 factors have been shown to influence amorphous drug 
crystallization.    
 
The behavior of amorphous systems in aqueous media, however, tends to be more complex, 
with many interdependent factors affecting the concentration-time profiles16.  Even though 
many reports show in vitro dissolution enhancement of ASDs, compared to the crystalline 
or neat amorphous drugs, the exact mechanisms by which polymers stabilize the 
amorphous drugs in solution are poorly understood11,16.  Thus, polymer selection for ASD 
formulation remains largely empirical.  Research efforts geared towards understanding the 
physical chemistry of ASDs and their supersaturated solutions, with a broader goal of 
linking the solid state behavior to in vitro dissolution profiles and in vivo performance, are 
thus required11.   
 
From the perspective of aqueous solubility enhancement, the amorphous form is the most 
widely-used disordered form.  However, it is also highly unstable.  Intermediate between 
the amorphous (completely disordered) and the crystalline (fully ordered) states, are a 
number of mesomorphic states20.  With free energy levels intermediate between the energy 
levels of the amorphous and crystalline states, mesomorphic forms may give rise to an 
increased drug dissolution rate relative to the crystalline form, while maintaining better 
physical stability than the amorphous form.  An organic compound having a rod-like or 
disc-like shape, may form mesomorphic (also called liquid crystalline, LC) phases20.  Many 
small molecule drugs have these characteristics, such that if they do possess LC phases, 
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the dual advantage of good physical stability and optimal dissolution may be realized21.  
Yet, mesomorphic compounds are not given adequate attention in the pharmaceutical 
sciences21,22.   
 
Polymers are the main carriers for ASDs.  Other excipients such as small-molecule 
plasticizers, surfactants and acidity modifiers may also be included in ASD formulations, 
to aid processing or to improve drug dissolution23.  The polymeric additives for ASDs are 
typically already used in the pharmaceutical industry as excipients, and there is a wealth of 
information on their properties12.  The effects of non-polymeric additives on the physical 
stability of amorphous drugs have, however, not been adequately investigated.  
 
The central goal of the thesis was therefore to gain fundamental insight into the 
mechanisms by which additives stabilize disordered pharmaceuticals, in the solid state, and 
in aqueous solution.  In the solid state, we investigated how glycerol, a small molecule 
plasticizer, affects the thermodynamic behavior and physical stability of itraconazole.  
Itraconazole was of interest because it can exist either as an amorphous compound, or as a 
liquid crystal.  In aqueous solution, we investigated the impact of drug–polymer 





1.2 THEORETICAL BACKGROUND AND LITERATURE REVIEW 
1.2.1 Pharmaceutical solid forms: crystalline and amorphous 
The majority of small-molecule active pharmaceutical ingredients (APIs) are crystalline 
solids.  The crystalline form, possessing long-range orientational and positional order in 
three dimensions, is usually the most thermodynamically stable25.  Amorphous materials 
on the other hand, lack long-range order, even though they often possess a limited degree 
of short-range order.  The disordered state is characterized by higher free energy, compared 
to the corresponding crystalline form, which may lead to an enhanced dissolution rate and 
consequently an increase in bioavailability. 
 
Figure 1.1.  Schematic depicting the variation in enthalpy as a function of temperature.  𝑇𝑚 
is the equilibrium melting point, 𝑇𝑔 is the glass transition temperature, 𝑇𝑓 is the fictive 
temperature, 𝑇𝑎 is the annealing temperature, and 𝑇𝑘 is the Kauzmann (or zero mobility) 




Figure 1.1 is a schematic representation of enthalpy as a function of temperature, for 
crystalline and amorphous materials26. The vertical axis could also depict entropy, or 
specific volume.  When a crystalline solid is heated, the enthalpy or volume does not 
increase much with respect to temperature, until the melting temperature (𝑇𝑚) is reached.  
At 𝑇𝑚, there is a sharp discontinuity in the enthalpy, indicating a first-order solid-to-liquid 
phase transition.  When the isotropic melt is cooled very slowly, the liquid usually 
crystallizes at 𝑇 < 𝑇𝑚.  However, with rapid cooling rates, the liquid may fail to crystallize 
resulting in the supercooled liquid (or the amorphous) state.  Although the supercooled 
liquid is a nonequilibrium state relative to the crystalline state, it is an equilibrium state 
with respect to structural changes with temperature26.  In other words, the supercooled 
liquid is in “structural equilibrium”.   
 
Upon further cooling, the timescale for structural rearrangement within the supercooled 
liquid eventually becomes too slow to keep up with the cooling rate.  The temperature at 
which the supercooled liquid eventually falls out of structural equilibrium, is the glass 
transition temperature (𝑇𝑔).  At 𝑇 < 𝑇𝑔, the amorphous material is in the glassy state.  The 
state defined by an extension of the supercooled liquid line at 𝑇 < 𝑇𝑔, represents the glassy 
state that would have been in structural equilibrium.  When the real glass is stored 
isothermally at an annealing temperature 𝑇𝑎 < 𝑇𝑔, the enthalpy, entropy and specific 
volume approach this extrapolated “equilibrium glassy state” asymptotically, in a process 
referred to as aging.  The fictive temperature, 𝑇𝑓, is conceptually the temperature at which 
the equilibrium supercooled liquid would have the same properties as the aged glass.  At 
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𝑇𝑓, the property of interest (enthalpy, specific volume, or configurational entropy) when 
extrapolated along the glass line, intersects the extrapolated equilibrium supercooled liquid 
line27.  The fictive temperature can thus be used to define the structure(s) of different 
glasses.  The Kauzmann temperature, 𝑇𝑘, also known as the temperature of zero mobility, 
marks the theoretical lower limit of excess entropy.   
 
1.2.2 Pharmaceutical solid forms: mesomorphic forms (liquid crystals) 
Crystalline and amorphous materials, as introduced in Section 1.2.1, are in the solid and 
super-viscous liquid states, respectively.  Some materials however show a series of 
transitions between the solid and the liquid states, as temperature is varied.  The new phases 
have mechanical, optical and structural properties between those of the crystalline solid 
and the corresponding isotropic liquid.  The intermediate phases are thus termed liquid 
crystalline (LC) phases, mesomorphic phases or mesophases.  Mesophases are indefinitely 
stable at defined temperatures and pressures28, and thus considered a fourth state of matter 
(besides the well-known solid, liquid, and gaseous states).  Mesophases, observed above 
the melting point during heating are termed enantiotropic, whereas those occurring below 
the melting point on supercooling of the crystal, are monotropic28.  In general, transitions 
between the various mesophases, which occur at defined temperatures, are reversible, with 




1.2.2.1 Thermotropic and lyotropic liquid crystals 
Liquid crystals (LCs) are generally divided into two broad categories: (i) thermotropic LCs 
and (ii) lyotropic LCs. Thermotropic LCs are formed by heating a solid, or cooling an 
isotropic liquid, or by heating or cooling a thermodynamically stable mesophase28. Organic 
molecules with rod-like (calamitic or prolate) or disc-like (discotic or oblate) shapes 
typically form thermotropic mesophases.  The minimum number of components necessary 
to form a thermotropic mesophase is one (i.e. only the mesogen is needed); and the degrees 
of freedom that need to be specified, according to the Gibbs phase rule is one (usually 
temperature).  On the other hand, lyotropic LCs are formed by dissolving compounds 
having amphiphilic character in a suitable protic solvent, such as water or glycerol, under 
appropriate conditions of concentration and temperature28.  Lyotropic LCs require a 
minimum of two components to form, such that both composition and temperature must 
be specified to describe the mesophases.  
 
Additives (commonly referred to in the literature, as guest molecules) are sometimes 
incorporated into liquid crystals (host molecules), to form LC binary mixtures29.  The goal 
for researching such host-guest mixtures, is often to explore unusual phase sequences of 
the host LC.  Many novel LC phases resulting from binary mixtures have been identified, 
which have found practical application for electronic displays and thermal sensors29.  When 
the guest molecule is a non-mesogenic solvent, it is important to note that such binary 
mixtures are not lyotropic systems.  Polymer-dispersed liquid crystals (PDLCs) are another 
class of host-guest systems, in which LCs are dispersed in amorphous polymers.  Many 
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large-area displays, commonly used as road signs and advertisements boards, as well as 
electrically switchable windows, are PDLCs29.   
 
1.2.2.2 Thermotropic mesophases  
Thermotropic mesophases are generally grouped based on their degree of anisotropy, as 
well as their molecular orientation28.  The average direction, along which the molecules 
point, is termed the director of the phase, 𝒏.  The most common phases are the nematic (N) 
and smectic (Sm) phases.  Upon cooling from the isotropic liquid, the nematic (N) phase 
is first encountered, where rod-like molecules align parallel to each other, with their long 
axes all pointing roughly in the same direction28.  Molecules in the nematic phase rotate 
about their long axes, and to some degree about their short axes.  When cooled further, the 
molecules in the nematic phase may subsequently separate out into layers, resulting in the 
smectic (Sm) phase.  The N phase therefore has only orientational order, whereas the Sm 
phase has both orientational and translational (or positional) order. 
 
Smectic phases therefore have at least two directions; the director and the layer normal. 
Multiple smectic phases exist (labeled A, B, C… G, etc.) depending on the relationship 
between the two directions.  In the simplest smectic phase (the smectic A phase), the 
director and layer normal are collinear.  In the smectic C phase, the director is tilted, making 
an angle with the layer normal.  Other subtle variations in smectic phases lead to smectic 
sub-classes (eg. SmA1, SmA2, SmAd, etc)




1.2.2.3 Orientational and translational order parameters 
Order parameters “quantify” the quality of orientation and layering. The degree to which 
rod-like molecules are aligned along the director, is termed the orientational order 




〈3𝑐𝑜𝑠2𝜃 − 1〉 
where 𝜃 is the angle between the long axis of each individual rod-like molecule, and the 
director 𝒏.  An 𝑆 value of 0 indicates no order (isotropic liquid) and 1 indicates perfect 
orientational order.  Translational order refers to a distribution function, 𝐷(𝑟), which is a 
measure of the probability of finding the center of mass of a molecule at position 𝑟 with 
respect to a test molecule at 𝑟 = 0.  To quantify the quality of layering (i.e., the extent to 
which the molecules are organized into layers), McMillan30–32 introduced the translational 
(positional) order parameter, Σ, defined as the amplitude of the density wave that 
originates from the one-dimensional periodic layers28,30.  The translational order parameter 
also takes values ranging from 0 (no positional order) to 1 (perfect positional order).  Thus, 
the more the molecules are segregated into well-defined layers, the higher the translational 
order parameter. 
 
1.2.3 Phase transitions in rod-like liquid crystals 
Liquid crystalline materials show a rich variety of phase transitions33.  Calorimetric studies 
provide information on the energy effects.  Complementary structural information can be 




1.2.3.1 General classification of phase transitions – first and second order transitions 
Phase transitions in liquid crystals can be first-order, or second-order33.  In first-order 
transitions, there are discontinuities in the first derivative of the free energy with respect to 
other thermodynamic variables.  Solid-to-liquid, and liquid-to-gas transitions are typically 
first-order.  First-order transitions also involve a latent heat.  The magnitude of the latent 
heat, and the presence (or absence) of pretransitional heat capacity effects, are used to sub-
classify first-order transitions as strong or weak transitions.  Second-order phase transitions 
are continuous in the first derivative but exhibit discontinuity in the second derivative of 
the free energy.  The heat capacity (𝐶𝑝), exhibits either a discontinuous jump (mean-field 
behavior) or a divergence (critical fluctuation behavior)20.  Table 1.1 gives a summary of 
the characteristic behavior of enthalpy (𝐻) and the specific heat capacity (𝐶𝑝) as a function 
of temperature (𝑇), near the transition temperatures (𝑇𝑡𝑟) for first-order, and second-order 
phase transitions33.   
 
1.2.3.2 Liquid crystalline phase transitions 
The most extensively studied transitions in calamitic LCs are the isotropic-to-nematic (I-
N) and the nematic-to-smectic A (N-SmA) transitions34.  Direct transition from the 
isotropic to the smectic phase (I-Sm) is relatively less common, and not as well-studied35.  
 
Isotropic-Nematic Transition: Thermodynamic behavior in the vicinity of the I-N 
transition, is often described by the Landau–de Gennes model, based on an expansion of 
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the excess free energy as a function of the orientational order parameter 𝑆36,37.  For 
calamitic LCs, the I-N transition is mostly a first-order (or weakly first-order) transition.   
 
Nematic-Smectic Transition: According to McMillan31,38, the N-SmA transition is 
generally a second-order (continuous) transition, even though it may also be first-order.  It 
becomes first-order, when a coupling exists between the translational and the orientational 
order parameters31,38.   
 
Isotropic-Smectic Transition: Direct transition from the isotropic (I) to the smectic (Sm) 
phase has been described based on the Landau–de Gennes theory, as a prototype symmetry 




Table 1.1.  Variation of enthalpy (𝐻) and specific heat capacity (𝐶𝑝) with temperature for liquid 
crystalline phase transitions. 
𝐻𝐿 = latent heat, 𝛿𝐻 = pretransitional enthalpy increase, CP = critical point.  The heat capacity 
and enthalpy of the vertical axes increase upwards. Temperature (horizontal axes) increases to 
the right. Marks on the horizontal axes indicate the transition temperatures. Figures are 
reproduced from reference 33.  
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1.2.3.3 Thermal characterization of phase transitions in liquid crystals  
Differential scanning calorimetry (DSC) is an ideal survey technique for locating 
different phases and determining the major thermal features associated with phase 
transitions.  However, DSC is not suited for making detailed quantitative measurements of 
latent heats, making it difficult to distinguish first- and second- order transitions20,33.  It is 
also impossible to identify weak first-order transitions with significant pretransitional heat 
capacity variations using DSC alone. The main problem of the DSC, in this regard, stems 
from the requirement of rapid scan rates20,33. 
  
Adiabatic scanning calorimetry (ASC) provides greater accuracy and resolution, 
allowing detailed study of the phase transitions in liquid crystals.  ASC continuously 
measures, with high precision, the evolution of the heat capacity 𝐶𝑝 and the enthalpy 𝐻 of 
a sample as a function of temperature while maintaining thermal equilibrium within the 
sample. The basic measurement principle is as follows: a constant power 𝑃 is supplied to 
the sample and the resulting change in temperature 𝑇 is measured as a function of time 





The enthalpy as a function of temperature, 𝐻(𝑇), can also be obtained from the relation: 
𝐻(𝑇) = 𝐻(𝑇0) + 𝑃[𝑡(𝑇) − 𝑡(𝑇0)] 
where 𝑇0 is the starting temperature, and 𝑡(𝑇0) is the start time for a run.  Continuous 
determination of 𝐻(𝑇), provides a unique tool for confirming the order of phase transitions.  
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If the enthalpy shows a jump at a certain temperature, a latent heat is present, and the 
transition is discontinuous (first-order).  However, if such a jump is absent, the transition 
is continuous (or second-order).   
 
1.2.3.4 Theoretical analysis of heat capacity data of phase transitions 
When the heat capacity 𝐶𝑝(𝑇) and/or enthalpy 𝐻(𝑇) data has been acquired 
experimentally, an essential second step is the theoretical analysis to gain insight into the 
basic physical model that explains the thermal properties of the phase transitions20.  The 
magnitude of the latent heat ∆𝐻𝐿, relative to the pretransition enthalpy 𝛿𝐻, indicates how 
close the system is to either an isolated critical point (the critical point is the end point of 
a phase equilibrium curve), or to a tricritical point (the point in a phase diagram, at which 
three-phase coexistence – the triple point – terminates).  The liquid-to-gas transition, for 
example, is at an isolated critical point.  The SmAd-to-SmA2 transition was also shown to 
be an isolated critical point40.  At a tricritical point, a first-order phase transition can change 
into a second-order transition (and vice versa).  This unusual effect, has been shown, in the 
N-SmA transition of some liquid crystals33,41.      
 
The variation of certain physical properties near the phase transition point of a system, can 
be defined in terms of critical exponents20.  There are many different kinds of critical 




, [where 𝑇𝑐 (critical temperature) is the temperature at which the 
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transition occurs] via the relation, 𝐶𝑝 = 𝐴|𝜏|
−𝛼 + 𝐵.  In the latter expression, 𝐴 and 𝐵 are 
the critical amplitude and background term, respectively20. 
 
The critical exponent can be determined by analyzing adiabatic scanning calorimetry heat 
capacity data, measured above and below the phase transition. Different universality 
classes have unique theoretical 𝛼 values.  For example, when 𝛼 = 0.5, the transition is at 
a tricritical point; 𝛼 = 0 indicates mean field behavior.  The critical exponent from heat 
capacity data, can be related to the order parameter from x-ray experiments, using the 
Rushbrooke scaling relation (𝛼 + 2𝛽 + 𝛾; where 𝛽 is the order parameter exponent, and 𝛾 
is from susceptibility) or the hyperscaling relation (2 − 𝛼 = 𝑑𝑣; where 𝑣 is the correlation 
length exponent)20.  
 
To summarize, adiabatic scanning calorimetry heat capacity data analysis is thus useful for 
(i) locating phase transitions, (ii) establishing the global behavior at critical points, (iii) 
testing the consistency of independent experimental quantities, and (iv) testing the level of 
agreement with theoretical models. 
 
1.2.4 Potential benefits of pharmaceutical liquid crystals 
Despite being widely used in optics and electronic displays, liquid crystals are not 
extensively studied in the pharmaceutical literature29.  Pharmaceutical compounds that 
have been reported to have LC phases include fenoprofen, nafcillin sodium, cromolyn 
sodium, folic acid, ritonavir, nafoxidin hydrochloride, itraconazole, salvarsan, 
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neosalvarsan, palmitolyl propranolol hydrochloride, penbutolol sulfate, ciclosporin, 
cholesteryl myristate22. The majority form lyotropic LC phases, and find use in topical 
preparations such as creams and lotions because of their interactions with phospholipids29.  
Thermotropic LC drugs are relatively less common.  Thus, not much has been documented 
about their structure/property relationships, and their pharmaceutical benefits42. 
 
1.2.5 Molecular mobility 
In the context of amorphous (supercooled) materials, molecular mobility refers to the 
molecular movement that results from the constant rearrangement towards structural 
equilibrium.  There are two main groups of motions – global motions (characterized by 𝛼-
relaxation times) and local motions (characterized by 𝛽-, 𝛾, 𝛿 relaxation times).  Global 
motions, the slower of the two groups, are co-operative and responsible for the glass 
transition19. Local motions, which are non-cooperative, result from movements of branch 
chains (in the case of large polymers), or movements of the entire molecule43,44.   
 
In the supercooled state, 𝛼-relaxation times are very short (typically <100 s) and the 
temperature-dependence is often well-described by the Vogel-Fulcher-Tammann 
equation45: 








where 𝜏0, 𝑇0 and 𝐷 are fitting parameters: 𝜏0 is the relaxation time of the unrestricted 
material, 𝐷 is the strength parameter, an indicator of the kinetic fragility of the material, 
and 𝑇0 is the temperature of zero mobility (theoretical Kauzmann temperature).   
 
In the glassy region, 𝛼-relaxation times become extremely slow, with an Arrhenius-like 
temperature dependence46,47.  Local motions on the other hand, become more prominent, 
exhibiting Arrhenius temperature dependences46,47.  
 
1.2.6 Polymeric additives 
A wide range of polymers have been used for ASD formulations.  Based on comprehensive 
reviews by Leuner & Dressman (2000)12, and Liu & Edgar (2016)48, the common 
polymeric excipients have been categorized in Table 1.2.  Several novel polymers have 
also been developed specifically for ASDs, including carboxyl-containing cellulosic 
materials49, and amphiphilic block copolymers such as Soluplus® (polyvinyl caprolactam–
polyvinyl acetate–polyethylene glycol graft copolymer)50.  The novel polymers tend to 
have bifunctional character, as matrices for solid solutions and as active solubilizers 
through micelle formation in water.  Soluplus®, the most well-known and earliest example 
of such “novel” polymers, was also designed to be self-plasticizing such that it would be 







Table 1.2.  Polymers used in ASDs.  
Polymer types General classification Examples 
Synthetic 
Polymers 
Hydrophilic polymers  Polyvinylpyrrolidone (PVP) 
Polyethylene Glycols (PEG) 
Hydrophobically modified polymers Polyvinylpyrrolidone vinyl acetate (PVPVA) 
Polyvinyl acetate phthalate (PVAP) 
Methacrylate-based polymers Polyhydroxyethyl methacrylate (PHEMA) 
Eudragit® (copolymers derived from esters of 
acrylic and methacrylic acid) 
Cellulose 
Derivatives 
pH Independent Cellulose Esters 
and Ethers 
Cellulose acetate  
Cellulose butyrate 
Cellulose acetate phthalate 
Hydroxypropyl methyl cellulose phthalate 
(HPMCP) 
pH responsive cellulose derivatives Carboxymethyl cellulose acetate butyrate 
Cellulose acetate phthalate 
Hydroxypropyl methyl cellulose Phthalate 




1.2.6.1 Mechanisms by which polymers stabilize amorphous drugs 
The main mechanisms by which polymers stabilize amorphous solid dispersions, in the dry 
“solid” state, include (i) reduction in molecular mobility of the drug, (ii) specific 
interactions with functional groups of the drug (iii) increase in the glass transition 
temperature (𝑇𝑔) of the system (antiplasticization), and (iv) the polymer as a “physical” 
barrier to crystallization (i.e. polymer dilution).  Though often investigated as separate 
phenomena, in reality, all four mechanisms are interrelated.  For example, specific drug–
polymer interactions result in reduced molecular mobility, which could further manifest as 






1.2.6.1.1 Reduction in molecular mobility 
Because molecular mobility precedes or accompanies crystallization, the two phenomena 
may be coupled19.  Thus, an additive that restricts mobility of the amorphous drug, can 
potentially suppress drug recrystallization; the converse also holds true.  As an example, in 
the supercooled liquid region, polyacrylic acid (PAA) reduced the molecular mobility of 
acetaminophen to a greater extent than an equal amount of polyvinylpyrrolidone (PVP)53. 
The acetaminophen-PAA ASDs were thus more physically stable than the acetaminophen-
PVP ASDs53.  Reduced drug mobility due to the presence of the polymer, has also been 
linked to improved physical stability of ASDs in the glassy region54. 
 
The extent of coupling between molecular mobility and crystallization, in both the 
supercooled and glassy states, can be obtained by comparing the timescales of various 
kinds of molecular motions (global or local mobility) to the timescales of crystallization, 
using a logarithmic correlation plot19.  In the supercooled region, high coupling values have 
been obtained for ASDs prepared from several drug–polymer systems such as nifedipine-
PVP55, itraconazole-HPMCAS56, celecoxib-PVP57, and indomethacin-PVP58, thereby, 
further underscoring the relevance of molecular mobility in physical stabilization. 
 
1.2.6.1.2 Specific drug–polymer interactions 
In general, the strengths (inferred from theoretical bond energies) of intermolecular 
interactions can be rank-ordered as: ionic interactions (~1000 kJ/mol) > hydrogen-bonding 
(~100 kJ/mol) > dipole-dipole interactions (~10 kJ/mol)59.  Several studies have 
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highlighted a general correlation between the strength of drug–polymer interactions, and 
the physical stability of ASDs upon storage52,60–63.  Strong interactions between drug–
polymer pairs have been linked to increased crystallization inhibition. Examples include 
ionic interactions (ketoconazole–polyacrylic acid52, lapatinib–hydroxypropyl methyl 
cellulose phthalate60, and acetaminophen – polyacrylic acid) as well as hydrogen bonding 
(indomethacin–PVP61,62, nifedipine–PVP63, and celecoxib–PVP).  Strong drug–polymer 
interactions cause the movements of the drug molecules to be restricted, thereby leading to 
reduced crystallization.  The effect of interactions can be easily assessed in ASDs with low 
polymer content (<5% w/w), where the 𝑇𝑔 of the system is not raised relative to the 𝑇𝑔 of 
the neat drug52.   
 
1.2.6.1.3 Antiplasticization 
Polymers with high glass transition temperatures (𝑇𝑔), when miscible with the drug, can 
result in single-phase ASDs with 𝑇𝑔 values higher than that of the neat drug.  When the 𝑇𝑔 
of the ASD is sufficiently raised by the polymer, molecular mobility can be substantially 
reduced, at pharmaceutically-relevant storage temperatures (in the glassy region).  An 
increase in 𝑇𝑔 is often considered an indicator of reduction in molecular mobility.  The 
extent of antiplasticization (or plasticization) is often quantified by mathematical models 




1.2.6.1.4 Polymer as a physical barrier to drug diffusion 
The polymer may also prevent drug crystallization, by simply forming a physical barrier 
around the drug molecules, thereby reducing drug diffusion.  This is usually suggested as 
the main mechanism when specific drug–polymer interactions are absent, the 𝑇𝑔 of the 
system is not affected relative to the neat drug, and there is no measurable difference in 
molecular mobility.  As an example, three polymers – PVP, HPMC and HPMCAS – were 
found to be equally effective in reducing the crystallization rate of felodipine from 
amorphous solid dispersions (at comparable polymer loading)65.  There was no correlation 
between the nucleation rate and either the 𝑇𝑔 of the ASDs relative to the neat drug, or the 
presence of drug–polymer hydrogen bonding.  The authors reasoned, therefore, that the 
polymers simply increased the kinetic barrier to nucleation65.  Similarly, small amounts of 
PVP (up to 10% w/w) in dispersions resulted in marked increases in the crystallization 
induction times of sucrose66.  The polymer caused very little change to the 𝑇𝑔 of sucrose, 
in the concentration range where significant inhibition of crystallization occurred66.  
Similar effects have been reported, where polymer dilution inhibited crystal growth and 
disrupted crystallite morphology67,68.  
 
1.2.7 Plasticizers 
Plasticizers are materials (typically low molecular weight, low viscosity, low 𝑇𝑔 liquids), 
generally added to polymers or amorphous compounds, to increase plasticity/flexibility, or 
to reduce brittleness69.  Plasticizers are incorporated in ASDs to facilitate manufacturing 
processes such as hot melt extrusion or to alter the physicochemical properties of the final 
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product51.  Common plasticizers include polyalcohols (e.g. glycerol), citrate esters (e.g. 
triethyl citrate), fatty acid esters (glycerol monostearate, stearyl alcohol), glycol derivatives 
(polyethylene glycol, propylene glycol), vitamin E TPGS, mineral and castor oils, etc51.  
Surfactants such as polysorbate 80, sodium lauryl sulfate and docusate sodium, have also 
been evaluated as plasticizers for polymer systems.  Water, a universal plasticizer, may 
also inadvertently be introduced into amorphous formulations, from the atmosphere or 
during processing.  Despite their importance in processing, plasticizers are known to 
accelerate drug crystallization, which is an undesired effect51,70.  Nonetheless, some 
plasticizers, at low concentrations, may counterintuitively exert an anti-plasticization 
effect71. 
 
1.2.7.1 Mechanisms of plasticization 
The lubricity, gel, viscosity and free volume theories are the main theories that explain 
plasticization72.  The theories were developed based on polymer models, but the principles 
also apply to small molecules.  Other quantitative models have also been developed from 
computational methods72.   
 
According to the lubricity theory, plasticizers reduce intermolecular friction between the 
host molecules, causing the molecules to slip over each other more easily.  The reduced 
internal resistance to sliding, leads to increased molecular movement72.  The gel theory 
considers the polymer as having a rigid three-dimensional “honeycomb” structure, with 
lose attachments/interactions between the polymer molecules.  The plasticizer reduces the 
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number of points of attachment, (i.e. reduces the polymer-to-polymer interactions) causing 
the rigid polymer structures to be deformed or disaggregated72,73.  The free volume theory, 
postulated by Fox and Flory74, indicates that between atoms and molecules, there is nothing 
but free volume (defined as the difference between the volume observed at absolute zero 
temperature, and the volume measured for the real crystal, glass or liquid, at a given 
temperature)74.  The free volume gives enough “room” for the host molecules to move. 
Plasticizers typically increase the free volume of the system, leading to additional 
flexibility and ease of movement to the host molecules.  Many mathematical models, based 
on the free volume additivity rule have been developed, which correlate the glass transition 
temperature (𝑇𝑔) of the plasticized systems, with the individual 𝑇𝑔s of the host compound 
and the plasticizer74.  The extent to which a plasticizer reduces the 𝑇𝑔, is usually a measure 
of the plasticizer efficiency75.  
 
1.2.8 Dissolution of amorphous solid dispersions 
 
Figure 1.2.  The spring and parachute concept, to describe achieving high apparent 




The dissolution of amorphous systems is usually described by the “spring and parachute” 
concept4,77.  When introduced into an aqueous medium, the neat amorphous compound 
rapidly dissolves, yielding a highly supersaturated solution (the spring in Figure 1.2).  The 
peak solubility occurs due to a combination of factors, such as the higher free energy, 
reduced particle size, randomization of molecules, larger surface area and the higher 
wettability of the amorphous drug4.  The high supersaturation however becomes a driving 
force for crystallization, leading to a rapid concentration decline.  
 
The initial dissolution rate of an ASD may be drug-controlled or polymer-controlled16.  
Drug-controlled dissolution typically occurs when the ASD has a low polymer content.  A 
drug-rich layer forms at the dissolving surface, which crystallizes rapidly, preventing 
further drug release.  When the ASD has high polymer content, drug release is independent 
of the drug properties, and thus referred to as polymer-controlled dissolution.  These 
mechanisms mainly apply to hydrophilic polymers.  
 
For the ASD to maintain the peak drug concentration (i.e. for the metastable zone/ 
“parachute” in  Figure 1.2 to be prolonged), the amorphous-to-crystalline phase 
transformation must be inhibited by the polymer. The mechanisms of stabilization in the 
“solid” state (explained in section 1.2.6.1), may also be relevant in aqueous solution.  Thus, 
the polymer may prevent drug concentration decline, by maintaining specific interactions 
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with the functional groups of the drug, by reducing mobility of the drug molecules, or by 
acting as a physical barrier to drug aggregation.   
 
Drug–polymer interactions formed in the dry ASD (ionic interactions, hydrogen bonding, 
and other weaker intermolecular attractive forces) can, in principle, be disrupted by 
competing polymer–water interactions, especially when the polymer is substantially 
hydrophilic.  Of the main types of interactions, hydrogen bonding may be the most 
susceptible to disruption by water molecules78.  Comparatively, drug–polymer 
hydrophobic associations may be more stable in aqueous media.  Thus, amphiphilic 
polymers with high hydrophobic content have been found to maintain drug supersaturation 
for longer durations79,80.  Measures of molecular movement in solution (i.e. Brownian 
motion) such as diffusion or sedimentation, can reveal the impact of heterogeneous 
interactions.  Diffusion measurements in particular, have been used to characterize ligand-
protein interactions in aqueous media78.  The polymer may also act as a physical barrier to 
crystallization in solution, by changing the hydrodynamic boundary layer of the crystal 
surface, thereby decreasing the rate of molecular migration to the crystal.  Adsorption of 
the polymer to any crystal nuclei formed, can also prevent further crystal growth81. 
 
1.2.9 Characterizing drug–polymer interactions in aqueous solution 
Analytical methods routinely used for characterizing ligand–protein, or protein–excipient 
interactions in solution, may be used for drug–polymer interaction studies.  The most 
commonly used are spectroscopy (e.g. FTIR, Raman, vibrational optical activity, NMR, 
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fluorescence) and calorimetry (e.g. isothermal titration calorimetry)78.  The biggest 
challenge with using any of the techniques for characterization of drug–polymer 
interactions in water, is the poor aqueous solubility of the model drug compounds, which 
leads to weak signals.  
  
1.2.9.1 Analytical ultracentrifugation 
An analytical ultracentrifuge is simply a high-speed (up to 60,000 rev/min) centrifuge, with 
an appropriate detecting system for simultaneously recording solute migration in solution.  
AUC experiments are generally in two classes: (1) sedimentation velocity (SV-AUC) and 
(2) sedimentation equilibrium (SE-AUC), the key difference being the strength of the 
centrifugal field applied.  SV-AUC experiments typically utilize higher centrifugal fields, 
and shorter run times.  In SV-AUC, the centrifugal field causes the solute to migrate from 
the meniscus to the base of the AUC cell. The migration of molecules as a function of time 













where 𝜔2𝑟 is the centrifugal field, 𝑟 the radius, 𝑡 time of sedimentation, 𝑚 the buoyant 
molecular mass and 𝑓 the frictional coefficient. The sedimentation coefficient is expressed 
in the unit of seconds, but usually reported in Svedbergs, S, where 1 S = 10-13 seconds. The 
sedimentation coefficient is also governed by the famous Svedberg equation,  
 
𝑠 =






      
where 𝑀 is the molar mass, 𝑣 the partial specific volume of the solute, 𝜌𝑠 the density of 
the solvent, 𝑓 is the friction coefficient and 𝑁 Avogadro’s number.  Assuming validity of 
Stoke’s law, the Svedberg equation can be manipulated to obtain particle sizes (or more 








where  𝑑𝑝 is the particle diameter (Stoke’s equivalent diameter), 𝜂𝑠 is the dynamic viscosity 
of solvent and 𝜌𝑝 is the particle density.    
 
Experimentally observed sedimentation coefficients vary with temperature and solution 
density.  Thus, 𝑠-values are usually converted to a standard state of 20 °C in water, at 
infinite dilution (denoted 𝑠20,𝑤).  When the measured 𝑠20,𝑤 value is compared with the 
𝑠20,𝑤 predicted theoretically for a smooth compact sphere of the same mass and density, 
the frictional ratio, 𝑓/𝑓0 is obtained
82.  The frictional ratio characterizes the shape of the 
molecule.  Additional details of the basic theory of Analytical Ultracentrifugation can be 





1.3 CHAPTER DESCRIPTIONS AND HYPOTHESES 
1.3.1 Chapter 2 
In an earlier report, the influence of the strength of drug–polymer interactions on the 
molecular mobility and physical stability of amorphous solid dispersions formulated with 
ketoconazole (KTZ) and each of the three polymers – (i)  poly(acrylic acid), (PAA) (ii) 
poly hydroxy methyl methacrylate, (PHEMA) and (iii) poly vinyl pyrrolidone, (PVP) – 
was investigated52.  Ionic, as well as hydrogen-bonding interactions were characterized 
between KTZ and PAA and hydrogen bonding was characterized between KTZ and 
PHEMA. There were no specific interactions between KTZ and PVP.  The drug–polymer 
interaction strengths, as well as the physical stability of the ASDs, were rank-ordered as 
KTZ-PAA > KTZ-PHEMA > KTZ-PVP. The interactions, molecular mobility and 
crystallization measurements were conducted in the dry “solid” form, without any organic 
or aqueous solvents.  An unanswered question, however, was if the interactions observed 
in the “solid” state, would be maintained in aqueous solution, and if such interactions 
would translate to improved dissolution performance.  In Chapter 2, the work was extended 
into aqueous solution, using the same model systems.  The hypothesis was: 
Strong drug–polymer interactions in the solid state, can translate into 
interactions in aqueous solution, resulting in an increased extent and duration 




Potential interactions in water were investigated with two-dimensional NMR and 
isothermal titration calorimetry.  Crystallization (monitored with synchrotron X-ray 
diffractometry) and dissolution tests (USP apparatus IV) were used to gauge the ASD 
performance in water.     
 
1.3.2 Chapter 3 
A link between strength of interactions in the dry ASD, and the strength of interactions in 
aqueous media was shown, with ketoconazole ASDs in Chapter 2.  It was our intention to 
extend this study to other model systems, to determine if the hypothesis could be 
generalized.  Model drugs of interest included indomethacin58,61, nifedipine63 and 
griseofulvin84.  In each of the literature sources cited, the solid-state interactions of the 
drugs with various polymers had been characterized, and there was a good correlation 
between the drug–polymer interaction strengths and the physical stability of the ASDs. Our 
approach was to investigate whether the drug–polymer interactions persist in aqueous 
media, using two-dimensional NMR and isothermal titration calorimetry.  However, we 
encountered a significant challenge; the low aqueous solubility of these compounds caused 
very low signal strengths, below the limit of quantification of the analytical techniques. 
This challenge highlighted the need for other analytical techniques that could characterize 
drug–polymer interactions at the molecular-level, in aqueous media, with enough 




We therefore explored the use of analytical ultracentrifugation (AUC) for the 
characterization of drug–polymer interactions, in Chapter 3.  We used the principle of co-
sedimentation, to infer interactions. Our hypothesis was as follows: 
Drug–polymer interactions in solution will cause the sedimentation behavior of 
a drug, in the presence of a polymer, to change and approach the sedimentation 
behavior of the neat polymer.  
 To test this hypothesis, we selected three drug–polymer pairs (that had been shown by 
other techniques, to interact in aqueous solution) as model systems, and investigated their 
sedimentation patterns with analytical ultracentrifugation.   
 
1.3.3 Chapters 4 and 5 
Chapters 4 and 5, are two parts of an investigation into the effect of glycerol, on the liquid 
crystalline phase transitions of itraconazole.  Itraconazole (ITZ) is a thermotropic liquid 
crystal with isotropic, nematic and smectic A phases.  When glycerol, a plasticizer, was 
incorporated into ITZ by solvent evaporation, unusual effects were observed:  
(i) the mesophase sequence was altered in a glycerol-concentration dependent 
manner.  
(ii) drug crystallization was not observed for more than 2 years, when the ITZ-
glycerol mixtures were stored in the glassy region.   
The goal was therefore to understand the mechanism by which glycerol modulated the 
mesomorphic sequence and the physical stability of ITZ.  The hypothesis to be tested for 
both chapters was: 
33 
 
Additives with fast dynamics, can accelerate the development of smectic order in 
itraconazole, by a coupling of the additive concentration to the translational and 
orientational order parameters of the neat drug.  
 
In Chapter 4, we investigated the thermal behavior of neat ITZ as well as the ITZ-glycerol 
mixtures, using differential and adiabatic scanning calorimetry (DSC and ASC). The 
transition temperatures and total enthalpy changes were located with DSC. Then, the 
critical behavior and the order of the mesomorphic transitions were established with ASC.  
Finally, in Chapter 5, the structural packing arrangement, molecular mobility, physical 
stability and dissolution behavior of the samples were investigated using synchrotron X-








2 The Influence of the Strength of Drug–Polymer Interactions 






In an earlier report, ionic interactions between ketoconazole (KTZ), a weakly basic drug, 
and poly(acrylic acid) (PAA), an anionic polymer, resulted in a dramatic decrease in 
molecular mobility as well as reduced crystallization propensity of amorphous solid 
dispersion (ASD) in the solid state.  On the other hand, weaker dipole–dipole interactions 
between KTZ and polyvinylpyrrolidone (PVP) resulted in ASDs with higher crystallization 
propensity (Mistry et al, Mol Pharm. 2015;12(9):3339-3350).  In this work, we 
investigated the behavior of the ketoconazole (KTZ) solid dispersions in aqueous media.  
In vitro dissolution tests showed that the PAA ASD maintained the level of supersaturation 
for a longer duration, than the PVP ASD at low polymer contents (4 to 20% w/w polymer).  
Additionally, the PAA ASDs were more resistant to drug crystallization in aqueous 
medium, when measured with synchrotron X-ray diffractometry.  Two-dimensional 1H 
NOESY NMR cross peaks between ketoconazole and PAA confirmed the existence of 
drug–polymer interactions in D2O.  The interaction was accompanied by a reduced drug 
diffusivity as monitored by 2D DOSY NMR, and enthalpy-driven when characterized by 
isothermal titration calorimetry (ITC).  On the other hand, drug–polymer interactions were 
not detected between ketoconazole and PVP in aqueous solution, with NOESY, DOSY or 
ITC.  The results suggest that the interactions that stabilize ASDs in the solid state, can 






The rate and extent of drug absorption following oral administration is influenced by 
solubility in the gastro-intestinal (GI) fluid and permeability through the GI membrane8.  
Advances in combinatorial chemistry and high through-put screening methods have led to 
an increase in target specificity and hydrophobicity of drug candidates1,85.  With more than 
70% of drugs under development having high permeability but poor aqueous solubility 
(BCS Class II compounds), strategies that enable increased apparent aqueous solubility, 
have become important8,86.  One strategy is to use amorphous solid dispersions (ASDs), 
which refer to molecular-level mixtures of drug and polymer, formulated with the aim of 
improving oral bioavailability.  From a formulation perspective, the first step towards 
stabilization of ASDs is to prevent drug crystallization in the solid state, during storage, 
and polymers have proven effective in that regard87.  The ability of the polymer to raise the 
glass transition temperature (𝑇𝑔) of the dispersion
88, to reduce molecular mobility19, and to 
act as a physical barrier to molecular aggregation65–68, have all been linked to 
crystallization inhibition in the solid state.   
 
If the drug is retained in the amorphous state until used by the patient, but crystallizes 
rapidly following oral administration, the potential solubility advantage may be negated.  
Adequate supersaturation in the GI fluid must be maintained for a period, long enough to 
translate to enhancement in absorption and consequently bioavailability. Therefore, in 
addition to stabilizing the drug in the dry solid dispersion, polymers must help maintain 
drug supersaturation in solution. To gauge the extent and duration of solubility 
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enhancement, amorphous formulations are usually evaluated using in vitro dissolution 
tests.  The physicochemical properties (such as the degree of lipophilicity and ionizability) 
of both the polymer and the drug, viscosity of the diffusion layer, the drug-to-polymer ratio 
of the formulated ASD, and the nature and strength of drug–polymer interactions are all 
key factors that can influence the degree of supersaturation, as well as the drug 
concentration in solution as a function of time.   
 
The strength of intermolecular interactions can be rank-ordered as ionic interactions > 
hydrogen bonding > dipole-dipole (non-specific) interactions59.  Several studies have 
highlighted a general correlation between the strength of drug–polymer interactions, and 
the physical stability of ASDs upon storage52,60–63.  Strong drug–polymer interactions may 
prevent drug crystallization in the solid state by increasing miscibility, improving phase 
homogeneity and/or decreasing molecular mobility52,63,89,90.  In an aqueous environment, 
however, the role of the type and strength of drug–polymer interactions on the dissolution 
enhancement, is not as clear.  On the one hand, it is believed that when the strong solid 
state interactions persist in aqueous solution, the initial dissolution rate of the drug 
increases, and the level of supersaturation is sustained for a much longer duration91.  
Specific interactions that are resistant to disruption by water molecules, would thus be most 
beneficial.  On the other hand, it has also been suggested that strong solid-state drug–
polymer interactions may be detrimental to ASD performance in aqueous solution.  As an 
example, drug–polymer hydrogen bonding in the solid state, was posited to cause a 
reduction in the dissolution rate, for ASDs with low polymer content92.  There is a need for 
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studies that comprehensively characterize interactions in the solid state as well as in 
aqueous solutions, to enable rational selection of polymers during the development of 
ASDs. 
 
We demonstrated in an earlier report, that the weakly basic drug ketoconazole (KTZ) 
exhibited ionic as well as strong hydrogen bonding interactions with poly(acrylic acid) 
(PAA), when formulated as an ASD52.  As a result, there was a dramatic reduction in the 
molecular mobility of the system, and a consequent reduction in  crystallization rate, both 
in the supercooled52 and glassy states93.  In contrast, poly (2-hydroxyethyl methacrylate) 
(PHEMA) and polyvinylpyrrolidone (PVP), showed weaker hydrogen bonding and dipole–
dipole interactions with KTZ, respectively. The strength of drug–polymer interactions, 
reduction in molecular mobility, and the enhancement in physical stability followed the 
same rank order: PAA>PHEMA>PVP.  The pronounced physical stabilization afforded by 
PAA raised the question: Is the KTZ-PAA interaction, observed in the solid state, retained 
in aqueous medium following dissolution of the dispersion?  If so, does the interaction 
prolong supersaturation?  To extend our work, we hypothesize that strong drug–polymer 
interactions in the solid state can translate to interactions in solution, thereby facilitating 
sustained supersaturation.   
 
Our first objective was to evaluate the performance of the amorphous dispersions in 
aqueous media.  Two complementary approaches were taken. (i) In vitro dissolution tests 
provided a measure of the drug concentration in solution and the duration of 
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supersaturation.  (ii) The extent of drug crystallization as a function of time, monitored 
following wetting of the dispersion, provided a measure of the ability of the dispersion to 
resist crystallization.  Our second objective was to identify and characterize the drug–
polymer interactions in aqueous solution.  Two-dimensional nuclear Overhauser effect 
spectroscopy (2D-NOESY) was used to probe the spatial proximity of drugs and polymers 
in solution94.  The impact of interactions on drug diffusivity was assessed with diffusion 
ordered spectroscopy (DOSY)95–98.  Finally, the thermodynamic “binding” signature and 




2.3 EXPERIMENTAL SECTION 
2.3.1 Materials 
Crystalline ketoconazole was obtained from Laborate Pharmaceuticals (Haryana, India). 
PAA (Mw ≈ 1800 g/mol) was purchased from Sigma-Aldrich (Missouri, USA), PVP-K12 
(Mw ≈ 2000−3000 g/mol) was obtained from BASF (New Jersey, USA), and PHEMA 
(Mw ≈ 3700) was obtained from Polymer Source (Quebec, Canada).  All solvents and 
chemicals were of analytical grade. The structures of all the compounds used are given in 
Figure 2.1.  
(a) Ketoconazole (KTZ) 
 
 














2.3.2 Preparation of amorphous systems 
Neat amorphous KTZ was prepared by melting crystalline KTZ at 160°C and rapidly 
cooling in liquid nitrogen.  The glass was gently ground using a mortar and pestle to obtain 
the free-flowing powder.  Solid dispersions of KTZ with polymer contents ranging between 
4 and 40% w/w, were prepared by solvent evaporation, followed by melt-quenching.  The 
drug and polymer were dissolved in methanol, and the solvent was rapidly evaporated 
(IKA-HB10 digital system rotary evaporator, Werke GmbH and Co., Staufen, Germany) 
at 50 °C under reduced pressure.  The powder was further dried under reduced pressure, at 
room temperature, for ~24 hours, to remove residual solvent before melt-quenching.  As 
controls, physical mixtures were prepared by geometrically mixing neat amorphous KTZ 
with each polymer (4 to 40% w/w polymer content).  All powders were sifted through 250 
µm pore-size sieves, before use.  Additional details of the preparation methods, as well as 
baseline characterization of the samples by differential scanning calorimetry, infra-red 
spectroscopy, thermal gravimetry, and Karl-Fischer titration have been reported 
elsewhere52,100. 
 
2.3.3 In vitro powder dissolution testing 
Dissolution tests were conducted in aqueous phosphate buffer (pH 7.4), using a flow-
through cell with a 22.6 mm internal diameter (USP Apparatus 4, Sotax Ltd) attached to a 
UV analyzer (Specord 210 Plus).  A glass bead (5 mm diameter) was placed at the bottom 
of the cell to prevent the powder from entering the inlet tubing.  The bottom cone of the 
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cell was filled with 1 mm diameter glass beads.  A glass microfiber filter (Whatman®, 25 
mm diameter, 0.7 µm pore size) prevented the undissolved powder from escaping from the 
top of the cell.  
 
An accurately weighed quantity of the powder sample (50 mg drug equivalent) was 
distributed throughout the 1 mm glass beads of the flow-through cell.  The dissolution 
medium, maintained at 37 °C, was pumped through the cell at a flow rate of 4 mL/min.  
The flow-through cell was operated in the open-loop mode, wherein fresh dissolution 
medium from the reservoir continuously passed through the cells.  At pre-determined 
timepoints, the UV absorbance of the filtered sample was measured in line at 225 nm, 
against a reference cell containing the blank dissolution medium.  The absorbance readings 
were converted to dissolved drug concentration values, using a calibration curve.  
 
Experiments were run in triplicate and the mean and standard deviation values (as error 
bars) are presented.  From each concentration-time dissolution profile, the area under the 
curve from the start of experiment to the last time point (AUC)(0→t), the maximum 
concentration (𝐶𝑚𝑎𝑥), and the time to reach the maximum concentration (𝑇𝑚𝑎𝑥) were 
determined.  The ratio [AUC(0→t), sample]/[AUC(0→t), crystalline KTZ], was used to 
quantify the extent of dissolution enhancement.  The dissolution enhancement factors were 
compared using the student’s t-test. A 𝑝-value ≤ 0.05 was used to assess statistical 





2.3.4 Synchrotron X-ray diffractometry 
Approximately 20 mg of each sample was accurately weighed in a DSC pan (T-zero®, TA 
Instruments, DE) and 25 μL of phosphate buffer (pH 7.4) was added to uniformly wet the 
sample.  The pan was hermetically sealed, mounted on a custom-made holder, and exposed 
to synchrotron radiation at pre-defined time intervals, for approximately 4 hours.  
Measurements were performed in triplicate using fresh amorphous sample for each run. 
Details of the experimental set-up and data analyses procedures were presented earlier100.  
Diffraction patterns are presented as one-dimensional scattering intensity (𝐼) versus 
scattering wavevector (𝑄 = 4𝜋𝑠𝑖𝑛 𝜃/𝜆) plots, where 𝜃 is the angle of incidence and 𝜆 is 
the wavelength.  The crystallinity at each time point was quantified using equation (2.1), 
where 𝐼𝑐 is the intensity of the crystalline contribution (total area of all crystalline peaks) 
and 𝐼𝑎 is the intensity of the amorphous contribution (area of the amorphous halo)
101. The 








2.3.5 Solution NMR 
Sample preparation for solution NMR experiments 
Two methods were used to prepare drug–polymer mixtures for the NMR experiments.  In 
the first method, an accurately weighed amount of polymer was dissolved in D2O.  The 
polymer solution (1 mL) was then added to an excess of KTZ (~20 mg) in a glass vial, 
shaken in a vortex mixer at room temperature for approximately 40 minutes, filtered (0.45 
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µm PTFE filter), and transferred to 5 mm NMR tubes for data acquisition.  The 
concentration of KTZ in the filtrate was confirmed by HPLC (USP 25 Assay method for 
Ketoconazole Solution).   
 
In the second approach, D2O acidified to pH 2.5 with concentrated hydrochloric acid, was 
used as solvent.  Stock solutions of ketoconazole and each polymer were separately 
prepared in the solvent.  Aliquots of the drug and polymer stock solutions were pipetted 
into a vial, and diluted with an appropriate amount of solvent, such that the final drug and 
polymer concentrations were 5 and 20 mg/mL respectively.  Spectra of the drug–polymer 
mixtures prepared using both methods were qualitatively similar, except for minor 
differences that could be explained by expected solution pH variations.  Data presented 
within the text, are from the second method of preparation. 
 
As controls, spectra of the neat drug and neat polymer solutions in acidified D2O, were also 
acquired.  Of note, KTZ did not dissolve in D2O (with or without organic co-solvents), at 
concentrations high enough for detection.  PHEMA was also not soluble in D2O at relevant 
concentrations. 
 
One-dimensional proton nuclear magnetic resonance spectroscopy (1D 1H NMR) 
1D 1H-NMR experiments were performed on either a Bruker Avance III HD 500 MHz 2-
channel spectrometer equipped with a 5 mm Prodigy TCI cryoprobe with z-axis gradients 
in the magnet, or on a Bruker AV 400 spectrometer.  Spectral assignments were made, 
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based on standard 2D methods such as COSY, HSQC and HMBC experiments (data not 
shown), and compared with published data for KTZ102,103, PVP96 and PAA104.  Spectra 
were processed with the Bruker Topspin software (version 3.2). 
 
Two-dimensional proton nuclear Overhauser effect spectroscopy (1H/1H NOESY) 
Experiments were performed on a Bruker Avance III HD 500 MHz 2-channel spectrometer 
equipped with a 5 mm Prodigy TCI cryoprobe with z-axis gradients in the magnet.  Spectra 
were recorded using standard NOESY pulse sequence with water suppression using 
excitation sculpting, from the Bruker pulse-program library. All measurements were 
carried out at ambient temperature, ~25 °C.  In a typical experiment, data were acquired 
with 2048 data points in F2, 256 increments in F1, and 16 scans per increment, over a 
spectral width of 12 ppm, with NOE mixing time of 1 s, and a relaxation delay of 2 s.  Data 
analysis was done with the Topspin 3.2 software package. 
 
Two-dimensional diffusion ordered spectroscopy (2D DOSY) 
Experiments were performed on a Bruker Avance III (500 MHz) instrument with a 5 mm 
broadband fluorine observe (BBFO) probe, at ambient temperature (~25 °C).  The 
longitudinal eddy current delay bipolar gradient pulse sequence acquired in 2D (ledbpgp2s) 
was employed for self-diffusion coefficient measurements.  Gradient strength was 
incremented in steps along a linear ramp from 2 to 95% of the maximum strength of ~60 
Gauss cm-1.  Gradient lengths and diffusion times were optimized for each sample, in order 
to achieve sufficient signal attenuation.  The relaxation delay was 2 s and a total of 16 scans 
was used for each sample.  Data was analyzed with the Topspin 3.2 software.  The diffusion 
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coefficient (D) for each species was determined from a fit of selected resonances to 
equation (2.2). 
 
 𝐼 = 𝐼0 ∗ exp [−𝐷 ∗ (2𝜋𝛾𝑔𝛿)
2 ∗ (∆ −
𝛿
3
) ∗ 1e4] (2.2) 
 
 
where 𝐼 is the recorded signal intensity as a function of gradient strength 𝑔, 𝐼0 the 
unattenuated signal intensity, 𝛾 the gyromagnetic ratio of 1H, 𝛿 the length of the gradient 
pulse (2 ms), and ∆ the diffusion time (~100 ms). 
 
2.3.6 Isothermal titration calorimetry (ITC) 
The objective of the ITC experiment was to obtain a quantitative measure of the drug–
polymer interaction strength in aqueous solution.  To make this possible, the drug solution 
concentration had to be high, such that an accurately measurable heat (> 0.5 µcal, for the 
largest heat) would be absorbed/released105.  High KTZ concentrations (40 mM) could be 
prepared in acidic solvent (pH 1.1 buffer), but not in neutral buffers. 
 
Sample preparation for ITC experiments 
KTZ solution (40 mM) was prepared in buffer (pH 1.1 ± 0.1; comprising 106 mM HCl and 
50 mM KCl), and filtered (0.45 µm PTFE), immediately before each ITC experiment. 
Solutions of each polymer (3 mM, calculated based on the weight-average molecular 





ITC experimental details 
Experiments were performed on a MicrocalTM Auto-ITC200 system (Malvern Instruments, 
MA) which has a 200 µL sample cell and an identical reference cell.  The sample cell was 
filled with the polymer solution and titrated with sequential injections of the drug solution 
at a constant stirring rate of 750 rpm.  Control experiments were performed by (i) titrating 
the drug solution into blank buffer and (ii) titrating the buffer into the polymer solution. 
Unless otherwise stated, the sample chamber was maintained at 25 °C.  The first injection 
was a 0.4 µL aliquot to remove the effect of solute diffusion across the syringe tip during 
the equilibration period.  This first/initial injection was not considered for analysis. 
Subsequently, 4 µL injections were made into the sample cell for an experimental run time 
of 150 minutes.  The duration of each injection was 20 s, and the time interval between 
successive injections was 180 s.  To extend the run time, experiments were performed in 
an automated “continued injection” mode, wherein, when full, 30 µL of solution was 
withdrawn from the sample cell and discarded, to make room for more sequential injections 
of the titrant.  This process of withdrawing solution from the sample cell and continuing 
the titrations was repeated for up to six experiments.  Microcal origin® concat (add-on) 
software was used to concatenate experiments and to correct for concentration and baseline 
offsets.   
 
ITC data analysis 
The heat (𝑄) measured over time (𝑡) was integrated to obtain the incremental heat ∆𝑄, 
which was normalized to the molar concentration of injectant, and plotted as a function of 
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the molar ratio between drug and polymer.  Data processing, peak integration and fitting 
to the standard binding model was done with the Affinimeter® ITC software (Software for 
Science, Spain)106.  Additional details of the ITC data analysis procedure and the fitting 
model are provided in the Supplementary Information. 
 
 
2.4 RESULTS AND DISCUSSION 
Ketoconazole (KTZ, Figure 2.1a) is weakly basic, with pKa values of 6.5 and 2.9107.  As 
an ionizable compound, KTZ exhibits pH-dependent aqueous solubility, being practically 
insoluble at pH > 4, but highly soluble in acidic media (pH < 2.5), at room temperature107.  
The speciation profile of ketoconazole, as a function of pH, is given in Figure S1.  PAA 
and PVP are water-soluble over a wide pH range, whereas PHEMA is a “water-swellable” 
hydrogel, with limited aqueous solubility108 (see Figure 2.1b-d).  The carboxylic acids 
within the monomer unit of PAA exhibit pH-dependent ionization (pKa 4.5), being 
substantially unionized at pH < 2.5, and almost completely ionized at pH > 6.5109.  PVP on 
the other hand, is a relatively ‘neutral’ polymer 110,111.   
 
In our earlier reports52,93, significant differences in the drug–polymer interaction strength, 
molecular mobility, and the drug crystallization propensity were observed, when ASDs 
formulated with each of the three polymers, at low (4 – 40% w/w) polymer contents, were 
characterized.  Since low excipient contents in ASDs offer the advantage of reducing the 
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pill burden, it was of interest, to evaluate the behavior of the ASDs having such low 
polymer contents, in aqueous media.     
 
2.4.1 Powder dissolution 
Figure 2.2 shows the dissolution profiles of neat ketoconazole, as well as the solid 
dispersions.  Crystalline KTZ yielded a concentration of ~3 µg/mL in solution, about the 
same as its reported equilibrium solubility of 2 µg/mL (pH 7.8, 37 °C)112.  Neat amorphous 
KTZ, however, showed an initial rapid rise in concentration to ~18 µg/mL, a six-fold 
increase compared to the concentration of crystalline KTZ, but still far below the estimated 
“amorphous solubility” of 57 µg/mL (pH 10, 37 °C)113.  The increased drug concentration 
from amorphous KTZ persisted for approximately 40 minutes before declining.  The rapid 
rise and decline in concentration, is the classical “spring” effect exhibited by amorphous 
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Figure 2.2.  Dissolution profiles of crystalline KTZ, amorphous KTZ, and ASDs 
formulated with (a) PAA and (b) PVP at polymer contents ranging between 4 and 40% 
w/w (mean ± standard dev; n = 3). Experiments were in performed in pH 7.4 phosphate 
buffer at 37°C.  Profiles of KTZ-PHEMA ASDs, are presented in the supplementary 





Dissolution profiles of the PAA ASDs are shown in Figure 2.2a.  At the lowest polymer 
loading (4% w/w PAA), the drug concentration increased rapidly to ~20 µg/mL, and 
leveled off, with a slight decline.  As the polymer content of the dispersion increased (with 
10 and 20% PAA), progressively higher maximum drug concentration (𝐶𝑚𝑎𝑥, see Figure 
S3a) levels were reached rapidly, though these could not be sustained.  The acidic 
microenvironment created around the weakly basic drug particles, by the rapidly dissolving 
polymer, PAA, increased the drug solubility, resulting in the high 𝐶𝑚𝑎𝑥 values.  As recently 
shown, a 2 to 3 unit decrease in the microenvironmental pH of the dissolving particles 
could double the initial dissolution rate of KTZ114.  The high degree of supersaturation 
however becomes a driving force for crystallization, manifesting as the decline that follows 
the initial surge in drug concentration115.  Nonetheless, at all polymer contents, the PAA 
ASDs maintained ~six-fold higher drug concentration levels by the end of the experimental 
runs, compared to crystalline KTZ.  The supersaturation, observed after 40 min, is very 
likely sustained by a different mechanism, since the pH of the dissolution medium in the 
bulk phase did not reduce significantly (due to the buffer capacity, as well as the constant 
flow of fresh dissolution medium).  We hypothesize that drug–polymer interactions in 
solution, will be relevant.  Of note, an increase in PAA content from 20 to 40% w/w 
(Figure 2.2a), did not translate to any solubility enhancement. 
 
Dissolution profiles of the PVP ASDs, shown in Figure 2.2b, differ in two main aspects, 
when compared to the profiles of the PAA ASDs.  Firstly, the ASDs containing less than 
40% PVP, do not show the initial spike in drug concentration within the first 40 minutes.  
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This is understandable, since PVP, being a relatively “neutral” polymer, does not lower the 
pH of the microenvironment of the dissolving drug particles as much as PAA does.  Thus, 
the effect of rapid polymer dissolution driving an increased supersaturation is observed, 
mainly at higher (>40%) polymer contents.  The second general feature identified from the 
dissolution profiles of the KTZ–PVP ASDs (Figure 2.2b) is, that the drug concentration 
levels drop after ~40 minutes, an indication that PVP is not as effective as PAA, at 
inhibiting drug crystallization.  The profile of the ASD with 4% PVP content, was quite 
similar to that of neat amorphous KTZ, and a polymer content of at least 20% w/w was 
required to sustain the KTZ supersaturation for practically useful timescales.   
  
The PHEMA ASDs exhibited slightly different dissolution characteristics (see Figure 
S2a).  The 𝐶𝑚𝑎𝑥 values at all polymer contents, were not significantly different from the 
𝐶𝑚𝑎𝑥 of neat amorphous ketoconazole.  The level of supersaturation was, however, 
sustained much longer in the PHEMA ASDs, at all polymer contents, than in the PVP 
ASDs.  Both effects – i.e. low 𝐶𝑚𝑎𝑥 values and the sustained supersaturation – can be 
explained by the “diffusion-controlled” mechanism of drug release, proffered for ASDs 
formulated with hydrogels116,117.  When the ASD is introduced into the aqueous medium, 
the polymer immediately imbibes water and swells, trapping the drug molecules and 
preventing the rapid surge in drug concentration, resulting in the low 𝐶𝑚𝑎𝑥.  With time, 
however, the dissolved drug slowly diffuses out of the gel-like polymer matrix at a steady 




The dissolution profiles of the ASDs are replotted in Figure 2.3, to enable a better 
comparison of the polymer effect.  Pronounced differences were observed at low polymer 
contents (4 – 20% polymer) where supersaturation was sustained for a longer duration in 
the PAA and PHEMA ASDs.   




(c) ASDs at 20% polymer loading (d) ASDs at 40% polymer loading 
  
Figure 2.3.  Comparison of dissolution profiles of ASDs formulated at different polymer 
contents.  (a) 4% w/w polymer, (b) 10% w/w polymer, (c) 20% w/w polymer, (d) 40% w/w 
polymer content. 
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As controls, binary physical mixtures (PMs) of neat amorphous KTZ and each polymer 
were subjected to the same dissolution testing experiments (PAA and PVP PMs in Figure 
2.4, PHEMA PMs in Figure S2b).  Generally, at all polymer contents, the physical 
mixtures achieved similar or even higher 𝐶𝑚𝑎𝑥 values when compared to the ASDs (see 
Figure S3a).  Interestingly, the KTZ-PVP physical mixture at 40% polymer content, 
showed the highest 𝐶𝑚𝑎𝑥 of ~80 µg/mL.  In spite of the high 𝐶𝑚𝑎𝑥 values, however, the 
drug concentration levels declined rapidly for all the physical mixtures, regardless of the 
polymer type.  This latter observation is in line with the current state of knowledge, that 
intimate mixing of the drug and polymer at the molecular-level, greatly helps in sustaining 





(a) KTZ-PAA Physical Mixtures 
 
(b) KTZ-PVP Physical Mixtures 
 
Figure 2.4.  Dissolution profiles of crystalline KTZ, amorphous KTZ, and physical 
mixtures formulated with (a) PAA and (b) PVP, at polymer contents ranging between 4 
and 40% w/w (mean ± standard dev; n = 3). Experiments were in performed in pH 7.4 
phosphate buffer at 37°C. Profiles of KTZ-PHEMA physical mixtures, are presented in the 
supplementary information (Figure S2b) 
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The composite effect of the extent and duration of supersaturation was quantified with the 
area under the dissolution curve (AUC).  The AUC(0→150min) of each formulation was 
normalized with the AUC(0→150min) of crystalline KTZ, and the resulting dissolution 
enhancement factors (AUC ratios) are presented in Figure 2.5.  Alternatively, for each 
sample, the total amount of KTZ dissolved after 150 min, is plotted in Figure S2.3b. The 
AUC ratios, or the total drug dissolved, allow the dissolution behaviors of the different 
amorphous systems to be compared.  For example, at low (4-20 % w/w) polymer contents, 
the dissolution enhancement from the PAA ASDs was significantly higher than the 
enhancement from the PVP ASDs.  The AUC ratios also allow the effects of polymer type 
and polymer loading to be compared.  A similar level of dissolution enhancement (an AUC 
ratio of 4.7) could be achieved with either 4% PAA or 20% PVP, revealing the superiority 
of PAA in maintaining KTZ in solution.  The dissolution enhancement for the PHEMA 






Figure 2.5.  Dissolution enhancement factors, obtained from dissolution profiles of 
amorphous solid dispersions (ASDs) and physical mixtures (PMs), prepared with different 
polymers (PAA, PHEMA or PVP) at polymer contents ranging between 4 and 40% w/w. 
Enhancement factors of crystalline and amorphous KTZ are included for comparison.  
Student’s t-test performed between selected ASDs at the same polymer loading: ns p > 0.05, 
⁎ p ≤ 0.05, ⁎⁎ p ≤ 0.01 
 
2.4.2 Crystallization in aqueous buffer 
Crystallization of the samples in aqueous environment was also evaluated. Each powder 
sample was wetted with buffer (pH 7.4) and monitored with synchrotron radiation as a 
function of time.  Representative diffraction patterns are shown in Figure 2.6a to c, from 
which the extent of crystallization was quantified (Figure 2.6d).  Even at the very low 

































































































































































































































































crystallization with less than 12% crystalline content by 4 hours.  The PVP ASD on the 
other hand crystallized rapidly (~90% crystalline content at 4 hours), with the rate of drug 
crystallization being very similar to that of neat amorphous ketoconazole.  Similar results 
were obtained for ASDs having higher (10 and 20%) polymer contents, where drug 
crystallization was absent in the PAA and PHEMA ASDs, even beyond 4 hours, but the 
PVP ASDs crystallized (data not shown).   
   
When the drug–polymer physical mixtures were evaluated (see Figure 2.6d), PAA was 
more effective than PHEMA in inhibiting drug crystallization in solution, even though for 
both polymers, the extent of suppression was much less than in the corresponding ASD.  
PVP, however, did not suppress drug crystallization as a physical mixture.    
 
The crystallization inhibition results complement the observations from the dissolution 
tests, in that, PAA and PHEMA were better at stabilizing the drug, than PVP.  For the 
water-soluble polymers (PAA and PVP), strong drug–polymer interactions that persist in 
solution, would possibly prevent the dissolved drug from crystallizing, and thereby 
contribute to sustaining the level of supersaturation.  For ASDs formulated with hydrogels 
(eg. PHEMA), however, the diffusion-controlled drug release mechanism would be more 





(a) 4% PAA ASD (b) 4% PVP ASD 
   
  





Figure 2.6.  (a-c) Synchrotron X-ray diffraction patterns of powder samples, wetted with 
dissolution medium (phosphate buffer, pH 7.4 at ~25 °C) and monitored as a function of 
time. (a) KTZ + 4% PAA ASD, (b) KTZ + 4% PVP ASD, (c) neat amorphous KTZ. Each 
pattern has been offset on the vertical axis, for clarity. (d) Percent crystallinity as a function 
of time (mean ± SD; n = 3). 
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2.4.3 Drug–polymer interactions in solution 
The potential interactions between KTZ and the water-soluble polymers, PAA and PVP, 
were investigated with solution proton NMR spectroscopy, as well as isothermal titration 
calorimetry.  The low solubility of PHEMA in water resulted in weak signals, which made 
it impossible to investigate KTZ–PHEMA interactions.   NMR spectra of the drug and 
polymers are described using the numbering scheme in Figure 2.1. 
 
1D 1H NMR 
Figure 2.7a shows spectra of the KTZ–polymer mixtures, as well as the individual 
components.  Peak assignments for the relevant KTZ protons are listed in Table S1.  Peaks 
of KTZ protons were observed at chemical shifts of ~2 ppm (N-acetyl methyl protons), 3–
5 ppm (piperazine, dioxolane and other aliphatic protons), 6–8 ppm (imidazolyl and phenyl 
groups) and >8 ppm (single resonance from the dichlorophenyl ring).  The aliphatic proton 
peaks for neat PAA were between 1–3 ppm.  The peak corresponding to the carboxylic 
acid proton of PAA, expected at ~12 ppm, did not appear, because of the rapid hydrogen-
deuterium exchange in D2O.  The spectrum of neat PVP showed the peaks of the vinyl 
backbone and the pyrrolidone functional group (1.5–4 ppm).  The spectral region between 
6 and 9 ppm of both polymers, PAA and PVP, had no peaks, and could therefore be used 
to characterize the behavior of KTZ in the presence of either polymer (see the highlighted 




In the presence of PAA, some of the peaks from the aromatic ring systems of KTZ shifted 
downfield (Figure 2.7b; red dashed arrows).  The most pronounced shifts were observed 
for the protons of the para-substituted phenyl ring of KTZ (H21/25 in Figure 2.1a) which 
moved from 7.06 ppm to 7.35 ppm in the presence of PAA.  The peaks assigned to protons 
of the imidazole group (H10, H12, H13) also shifted downfield.  Since neat KTZ was 
dissolved under acidic conditions (D2O at pH 2.5), the basic nitrogen sites (N11 and N26) 
were protonated (see Figure 2.1a, and the green profile of Figure S1b).  Yet, strong peak 
shifts were still observed, reflecting decreases in the electron densities around the hydrogen 
atoms, most likely induced by the electron-withdrawing carboxylic acids of PAA96,97.  In 
many host-guest complexation systems, peak shifts of 0.1–0.5 ppm typically indicate 
strongly interacting systems97.  Thus, both ion–dipole interactions between the positively 
charged NH groups of KTZ and the carboxylic acids of PAA, as well as hydrogen bonding 
between the oxygen atoms of KTZ (O19 or O34) and the carboxylic acid hydrogens of 
PAA, may be present.  The 1D results therefore provided the first indication of interaction, 
between PAA and KTZ in aqueous solution.  On the other hand, the KTZ proton peaks in 
the 6-9 ppm region, remained unaffected by the presence of PVP (Figure 2.7b, green 









Figure 2.7.  One-dimensional 1H NMR spectra KTZ alone, and with polymers in D2O at 
pH 2.5. (a) Overview of the entire chemical shift range.  The (6.5 to 8.8 ppm) region 
indicated by a dashed box, is expanded in panel (b).  Peak position changes for selected 

























2D 1H1H NOESY 
Two-dimensional (2D) nuclear Overhauser effect spectroscopy (NOESY) was used to 
probe the drug–polymer interactions in greater detail.  Generally, for small molecules (𝑀𝑤  
< 600 Daltons), a nuclear Overhauser effect (NOE) may be observed between protons that 
are less than 4 Å apart; for large molecules (𝑀𝑤 > ~1500 Daltons), NOEs are observed, 
when the protons are 5 Å apart119,120.  The sign (or the phase) of the NOE, is also related to 
Brownian motion.  In the free state, small molecules tumble rapidly in solution, giving 
positive NOEs.  Conversely, large molecules tumble slowly, showing negative NOEs119,120.  
Thus, the observation of negative NOEs for a small molecule – in the presence of a 
macromolecule – provides a clear indication of interaction. 
 
The 2D NOESY plot of neat KTZ in D2O (at pH 2.5), is shown in Figure 2.8.  Several off-
diagonal peaks with positive signs (red) are observed, arising from cross-correlations 
between protons of the drug molecules.  Of note, the diagonal peaks are negatively phased 
(blue).  The plot of neat KTZ can be contrasted with those of neat PAA and PVP shown in 
Figure S4, which have cross-correlations, same-phased with the diagonal peaks.  The 
controls confirm that neat KTZ tumbles rapidly while the neat polymers tumble slowly, as 






Figure 2.8.  2D 1H1H NOESY plot of KTZ alone in D2O at pH 2.5.  The drug-drug, off-
diagonal cross-peaks are red, indicating they are opposite-phased to the diagonal (blue) 
peaks. 
 
Figure 2.9 is the 2D NOESY spectrum of the KTZ-PAA mixture.  Cross peaks (circled in 
red for clarity), between the aromatic proton peaks of KTZ (H21/25 & H22/24; H12, 13; 
H3, 5, 6) and those of the aliphatic backbone of PAA (Ha, and to a lesser extent, Hb), 
indicate the spatial proximity of the KTZ and PAA molecules.  The cross peaks have the 
same phase as the diagonal peaks (negative; blue, in the color scheme), indicating that, in 
the presence of PAA, the tumbling of the drug molecules is reduced.  These results 




It should be noted that dipolar cross correlations only reflect the spatial proximity of 
protons.  Thus, it is not possible based on the NOESY spectra alone, to unequivocally 
identify the functional groups of the drug and polymer that interact.  Since the aliphatic 
backbone of PAA is spatially close to the aromatic regions of KTZ, hydrophobic drug–
polymer associations may be present.  It is also possible that the interaction occurs between 
the imidazole nitrogen of KTZ and the carboxylic acid of PAA, but result in the 
hydrophobic regions being close to each other and manifesting as cross peaks.  
 
 
Figure 2.9.  2D 1H1H NOESY plot of a mixture of KTZ and PAA in D2O.  Cross peaks 
(circled in red) between the aromatic proton peaks of KTZ and the aliphatic proton peaks 
of PAA indicate drug–polymer intermolecular interactions. All (off-diagonal) cross peaks 























In contrast, no cross peaks are observed between the protons of KTZ and PVP (Figure 
2.10).  Instead, only intramolecular (i.e. drug-drug or polymer-polymer) cross-correlations 
are observed.  Moreover, the drug-drug and the polymer-polymer cross peaks maintain 
their positive (red; compare with Figure 2.8) and negative (blue; compare with Figure 
S4b) phases respectively, indicating that the tumbling of KTZ molecules is unaffected by 
PVP.   
 
 
Figure 2.10.  2D 1H1H NOESY plot of a mixture of KTZ and PVP in D2O at pH 2.5.  No 
drug–polymer cross peaks are observed in the circled region.  Only drug-drug (red; some 





























2D 1H DOSY 
2D 1H NMR diffusion ordered spectroscopy (DOSY) is another useful tool for 
investigating molecular interactions in solution97,121.  The technique enables spectroscopic 
“separation” of the diffusion coefficients of individual components of a mixture.  Small 
molecule drugs, diffuse faster than bulky polymers97.  Interaction of the drug with the 
polymer should in principle, result in reduced drug diffusivity.  However, such an 
interaction should have a negligible effect on the polymer diffusion coefficient, because of 
the bulky nature of the polymer.  The change in the self-diffusion coefficient of the small 
molecule is thus considered a direct measure of molecular association and 
aggregation97,121,122.   
 
Representative 2D DOSY plots of the drug–polymer mixtures, and the controls (KTZ 
alone, PAA alone, and PVP alone), all prepared in D2O at pH 2.5, are presented in the 
supplementary information (Figure S5).  The corresponding diffusion coefficient values 
(D-values) are listed in Table S2.  The diffusion coefficient of KTZ alone, 3.5 × 10-10 m2s-
1, is in good agreement with the values of other similar small molecule drugs in D2O
123,124.   
The neat polymers, PAA and PVP, have similar diffusion values (~1.7 × 10-10 m2s-1), 
reflecting the similarity in their molecular weights and shape (1800 gmol-1 and 2500 gmol-
1 for PAA and PVP respectively, both linear with ~24 monomers per chain).  The polymer 




To gauge the magnitude of the influence of the drug–polymer interaction on the movement 
of the different species in solution, the measured D-values are normalized with the D-value 
of neat KTZ (D0).  The resulting (D/D0) values are presented in Figure 2.11 with the neat 
drug having a value of 1, and the neat polymers having values of ~0.5.  In the presence of 
PAA, the normalized D-value of KTZ is ~0.58, indicating that the drug movement is 
slowed down by the polymer.  The extent of reduction of drug diffusivity in the polymer 
solution, is likely correlated with solubility enhancement due to the polymer124.  In the 
presence of PVP, however, the diffusion coefficient of KTZ is similar to that of the neat 
drug (D/D0 = 0.91), indicating that the polymer has a negligible effect on drug diffusion, 
and further corroborating the absence of drug–polymer interactions.  As expected, the 
diffusivity of PAA or PVP, in the respective drug–polymer mixtures, remain unchanged, 
compared to the neat polymers.   
 
Figure 2.11.  Normalized diffusion coefficients of the neat drug (KTZ alone), neat 
















































Isothermal titration calorimetry (ITC) 
Figure 2.12a shows the raw ITC power compensation signals for the titration of KTZ into 
PAA.  An exothermic signal of ~6 µcal/sec, is initially registered.  The magnitudes of the 
peaks progressively decrease with sequential titration of drug into polymer solution, until 
the end of the experiments, when the signal is ~1 µcal/sec.  A separate control experiment, 
comprising titration of KTZ into the blank solvent (pH 1.1 buffer), was performed (labeled 
as KTZ control; Figure 2.12c) to obtain the dilution heats, which are of much smaller 
magnitude.  The pH values of the drug solution, the polymer solutions and blank buffer 
were within 0.2 units of each other.  The drug dilution heats observed are therefore not 
attributed to a mismatch in pH of the syringe and cell contents, but presumably from the 
entropic gain when drug molecules from the highly concentrated syringe solution spread 
through the buffer in the sample cell.  The drug dilution background heats could also 
indicate some form of aggregation such as dimerization of the drug molecules in solution, 
even though this is not expected in the case of ketoconazole.  In a second blank experiment, 
the heat of dilution of the polymer was also measured by titrating buffer from the syringe 
into the polymer solution in the sample cell (labeled PAA control; Figure 2.12d).  The heat 




Figure 2.12.  Isothermal titration calorimetry power compensation signals, obtained from 
sequential injections of (a) 40 mM KTZ into 3 mM PAA, (b) 40 mM KTZ into 3 mM PVP 
(c) 40 mM KTZ into plain buffer (pH 1.1), (d) plain buffer into 3mM PAA (e) plain buffer 
into 3 mM PVP. For clarity, b, c, d and e have been offset by 1, 2, 2.5 and 3 units 
respectively on the vertical axis.  
   
The peaks recorded following each stepwise injection of KTZ into PAA were integrated, 
normalized with respect to the moles of drug added per injection, and then plotted as a 
function of the drug-to-polymer molar ratio in the sample cell.  This representation is 
commonly referred to as the differential binding curve (Figure 2.13a).  The shape of the 
curve obtained for the titration of KTZ into PAA, is typical for binding interactions with 
weak affinity (𝐾𝑎 < 10
4 M-1)105,125. Similar profiles have been reported for drug-



























(a) KTZ + PAA






practice, a thermodynamic binding model is fitted to the differential binding data to provide 
additional insight into the ligand-macromolecular interaction mechanism128.  A good fit 
was obtained using an independent sites analysis approach, with one independent set of 
sites and an additional term that accounts for the contribution from drug dilution (see 
supporting information)106,128.  The stoichiometry parameter, 𝑛, was fixed to 1, an approach 
that can be used for analyzing data with weak binding affinity, to increase the confidence 
in the other fit parameters125,129,130.  The resulting fit to the binding isotherm, is shown in 
Figure 2.13a, and the corresponding thermodynamic binding signature is plotted in Figure 
2.13b.  The data analysis shows an association constant (𝐾𝑎) of 43.3 ± 0.4 M
-1, with a 
negative overall enthalpy change (∆𝐻 = -2.69 ± 0.02 kcal/mol) indicating an enthalpy-
driven interaction.  The enthalpic contribution from the drug dilution, is negligible 






Figure 2.13.  Isothermal titration calorimetry results.  (a) Integrated heat as a function of 
drug-to-polymer molar ratio, for the titration of 40mM KTZ into 3mM PAA.  The standard 

































































signature plot (overall change in free energy, enthalpy, and entropy factor) for the KTZ-
PAA titration.   
 
The overall enthalpy change extracted from ITC experiments, provides a measure of the 
energy content of bonds broken and formed in the interaction process.  In general, polar 
interactions tend to contribute favorably to the enthalpic component, the major contribution 
being from hydrogen bonds, whereas entropically favored interactions tend to be more 
hydrophobic.  Thus, the binding signature suggests polar interactions such as hydrogen 
bonding or ion-dipole interactions, most likely between the imidazole groups of KTZ and 
the carboxylic acids of PAA, being present.  The interaction is spontaneous and favorable 
due to the negative change in free energy (∆𝐺 = -2.3 kcal/mol).   
 
The ITC profile obtained for the titration of KTZ into PVP (Figure 2.12b) however, starts 
with very weak endothermic peaks (~0.5 µcal/sec), which become exothermic when the 
drug-to-polymer molar ratio is greater than 5.  The exothermic signals of the KTZ-PVP 
interaction, are of the same magnitude as the signal for the titration of KTZ into the blank 
buffer (~0.5 µcal/sec).  Subtraction of the heat of KTZ dilution, from the KTZ-PVP 
titration, results in a largely featureless differential enthalpy curve which cannot be fitted 
with any of the standard binding models.   
 
2.4.4 Possible mechanisms of interaction in aqueous solution  
Together, the NMR and ITC experiments clearly show that interactions between KTZ and 
PAA exist in aqueous solution, which are stronger than interactions, if any, between KTZ 
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and PVP.  Because KTZ is weakly basic, with ionizable functional groups, the ionization 
states of both the drug and the polymer will influence the type of interaction occurring in 
aqueous solution.  In acidic buffer (<pH 2.5), the imidazolyl group of KTZ is fully 
protonated assuming a net positive charge, whilst the carboxylic acids of PAA (pKa ~ 4.5), 
though protonated, remain uncharged.  In neutral medium where the dissolution 
experiments were conducted, the charges are reversed; KTZ becomes substantially neutral 
(~10% protonated) while PAA gains a net negative charge due to deprotonation of the 
carboxylic acid groups.  Thus, in either acidic or neutral medium, ion-dipole interactions 
between the drug and polymer would very likely be present.  Additionally, multiple 
avenues exist for hydrogen bonding between KTZ and PAA, which could contribute to the 
overall interaction strength.  The thermodynamic interaction signature from the ITC 
experiments also point to enthalpy-driven, polar interactions being dominant.  It is 
therefore reasonable to infer that strong interactions in the solid state translate to aqueous 
solution, explaining, at least in part, the sustained duration of supersaturation in the 
dissolution experiments.   
 
It is noteworthy, that the KTZ-PAA ASDs outperformed the KTZ-PVP ASDs when the 
polymer contents were low (4-20% w/w polymer); at 40% polymer content, the dissolution 
profiles of the ASDs, regardless of polymer type, were not statistically different (see 
Figure 2.5).  This suggests that for water-soluble polymers, the strong drug–polymer 
interactions may contribute substantially to sustaining the level of supersaturation at low 
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polymer content.  Other factors such as steric hindrance to precipitation, due to the 
bulkiness of the polymer, become equally important, at higher polymer contents. 
 
Finally, we will briefly address the relevance of our work to the in vivo situation, 
specifically following oral administration.  We will consider KTZ–PAA as the model 
system. The highly acidic gastric fluid will favor the solubility of KTZ.  As the dissolved 
ASD transitions to the intestine, drug crystallization would likely be prevented, if the drug–
polymer interaction persists.  Even though soluble drug–polymer complexes can, in 
principle, inhibit release of free drug, the low association constant (𝐾𝑎) obtained for the 
KTZ–PAA system, suggests that drug release and subsequent drug absorption, would not 
be inhibited.  
 
2.5 SIGNIFICANCE 
This study provides mechanistic insights into the factors that affect the dissolution of 
ASDs, providing a basis for rational polymer selection. When a polymer that can form 
strong (e.g. ionic) interactions with the drug is selected, stable ASDs can be prepared at 
low polymer loadings.  This could accomplish multiple goals of (i) reducing the pill burden 
(ii) preventing solid state drug crystallization in the dosage form and (iii) improving the 
dissolution performance of the ASDs.  To determine the extent of generalizability of the 
hypothesis, a wider range of drug–polymer systems needs to be studied.  The next step 
would be to investigate if the dissolution enhancement observed in vitro due to strong 





In our earlier work, we showed that strong interactions (ionic, as well as hydrogen bonding) 
between ketoconazole (KTZ) and polyacrylic acid (PAA), resulted in pronounced 
reduction in both the molecular mobility and the crystallization propensity of the 
amorphous solid dispersion (ASD), in the dry, “solid” state.  Weak dipole-dipole 
interactions between KTZ and polyvinylpyrrolidone (PVP) however resulted in an ASD 
that crystallized more rapidly.  In this work, using 2D nuclear Overhauser effect 
spectroscopy, diffusion ordered spectroscopy and isothermal titration calorimetry, we 
demonstrated the existence of KTZ-PAA interactions in aqueous solution.  The solution-
state interaction translated to prolonged duration of supersaturation, reflecting resistance 
to drug crystallization in aqueous media.  Conversely, no evidence of KTZ-PVP 
interactions were observed in aqueous solution. The sustainment of supersaturation with 
PVP was much less pronounced.  The results suggest that in this system, and possibly for 
other weakly basic drugs, the interactions that stabilize ASDs in the solid state, can also be 
relevant and important in sustaining the level of supersaturation in solution.   
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Figure S2.1.  (a) Solubility of ketoconazole as a function of pH. (b) Microspecies 
distribution of ketoconazole at different aqueous solution pH values.  Protonated regions 







(a) KTZ-PHEMA ASDs 
 
(b)  KTZ-PHEMA Physical Mixtures 
 
Figure S2.2.  Dissolution profiles of crystalline KTZ, amorphous KTZ, and (a) ASDs or 
(b) Physical Mixtures, formulated with PHEMA, at polymer contents ranging between 4 
and 40% w/w (mean ± standard dev; n = 3). Experiments were in performed in pH 7.4 
phosphate buffer at 37°C.  
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Figure S2.3.  (a) Maximum dissolved drug concentration (𝐶𝑚𝑎𝑥) values, (b) cumulative 
percent drug dissolved*, obtained from dissolution profiles of amorphous solid dispersions 
(ASDs) and physical mixtures (PMs), prepared with different polymers (PAA, PHEMA or 
PVP) at polymer contents ranging between 4 and 40% w/w.  Values for crystalline and 
amorphous KTZ are included for comparison.   




1D proton NMR 
Table S2.1.  NMR peak assignments for KTZ in D2O, acidified to pH 2.5. Based on 
structure numbering scheme of Figure 2.1.  
Assignment Group Chemical shift (ppm) 
H3 Dichlorophenyl ring doublet at 7.58  
H5 Dichlorophenyl ring doublet of doublets at 7.38 
H6 Dichlorophenyl ring doublet at 7.62  
H8 CH2 link AB quartet at 4.75, 4.85   
H10 Imidazole ring single resonance at 8.68 
H12 Imidazole ring triplet at 7.16 
H13 Imidazole ring triplet at 7.38 
H15 Dioxolane multiplet within 3.85 and 4.00  
H16 Dioxolane doublet of doublets at 3.38 and 3.77  
H18 CH2 (methoxy) link ~4 (doublet of doublets) 
H21, H25 Para substituted phenyl ring AA’BB’ centered at 7.06 
H22, H24 Para substituted phenyl ring  AA’BB’ centered at 6.85 
H27, H31 Piperazine ring pair of triplets at 3.04 and 3.09 
H28, H30 Piperazine ring overlapping pair of doublets of doublets 
within 3.64 and 3.67 





Nuclear Overhauser Effect Spectroscopy (NOESY) 
(a) Neat PAA 
 
(b) Neat PVP 
 
Figure S2.4. 2D 1H1H NOESY spectra of (a) neat PAA and (b) neat PVP.   Cross peaks 






Diffusion Ordered Spectroscopy (DOSY) 
(a) KTZ alone 
 
  (b) Representative fit 
 
(c) PAA alone 
 
 (d) PVP alone 
 
(e) KTZ + PAA 
 
 (f) KTZ + PVP 
 
 
Figure S2.5 (a, c-f). Representative 2D DOSY plots of the neat drug (KTZ), the neat 
polymers (PAA or PVP), and the drug+polymer mixtures.  The solvent was D2O at pH 2.5. 
(b) Representative fit of equation (2.2) to the peak intensity vs gradient strength data. 
 






















The DOSY results are displayed as a 2D matrix with the conventional 1D chemical shift 
spectrum plotted on the horizontal (top) axis, and the diffusion coefficients plotted along 
the perpendicular (right) axis.  Diffusion peaks on each horizontal dashed line correlate 
with signals in the chemical shifts dimension, and are attributed to a specific molecular 
species121.   
 
Table S2.2.  Diffusion coefficients of neat KTZ, PAA and PVP (lines 1 to 3), and the drug 
or polymer in the drug+polymer mixtures (lines 4 to 7).  Experiments were performed in 
D2O at pH 2.5 
# Sample D (m2s-1) × 10-10 * D/D0 
1 KTZ alone 3.548  1.00 
2 PAA Alone 1.778 0.50 
3 PVP Alone 1.769 0.50 
4 KTZ in (KTZ + PAA) mixture 2.042 0.58 
5 PAA in (KTZ + PAA) mixture 1.995 0.56 
6 KTZ in (KTZ + PVP) mixture 3.236 0.91 
7 PVP in (KTZ + PVP) mixture 1.715 0.48 
8 D2O 17.780 5.01 
*Standard errors from fit of equation (2.2) to the intensity vs gradient strength data, on the 






Isothermal Titration Calorimetry (ITC) 
 
 [𝐷𝑟𝑢𝑔] + [𝑃𝑜𝑙𝑦𝑚𝑒𝑟]
𝐾𝑎








1 − 𝑋𝑅 − 𝑟
2√(1 + 𝑋𝑅 + 𝑟)2 − 4𝑋𝑅
] + 𝑄𝑑𝑖𝑙 
(S2.2) 
 
Equation (S2.1) assumes as simple 1:1 interaction between the drug and polymer, with an 
association constant 𝐾𝑎. In equation (S2.2), 𝑄 is the heat recorded, [𝑋]𝑡 is the molar 
concentration of injectant at time t, ∆𝐻𝑜is the molar enthalpy change,  𝑉0 is the initial 
volume of the sample cell, 𝑋𝑅 is the mole ratio of drug to polymer in the sample cell, and 
𝑄𝑑𝑖𝑙 is the molar enthalpy of dilution, an adjustable parameter included to account for the 






where 𝑛 is the stoichiometric ratio and [𝑀]𝑡 is the molar concentration of polymer at time 
𝑡.  The Gibbs free energy change (∆𝐺), enthalpy change (∆𝐻) and entropy change (∆𝑆), 
can be calculated from the fundamental thermodynamic relation:  
 ∆𝐺 = −𝑅𝑇𝑙𝑛𝐾𝑎 = ∆𝐻 − 𝑇∆𝑆 (S2.4) 
 
where 𝑅 is the universal gas constant, and 𝑇 is temperature.  
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In the standard one-sites model, 𝑛, the stoichiometry number, represents the average 
number of drug binding sites per mole of macromolecule in the solution, with the 
assumption that all sites are identical and independent.  In standard ITC fitting, the 
stoichiometry number can be obtained from the fit. However, for isotherms with weak 
affinity, (commonly termed low “𝑐” data), the stoichiometry number can be fixed at 1, to 
reduce the number of variables, and increase the confidence in the fitted enthalpy change 
parameter.  A global fit of the individual isotherms obtained before concatenation (see 
methods section for additional details) was performed, and the thermodynamic signature 





3 Analytical Ultracentrifugation for the Characterization of 






3.1  OVERVIEW 
We present a new approach for characterizing drug–polymer interactions in aqueous 
media, using sedimentation velocity analytical ultracentrifugation (AUC).  We investigated 
the potential interaction of ketoconazole (KTZ), a poorly water-soluble drug, with 
polyacrylic acid (PAA) and polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol 
graft copolymer (Soluplus®) in aqueous buffers. The effect of the polymer on the 
sedimentation coefficient of the drug, was the observable metric. The drug alone, when 
subjected to AUC, exhibited a very narrow sedimentation peak at 0.2 Svedberg (S), in 
agreement with the expectation for a monomeric drug with a molar mass <1000 Dalton. 
Conversely, the neat polymers showed broad profiles with higher sedimentation 
coefficients, reflecting their larger more heterogeneous size distributions.  The 
sedimentation profiles of the drug–polymer mixtures were expectedly different from the 
profile of the neat drug. With KTZ-Soluplus®, a complete shift to faster sedimentation 
times (indicative of interaction) was observed, while with KTZ-PAA, a split peak indicated 
the existence of the drug in both free and interacting states.  The sedimentation profile of 
carbamazepine, a second model drug, in the presence of hydroxypropyl methyl cellulose 
acetate succinate (HPMCAS, another polymer), revealed multiple “populations” of drug–
polymer species, very similar to the sedimentation profile of neat HPMCAS.  The 
interactions probed by AUC, were compared with the results from isothermal titration 
calorimetry. In vitro dissolution tests performed on amorphous solid dispersions prepared 
with the same drug–polymer pairs, suggested that the interactions may play a role in 
prolonging drug supersaturation.  The results show the possibility of characterizing drug–
polymer interactions in aqueous solution with high hydrodynamic resolution, addressing a 
major challenge frequently encountered in the mechanistic investigations of the dissolution 
behavior of amorphous solid dispersions.  
 
Keywords: Sedimentation Velocity Analytical Ultracentrifugation, Amorphous Solid 





When given orally, a solid drug must first dissolve in the gastrointestinal fluid, before being 
absorbed into the bloodstream3.  Unfortunately, about 80% of drugs in the development 
pipeline are crystalline hydrophobic compounds, with poor aqueous solubility4,131.  
Therefore, a key focus in pharmaceutical science research is to develop strategies that could 
overcome this solubility challenge5.  One approach is to formulate amorphous solid 
dispersions (ASDs), wherein the drug is mixed with a polymer, at the molecular level, to 
form a homogeneous phase4,5,12.    
 
One major consideration in formulating an ASD into a solid dosage form, is to prevent 
drug crystallization during the shelf life of the product.  Strong intermolecular interactions 
between the drug and polymer (particularly ionic and hydrogen bonding interactions) can 
result in ASDs which are physically stable for timescales of pharmaceutical interest52,61,89.  
When the ASD is taken by the patient, supersaturated drug concentrations may be achieved 
in the gastrointestinal fluid12.  To realize the solubility advantage, drug crystallization 
should also be prevented for a period, long enough to allow absorption to occur2.  A widely 
held view is that an optimum strength of drug–polymer interaction in solution, is required 
to maintain the desired level of supersaturation14,94,132.  If the interaction is too weak, the 
drug may rapidly crystallize from solution.  If the interaction is too strong, it is possible 
that the drug–polymer complex may not dissociate and, in spite of being in solution, the 
drug may be unavailable for absorption.  Adequate characterization of the nature and 
strength of drug–polymer interactions in aqueous solutions therefore aids, both in 
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understanding and interpreting, the in vitro drug dissolution profiles14.  Analytical methods 
that can provide molecular-level information on the formation, composition, structure, size 
and stability of the drug–polymer complexes are thus required.  
 
Techniques for characterizing interactions between heterogenous species in solution 
include vibrational spectroscopy (e.g. infrared, Raman), fluorescence and nuclear magnetic 
resonance (NMR) spectroscopy and isothermal titration calorimetry78.  One dimensional 
(1D) vibrational spectroscopic techniques utilize shifts and general changes in 
characteristic vibrational bands of functional groups of the drug or polymer to indicate 
hydrogen bonding or ionic interactions15,89.  The congested nature of 1D spectra, with 
numerous overlapping vibrational modes, poses a significant challenge in making 
unambiguous peak assignments89.  Moreover, the broad infrared absorbance band from 
water, especially in the 3000 cm-1 region, occludes signals from functional groups of 
interest, making it impossible to observe spectral changes of drugs in aqueous 
solutions15,89,133,134.  Even though Raman spectroscopy is transparent to water, the signals 
from poorly soluble drugs tend to be very weak with high fluorescence backgrounds.   
 
As an advancement over 1D spectroscopy, two-dimensional (2D) NMR methods provide 
more reliable information on drug–polymer interactions. In 2D nuclear Overhauser effect 
spectroscopy (NOESY), resonances are spread along multiple axes, giving a frequency 
correlation spectrum120.  If the drug and polymer are within 5 Å of each other in solution, 
cross peaks will develop indicating interactions94,96,135.  Interactions in solution can also be 
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indirectly probed with diffusion measurements (via the principle of co-diffusion).97,121,122 
A reduction in drug diffusivity in the presence of a polymer, is often indicative of 
interaction.  Of the several solute diffusion measurement techniques (e.g. dynamic light 
scattering, fluorescence correlation spectroscopy, asymmetric flow field flow 
fractionation, or NMR diffusion), only two-dimensional diffusion ordered spectroscopy 
(2D DOSY) has been successfully adapted for this application.  DOSY allows simultaneous 
spectroscopic separation of the diffusion coefficients of heterogeneous species in solution 
(in a sense, reminiscent of chromatography)96,98,135.   
 
A significant barrier to the use of all these techniques stems from the weak signal of the 
drug–polymer systems in aqueous media.  NMR in particular, inherently has a lower 
sensitivity than many other spectroscopic methods136.  Similarly, the need for very high 
drug concentrations almost entirely precludes the use of isothermal titration calorimetry 
(ITC)105.  While organic solvents can be used, interactions probed in such systems, do not 
reflect interactions in aqueous solution137.  Other techniques that can address the challenge 
of poor signal sensitivity in aqueous media, must therefore be explored.  
 
Analytical ultracentrifugation (AUC) is a powerful fractionation-based technique, used 
extensively to characterize the hydrodynamic and thermodynamic properties of 
biomacromolecules (e.g. proteins), colloidal systems, and nanoparticles138–140.  AUC 
measures sedimentation or diffusion coefficients, from which the size, density, and shape 
of heterogeneous species in solution can be obtained141.  Detection systems based on UV-
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visible absorbance, fluorescence, or interference optics, make this technique amenable to 
a wide range of applications.  The high sensitivity of the detection systems is particularly 
valuable for analytes with low aqueous solubility.  Although AUC is suitable for the study 
of most macromolecules, the technique suffers low patronage in the investigation of 
synthetic polymers142,143.  There are no reports on the sedimentation behavior of 
pharmaceutically-relevant (mostly synthetic) polymers typically used in ASD 
formulations.  It is also not known, whether the interaction of such polymers with small 
molecule drugs in aqueous solution, can be adequately measured with AUC.   
 
In this work, we highlight an opportunity to semi-quantitatively characterize drug–polymer 
interactions in aqueous solution, using sedimentation velocity analytical 
ultracentrifugation (AUC).  The drug sedimentation coefficient, in the presence and 
absence of the polymer, is the metric.  The free drug (in this context, small molecule with 
low density and molar mass less than 1,000 Da), will hardly sediment.  In comparison, the 
bulky polymer (> 10,000 Da) should sediment rapidly.  We hypothesize that when the drug 
interacts with the polymer, the sedimentation rate of the complexed drug changes, and 
approaches the sedimentation behavior of the neat polymer.  The drug movement in the 
presence of the polymer can be monitored, if the UV-vis spectrum of the drug exhibits 
pronounced absorption in a wavelength region where the polymer does not absorb.  This 
new AUC-based method would be analogous to the co-diffusion method used for 




We tested this method with two model hydrophobic drugs – carbamazepine (CBZ, an anti-
epileptic) and ketoconazole (KTZ, an anti-fungal) – and three polymers.  The structures are 
shown in Figure 3.1, and the reasons for selecting each drug–polymer pair are given in 
Section 3.3.1.     
 
Our main objective was to evaluate the potential utility of sedimentation velocity analytical 
ultracentrifugation (AUC) to characterize drug–polymer interactions in aqueous media.  
We also compared the results of the AUC method, to interactions probed via isothermal 
titration calorimetry (ITC).  Finally, the possible effects of the interactions on the in vitro 
dissolution performance of amorphous solid dispersions were discussed.  
 
 
3.3 EXPERIMENTAL SECTION 
3.3.1 Selection of model systems 
Three drug–polymer pairs were used in this study: (i) ketoconazole (KTZ) and poly acrylic 
acid (PAA), (ii) ketoconazole and Soluplus® and (iii) carbamazepine (CBZ) and 
hydroxypropyl methyl cellulose acetate succinate (HPMCAS).  The structures are shown 
in Figure 3.1. 
 
In amorphous solid dispersions, the carboxylic acid groups of PAA, a linear polymer, were 
shown to interact with the imidazole nitrogen of KTZ52.  The strong (ionic and hydrogen 
bonding) interactions translated to a pronounced resistance to drug crystallization, 
following storage of the KTZ-PAA dispersions in both the glassy and supercooled 
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states93,100.  Our preliminary investigations (using 2D H1H1 NOESY and 2D DOSY) also 
showed that the drug–polymer interactions persisted in aqueous media144,145.   Soluplus®, 
the second model polymer, is a commercial polyvinyl caprolactam—polyvinyl acetate—
polyethylene glycol graft co-polymer that was specifically designed with amphiphilic 
groups for ASD formulation50,146. It forms micelles in water, conferring the  ability to 
enhance the solubility of  hydrophobic compounds146.  Having no ionizable functional 
groups, ionic interactions with KTZ would be unlikely.  Hydroxy propyl methyl cellulose 
acetate succinate (HPMCAS, the third polymer), is widely used in amorphous solid 
dispersion formulations and facilitates the formation of stable supersaturated 
solutions14,147.  Interaction of HPMCAS with CBZ in the dry solid form, was recently 
characterized148.  Furthermore, with NMR (2D NOESY and saturation transfer difference) 
experiments, it was shown that hydrophobic-driven associations between CBZ and 
HPMCAS exist in aqueous buffers94.  The interaction was correlated with a reduction in 
carbamazepine recrystallization from supersaturated solutions149. The three drug–polymer 
pairs, KTZ–PAA, KTZ–Soluplus and CBZ–HPMCAS, were therefore expected to provide 
different types of interactions in solution. 
 
3.3.2 Materials 
Carbamazepine (Sigma, USA), ketoconazole (Laborate Pharmaceuticals, Haryana, India) 
Soluplus® (BASF, USA), HPMCAS, HF grade (Ashland, USA) and PAA (Sigma, USA) 
were used as received (Figure 3.1). All reagents and chemicals used to prepare the buffers 








   
Figure 3.1.   Structures and average molecular weights (𝑀𝑤) of the drugs and polymers. 
(a) carbamazepine (CBZ), 236 Da, (b) ketoconazole (KTZ), 531 Da, (c) polyvinyl 
caprolactam—polyvinyl acetate—polyethylene glycol graft co-polymer (Soluplus®), 
115,000 Da (ref146), (d) hydroxypropyl methyl cellulose acetate succinate (HPMCAS), 
17,000 Da (ref150), (e) polyacrylic acid (PAA), 1,033,000 Da.  
  
(a) CBZ (b) KTZ 





3.3.3 Preparation of amorphous solid dispersions 
Amorphous solid dispersions (ASDs) with 33% w/w drug loading were prepared by solvent 
evaporation. For each system, the drug and polymer were individually dissolved in 
appropriate organic solvents (KTZ, Soluplus®, PAA and HPMCAS-HF in methanol; CBZ 
in ethanol).  The solutions were combined and the solvent rapidly evaporated, at 50 °C 
under reduced pressure (IKA-HB10 digital system rotary evaporator, Werke GmbH and 
Co., Staufen, Germany).  The solid dispersions were further dried at room temperature for 
24 hours to remove any residual solvent, lightly ground using a mortar and pestle in a 
glovebox (RH < 5%), sifted (250 µm pore size) and stored at -20 °C in desiccators 
containing anhydrous calcium sulfate, before use.  All ASDs prepared were found to be 
amorphous when characterized by powder X-ray diffractometry [model D8 ADVANCE; 
Bruker AXS, Madison, WI, using Cu Kα radiation (40 kV × 40 mA) over an angular range 
of 5−35° 2θ with a step size of 0.05° and a dwell time of 0.5 s]. 
 
3.3.4 Preparation of buffers and solutions 
Phosphate buffer (pH 6.8; 50 mM monobasic potassium phosphate and 22.4 mM sodium 
hydroxide) and hydrochloric acid buffer (pH 1.1; 106 mM hydrochloric acid and 50 mM 
potassium chloride) and were used.  Separate stock solutions of drug (up to 1 mg/mL) and 
polymer (~15 mg/mL) were prepared by dissolving an accurately weighed amount of 
material in the buffer followed by filtration (0.45 µm pore filter).  Aliquots of the stock 
solutions were pipetted into a vial and diluted with buffer to obtain solutions with the 
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required final compositions for ITC and AUC experiments (details in Table 3.1).  The pH 
of all samples (drug solutions, polymer solutions or their mixtures) did not differ by more 
than ±0.1 units of the required value. 
 
3.3.5 UV-Vis spectroscopy 
UV/visible absorbance spectra were recorded in the 200-600 nm range (Cary 100 Bio, 
Agilent Technologies), using a quartz cuvette with a path length of 1 cm. 
  
3.3.6 Analytical ultracentrifugation 
Concentrations of solutions (i.e. neat drug, neat polymer, and drug–polymer mixtures), as 
well as solvents used in each case, are summarized in Table 3.1.  Concentrations were 
chosen such that an optical density of ~0.6 would be obtained, at the desired wavelength 
of detection for the AUC experiments.  
 
Table 3.1. Solvents and solution concentrations used in the AUC experiments. 












Drug : Polymer 
ratio  
(by weight) 
Ketoconazole and PAA 1.1 0.25 0.5000 (0.25) + 0.50 1:2 
Ketoconazole and Soluplus®  1.1 0.25 0.0625 (0.16) + 0.33 1:2 
Carbamazepine and 
HPMCAS 
6.8 0.04 4.0000* (0.04) + 4.00 1:100 




KTZ, PAA and Soluplus experiments were performed at the Center for Analytical 
Ultracentrifugation of Macromolecular Assemblies at the University of Texas Health 
Science Center at San Antonio, using an analytical ultracentrifuge (Optima AUC, Beckman 
Coulter, Indianapolis IN) equipped with multi-wavelength UV-visible detection 
(absorbance optics).  Samples were placed into Epon centerpieces with quartz windows, 
and measured at 20°C, 45000 rpm, in an An50Ti rotor. CBZ and HPMCAS experiments 
were performed at the Canadian Center for Hydrodynamics at the University of Lethbridge, 
Alberta, Canada.  Samples were placed into titanium centerpieces (Nanolytics Instruments, 
Potsdam, Germany) with sapphire windows and measured at 20°C, 60000 rpm, in an 
An60Ti rotor.  Approximately 500 scans were collected for each wavelength.  Data 
analyses were carried out with standard models implemented in the UltraScan III® 
software151,152, using the two-dimensional spectrum analysis (2DSA)153, coupled with 
Monte Carlo analysis154, and the parametrically constrained spectrum analysis (PCSA)155.  
Briefly, these methods model sedimentation velocity data with linear combinations of finite 
element solutions of the Lamm equation156 to obtain sedimentation and diffusion 
coefficients (𝑠 and 𝐷 values respectively).  The 2DSA-Monte Carlo analysis was used to 
obtain an unconstrained sedimentation/diffusion profile of the hydrodynamic parameter 
space. Due to the lack of constraint, for experiments with low signal, there was a possibility 
that the 2DSA algorithm occasionally would fit the noise in the experimental data, leading 
to artifactual results. The PCSA analysis would further constrain the fitted data, reducing 
noise contributions, and also detect size-vs-anisotropy trends for polymerizing systems, 
should they exist.  Computationally intensive calculations were carried out on high-
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performance supercomputing platforms.  Sedimentation coefficient values were 
standardized to water at 20 °C (𝑠20,𝑤).  The profiles were normalized by dividing each data 
point in the original distribution by the maximum 𝑑𝐶/𝑑𝑠 data point, so that the peak 
maximum for each distribution was equal to 1. 
 
3.3.7 Isothermal titration calorimetry (ITC) 
KTZ solution (20 mg/mL) was prepared in buffer (pH 1.1 ± 0.1), and filtered (0.45 µm 
PTFE), immediately before each ITC experiment.  Solutions of PAA (5 mg/mL) and 
Soluplus® (5 mg/mL), were also prepared in the same buffer (pH 1.1 ± 0.1).     
  
A microcalorimeter (MicrocalTM Auto-ITC200 system, Malvern Instruments, MA) which 
has a 200 uL sample cell and an identical reference cell, was used.  The drug solution in 
the syringe, was sequentially injected into the polymer solution within the sample cell, with 
a constant stirring rate of 750 rpm.  The temperature was maintained at 25 °C.  The first 
injection was a 0.4 µL aliquot to remove the effect of solute diffusion across the syringe 
tip during the equilibration period.  Subsequently, 4 µL injections were made into the 
sample cell. The duration of each injection was 20 s, and the time interval between 
successive injections was 180 s. The run time was extended by performing experiments in 
an automated “continued injection” mode, wherein, when full, 30 uL of solution was 
withdrawn from the sample cell, to make room for more sequential injections of the titrant.  
This process of withdrawing solution from the sample cell and continuing the titrations was 
repeated for up to four experiments.  Individual experiments were concatenated using the 
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Microcal origin® concat (add-on) software.  Data processing, integration and analysis was 
done with the Affinimeter® software106. 
 
3.3.8 Powder in vitro dissolution 
Dissolution tests under non-sink conditions were performed with a USP Apparatus II 
(Varian 705 DS, Agilent Technologies, Santa Clara, CA).  Each sample, containing 250 
mg of drug, was dispersed in 250 mL of dissolution medium (pH 6.8 buffer) set at 37 °C 
and stirred with a paddle speed of 100 rpm.  Aliquots (2 mL) were withdrawn at each time 
point, filtered (0.45 µm pore size, Whatman® PP) and diluted appropriately with methanol.  
The drug concentration in the filtrate, was determined by high performance liquid 
chromatography (HPLC; Nexera XR® system, Shimadzu, Japan).   
 
Chromatographic separation was performed using a reversed-phase column (Zorbax® 
Eclipse XDB-C18, 4.6 x 150 mm, 5 μm, Agilent, USA). The mobile phase consisted of 
2.55 g of tetrabutylammonium hydrogen sulfate dissolved in 750 mL of water and diluted 
to 1000 mL with acetonitrile.  The flow rate was 1 mL/min at 30 °C.  Injection volumes, 
detection wavelengths and retention times were respectively; 20 µL, 223 nm, 4 min for 
KTZ and 5 µL, 230 nm, 14 min for CBZ.  Drug concentrations were calculated from linear 





3.4 RESULTS AND DISCUSSION 
In general, upon dissolution of an amorphous solid dispersion, the three main species that 
may exist in solution are: (i) free drug, (ii) free polymer, and (iii) various types of drug–
polymer aggregates or complexes14.  Both free and complexed drug contribute to the total 
drug concentration measured via in vitro dissolution tests14.  Any technique that can 
independently monitor the differing rates of solute transport (e.g. diffusion, sedimentation) 
and/or the relative amounts of each of these species in solution can, in principle, provide a 
measure of the drug–polymer interactions.  This formed the basis for the experimental 
design.   
 
In a typical sedimentation velocity AUC experiment, the dissolved solute within a sample 
cell, is exposed to a high centrifugal field, induced by the spinning of the centrifuge rotor.  
The solute transport is tracked by an optical detection system (in this case, UV multi-
wavelength absorbance optics) that measures the concentration change of the sample, as a 
function of time and sample cell radius (see supporting information).  The procedure for 
selecting UV absorbance wavelengths, which allows the sedimentation coefficient (𝑠-
value) distribution of different species in solution to be monitored, is explained in the next 
section.  
 
3.4.1 Wavelength selection for analytical ultracentrifugation 
Utilizing absorbance optics, the first step involved examination of the UV absorbance 
profiles of the (i) neat drugs (ii) neat polymers and (iii) drug–polymer mixtures.  The main 
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consideration was to identify a wavelength region where the neat drug has a strong 
absorbance, but where the neat polymer does not absorb. The spectra of the samples are 
shown in Figure 3.2. Solution compositions and buffers used as solvent are listed in Table 
3.1. 
  
Carbamazepine exhibits pronounced absorbance at wavelengths < 250 nm, as well as a 
peak at 270 nm (Figure 3.2a, blue-dashed profile).  The AUC optics can be tuned to any 
wavelength at which the drug absorbs, to observe the sedimentation of the neat drug.  The 
neat polymer HPMCAS, on the other hand, only absorbs significantly at wavelengths < 
250 nm (Figure 3.2a, violet dashed line profile), such that its sedimentation can only be 
monitored at wavelengths < 250 nm.  In the 250–330 nm wavelength region, the 
absorbance of the neat drug is much higher than the absorbance of the neat polymer, such 
that the polymer does not contribute significantly to the absorbance of the drug–polymer 
mixture.  The AUC optics can therefore be tuned to any wavelength in the 250–330 nm 
range, to observe the migration of the drug in the presence of the polymer.  The UV profiles 
of ketoconazole and the polymers, PAA and Soluplus®, exhibit qualitatively similar 
characteristics (Figure 3.2b).   
 
By monitoring the sedimentation profile of the drug–polymer mixture at a wavelength 
where only the neat drug absorbs, the sedimentation experiment becomes selective for the 
drug and any drug–polymer complexes formed. If the neat polymer sediments faster than 
the neat drug, any increase in the sedimentation coefficient of the drug within the polymer 
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matrix, will provide evidence of drug–polymer interactions.  This is the principle upon 
which the drug–polymer interactions were monitored.  It should be noted, however, that 






Figure 3.2. UV absorbance spectra of neat drugs, neat polymers, and (drug + polymer) 
mixtures. (a) carbamazepine alone, HPMCAS alone and the (CBZ + HPMCAS) mixture.  
(b) Ketoconazole alone, PAA alone, Soluplus® alone, the (KTZ + PAA) mixture and the 
(KTZ + Soluplus®) mixture. Solute concentrations and solvent systems are listed in Table 
3.1. 
 
3.4.2 Sedimentation profiles of neat drugs and polymers 
Sedimentation profiles of the neat drugs and neat polymers are presented in Figure 3.3.  
The corresponding experimental raw data plots, as well as the fitting residuals, which were 
mostly randomly distributed, are provided in the supplementary information (Figure S3.1 
to Figure S3.5; see AUC experimental methods for details of data analyses). When either 




































(a)  (b)  
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alone, a very narrow sedimentation peak at 0.2 S was observed.    Posaconazole, another 
drug with a slightly higher molecular weight (𝑀𝑤 = 701 Da), also showed a sedimentation 
coefficient at 0.2 S (data not shown).  The identical sedimentation profiles are in excellent 
agreement with the expectation that monomeric molecules with low molecular weights 
(<1000 Dalton) hardly sediment, and are at the limit of detectability by analytical 
ultracentrifugation141. 
 
The neat polymers, however, had very different sedimentation profiles. PAA, a linear 
polymer, was present in solution as a heterogeneous mixture sedimenting between 0 and 
50 S (Figure 3.3c).  The high molecular weight (1,031,000 Da), long chains (~14,300 
monomers per chain) and high dispersity index of 7.9, contribute to the broad, skewed 
sedimentation coefficient distribution.  The larger aggregates between 10 and 50 S are 
likely from chain entanglement109.  Soluplus®, with molecular weight an order of 
magnitude lower than that of PAA, had a narrower, more homogeneous size distribution 
(from 0-4 S) and a negligible number of larger aggregates (Figure 3.3d).  Soluplus® is 
amphiphilic, and the concentration examined was well above the reported critical micelle 
concentration of 0.0076 mg/mL146.  
 
The sedimentation profile of neat HPMCAS however showed five well-defined peaks, 
from 0 to 2 S (Figure 3.3e). The molecular weight (~17,000 Da) is significantly lower than 
that of PAA or Soluplus®, resulting in a narrower range of 𝑠-values.   The sharpness of the 
peaks however suggests that in solution, HPMCAS migrates as discrete, light species 
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which is a rather surprising observation.  Of note, all polymer solutions were measured at 
sufficiently low concentrations to avoid non-ideal sedimentation83,157,158.  Because of the 
amphiphilic nature of HPMCAS, a widely-held view is that any higher order structures in 
solution will be due to colloidal aggregation or gelation14,147.  Friesen et al, using cryogenic 
transmission electron microscopy, characterized a range of  nanometer-sized structures 
(mainly 10-20 nm polymer colloids, and a few 70-300 nm nanoaggregates) formed by 
HPMCAS in aqueous buffer (pH 6.8)14.  They posited that because HPMCAS is partially 
ionized at pH 6.8, the charge on the polymer allows the colloids to remain stable, while 
minimizing the formation of much larger aggregates14.  Ricarte et al however suggested 
that the large species, also observed with light scattering measurements over a wide 
concentration range (0.01 to 9 mg/mL), were from chain coupling (i.e. covalently cross-
linked chains) and not from colloidal aggregation159.  Both scenarios could result in the 
discrete sedimenting fractions observed in this study.  It is also possible, that the different 
combinations of acetyl and succinoyl substituents of the cellulose backbone (the R and R1 
groups of Figure 3.1d), result in polymer fractions that sediment at different speeds.  If the 
latter explanation holds, the sedimentation profiles of neat polymer solutions manufactured 
to different specifications may be characteristic, allowing use of the technique as a quality 
control measure. Clearly, this interesting sedimentation profile warrants further 













Figure 3.3.  Sedimentation profiles of the neat drugs and neat polymers. (a) CBZ alone, 
observed at 315 nm, (b) KTZ alone, observed at 262 nm (c) PAA alone observed at 215 
nm, (d) Soluplus® alone observed at 215 nm and, (e) HPMCAS alone observed at 220 nm.  
Solution concentrations and solvent systems are listed in Table 3.1. 
 











































































































3.4.3 Sedimentation profiles of drug–polymer mixtures  
Sedimentation profiles of the drug–polymer mixtures, each overlaid with the profile of the 
corresponding neat drug, are presented in Figure 3.4.  Experimental raw data for each 
sample, as well as the fitting residuals, have also been provided in the supplementary 
information (Figure S3.6 to Figure S3.8).  For each sample, shifts to higher sedimentation 
coefficient values (𝑠-values) were observed, which can be attributed to drug–polymer 
interactions.   
 
The KTZ-Soluplus® mixture (Figure 3.4a, bottom profile) showed a complete shift in 𝑠-
value, suggesting that the drug molecules migrate at the same rate (in a single distribution) 
in the presence of the polymer.  For the KTZ-PAA mixture, a split peak was observed; the 
first peak at 0.2 S, which matches the peak position of neat KTZ, and the second peak 
centered at 0.3 S, a faster sedimentation rate compared to the neat drug (Figure 3.4b).  This 
observation suggests a mixture of free (30%, at 0.2 S) and “interacting” (70%, at 0.3 S) 
drug fractions respectively, at the concentration level evaluated.   
 
The sedimentation profile of the CBZ-HPMCAS system shows four peaks, in the 0 to 2 S 
region (Figure 3.4c, green bottom profile).  Evidently, this profile is very different from 
the single sharp peak of the neat drug, and more closely resembles the profile of neat 
HPMCAS (Figure 3.4c, middle profile).  The first peak of the drug–polymer mixture 
appears at 0.3 S (~ 0.1 S shift in 𝑠-value, when compared to the neat drug) indicating that 
there is no free drug fraction.  The three additional peaks of the drug–polymer mixture, 
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which appear at 0.6, 1.1 and 1.7 S, match the peak positions of the neat polymer.  The peak 
positions and corresponding peak areas for all the drug–polymer pairs, are listed in  
Table 3.2.  If the multiple peaks of neat HPMCAS indeed result from the diverse 
substituent units of the cellulose backbone, this observation would mean that CBZ 
preferentially partitions into different polymer fractions.  The ability to quantify with high 
resolution, the different fractions of drug–polymer complexes, is indeed a key advantage 







Figure 3.4.  Sedimentation profiles of drug–polymer mixtures. (a) KTZ-Soluplus observed 
at 262 nm, stacked with KTZ alone.  (b) KTZ-PAA observed at 262 nm, stacked with KTZ 
alone. (c) CBZ-HPMCAS observed at 315 nm, stacked with CBZ alone and HPMCAS 
alone.  The peak positions of drug–polymer mixtures are indicated with dashed vertical 
lines.  The percentage abundance of different fractions are pointed out with arrows (see 
Table 3.2).  




























































Table 3.2.  Peak positions and peak areas for the neat drugs, the neat polymers and the 






Neat CBZ (or KTZ)  0.2  100.0 
Neat Soluplus® 1.2  100.0 
Neat PAA  4.4  100.0 










KTZ + Soluplus®* 0.3  100.0 
KTZ + PAA* 0.2  30.7 
0.3  69.3 
*The shifted peaks, when measured in the presence of the polymer, were baseline resolved 
from the peaks observed for the neat drug.  A 50-iteration Monte Carlo analysis (see 
Section 3.3.6 for details) did not detect any variation in the results.  
 
3.4.4 General inference from AUC results 
Overall, the AUC results suggest that the drugs form very weak associations with the 
polymers, that are much weaker than binding interactions conventionally probed by 
sedimentation velocity AUC, such as ligand-protein, or protein-protein interactions138,160. 
This inference is made because the magnitude of the shift in sedimentation coefficient of 
the drug–polymer mixture (relative to the drug alone), is rather small.   If the drug were 
tightly bound to the polymer, the sedimentation pattern of the drug–polymer mixture would 
have mirrored the sedimentation pattern of the neat polymer.  The CBZ-HPMCAS system 
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gives closest support of this expectation.  However, for the KTZ-polymer systems, only 
subtle shifts in drug sedimentation coefficient were observed, indicating that a weight 
average free- versus interacting-drug sedimentation is favored by the free state.  The weak 
shifts in the 𝑠-value, make it impossible to perform additional analyses of the sedimentation 
data, which could have allowed extraction of other thermodynamic information.  
Nonetheless, the percent abundance of the various species, obtained from the peak areas, 
allows for semi-quantitative rank-ordering of the interaction strengths.  
 
3.4.5 Isothermal titration calorimetry (ITC) 
Isothermal Titration Calorimetry (ITC) provided an avenue to assess the energetics of the 
drug–polymer interactions in aqueous solution.  Generally, ITC experiments require very 
high ligand (the drug in this case) concentrations so as to obtain data sets optimal for the 
reliable determination of thermodynamic parameters105.  This condition is typically not met 
for drugs with poor aqueous solubility.  However, we took advantage of the pH-dependent 
aqueous solubility of KTZ.  Being a weak base (pKa values of 6.5 and 2.9), KTZ is 
practically insoluble at pH > 4, but highly soluble in acidic buffers (pH < 2.5; 20°C)107.  A 
solution with a high drug concentration (~20 mg/mL) could thus be prepared in acidic 
solvent, making it possible to perform ITC experiments.  Conversely, because the aqueous 
solubility of CBZ is very low (<0.22 mg/mL) at all pH values, ITC experiments with CBZ 




Figure 3.5a shows the power compensation signals for the titration of KTZ into PAA.  
Exothermic peaks were initially registered, which progressively decreased in magnitude as 
the drug was titrated into the polymer solution.  The control experiments, comprising 
titration of drug solution into the blank buffer, or the titration of buffer into polymer 
solution (respectively labeled as KTZ, and PAA in Figure 3.5a) yielded negligible heats.   
 
The peaks obtained for the titration of drug into polymer, were integrated to obtain the heat 
change (∆𝑄) at each injection and then plotted as a function of the drug-to-polymer ratio 
in the sample cell (Figure 3.5c).  The shape of the curve obtained for KTZ-PAA, is typical 
for binding interactions with weak affinity (association constants less than 104 M-1)105,125.  
An overall enthalpy change of -10.2 kcal/g was obtained when the data was analyzed with 
an independent sites fitting method106, indicating an enthalpy-driven interaction.  The 
titration of KTZ into Soluplus (Figure 3.5b) however showed very weak peaks (~0.5 
µcal/sec), of the same magnitude as the peaks from the drug dilution experiment, resulting 
in a flat, featureless binding isotherm (Figure 3.5c).   
 
The ITC experiments (via the shape of the binding isotherm) confirm the inference from 
the AUC experiments, that drug–polymer interactions are generally very weak.  The KTZ-
PAA exothermic heats are most likely from electrostatic interactions between the 
carboxylic acids of the polymer (pKa 4.5) and the ionizable imidazole groups of the drug 
(see Figure 3.1).  Soluplus on the other hand, has no ionizable functional groups or 
hydrogen bond donors (except the end groups).  Thus, (ionic or hydrogen bonding) 
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interactions of KTZ with Soluplus would be unlikely, providing a reasonable explanation 




Figure 3.5. ITC raw data measured during the stepwise injection of KTZ (20 mg/mL) into 
(a) 5 mg/mL PAA (b) 5 mg/mL Soluplus.   The solvent was pH 1.1 buffer. Each panel also 
has the profile for the titration of drug into plain buffer (labeled as KTZ, offset by 2.5 units 
on the vertical axis for clarity) and the profile for titration of buffer into polymer solution 
(labeled PAA or Soluplus, offset by 5 units).  (c)Overlay of the integrated heat data (∆𝑄 
per gram of drug injected) as a function of the drug-to-polymer ratio in the sample cell 
(concentrations expressed in mg/mL).  
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3.4.6 Dissolution of amorphous solid dispersions 
The in vitro performance of amorphous solid dispersions (ASDs) prepared by solvent 
evaporation, was evaluated with powder dissolution studies, conducted in pH 6.8 buffer, 
under non-sink conditions.  The dissolution profiles are in Figure 3.6, and the results are 
summarized in Table 3.3.  The maximum concentration of the neat crystalline drugs 
recovered in solution were just about the same as the equilibrium solubility values reported 
in the literature (220 µg/mL for CBZ161, and 3 µg/mL for KTZ107 at 37°C, pH 6.8).  
 
The ASDs, each at a nominal drug concentration of 1000 µg/mL, resulted in substantially 
higher dissolved drug concentration levels, compared to the neat crystalline drugs.  For the 
KTZ-PAA ASD (Figure 3.6a), a rapid surge in drug concentration was observed (𝐶𝑚𝑎𝑥 ≈ 
390 µg/mL) followed by a sharp decline to ~55 µg/mL, presumably the result of drug 
crystallization.  In contrast, a gradual rise in drug concentration was observed for the KTZ-
Soluplus® ASD, with a substantially lower 𝐶𝑚𝑎𝑥 value (~140 µg/mL) even though the 
maximum level of supersaturation was sustained for a longer duration.  The profile of the 
carbamazepine-HPMCAS ASD (Figure 3.6b), showed complete drug release within the 
first 20 minutes, with the supersaturation sustained for 24 hours.   
 
The composite effect of the extent and duration of supersaturation was quantified, by 
normalizing the area under the dissolution profile of each ASD, with the area under the 
curve of the corresponding crystalline drug.  The resulting dissolution enhancement factors 
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are presented in Table 3.3.  The dissolution enhancement of the PAA dispersion, despite 
the rapid surge in drug concentration, was about the same as the enhancement from the 
Soluplus® dispersion, over the physiologically relevant time frame (up to 8 hours, ~5-fold 
enhancement), and even when extended to a 24-hour period (~10-fold enhancement).  A 
five-fold dissolution enhancement was obtained for the CBZ-HPMCAS dispersion in 24 
hours.  It is worth noting that the nominal drug concentration for the CBZ-HPMCAS ASD 
in the dissolution vessel (1000 µg/mL), was only 4.5 times higher than the CBZ crystalline 
solubility.  Dissolution experiments performed using a higher quantity of the ASD 
(nominal drug concentration of 2200 µg/mL, 10 times the crystalline solubility) yielded a 
qualitatively similar profile, with no decline in dissolved drug concentration beyond 24 
hours (data not shown).    
 
3.4.7 Possible effects of interaction strength on supersaturation 
The polymers used in this study are hydrophilic. Thus, the initial rate of drug release from 
their ASDs will most likely be controlled by the rate at which the polymer dissolves in the 
dissolution medium16,162,163.  Rapid polymer dissolution results in immediate liberation of 
the amorphous drug, generating supersaturated solutions, as observed for the KTZ-PAA 
and CBZ-HPMCAS dispersions.  Additionally, PAA creates an acidic microenvironment, 
favorable for the dissolution of the basic drug, KTZ114.  The slower initial drug release rate 
from the KTZ-Soluplus dispersion however suggests that, despite its hydrophilic nature, 





Once the drug is released in solution, however, it is likely that drug–polymer interactions 
will play a more substantial role in sustaining the level of supersaturation16.  When the 
polymer remains associated with the dissolved drug, nucleation and crystal growth (the 
two stages of crystallization) can be prevented16.  It is reasonable to expect that the duration 
of supersaturation will be related to the fraction of drug molecules that remains associated 
with the polymer in solution, and this information can be obtained from the AUC 
sedimentation profiles.    
 
If the drug–polymer interaction strengths revealed by AUC were to be rank-ordered, CBZ-
HPMCAS (Figure 3.4c; 100% of drug molecules associated with the polymer, with strong 
shifts in 𝑠-value) would be considered the strongest interacting system, followed by KTZ-
Soluplus (Figure 3.4a; 100% of drug molecules associated with polymer, but not as strong 
a shift in 𝑠-value).  The KTZ-PAA system (Figure 3.4b) would be considered the weakest 
interacting, since 30% of the drug remained free.   
 
Interestingly, the duration of maximum supersaturation observed for the dissolution 
profiles of the amorphous solid dispersions, appear to follow a similar trend.  In the CBZ-
HPMCAS ASD, supersaturation was sustained far beyond 24 hrs; for KTZ-Soluplus, 
supersaturation was sustained for up to 6 hours, and for KTZ-PAA, supersaturation was 
sustained for just ~2 hours.  The similarity in the trends may be merely coincidental, since 
the conditions for the analytical ultracentrifugation experiments were not identical to the 
116 
 
conditions for the in vitro dissolution tests.  Particularly, while the dissolution tests were 
performed in a neutral medium (pH 6.8), the AUC experiments for the ketoconazole 
systems were performed under acidic conditions (pH 1.1, in order to increase the signal 
strength and ensure solution stability).  Furthermore, the ionization behavior of both 
ketoconazole and PAA are  pH dependent107,109, which could potentially affect the drug–
polymer interaction strengths and dissolution profiles.  Ketoconazole in acidic solvent is 
positively charged, but substantially uncharged in neutral conditions.  PAA, on the other 
hand, remains uncharged with a somewhat globular conformation in acidic solvent, but 
negatively charged with a more extended conformation in neutral solvent109.  It would 
therefore be speculative, to unequivocally attribute the trends in dissolution profiles 
observed in the current study, solely to the interaction strengths probed by the AUC 
technique.  Nonetheless, analytical ultracentrifugation adds a new dimension, i.e. 
sedimentation metrics and other hydrodynamic parameters, to investigations aimed at 
unravelling the impact of drug–polymer interactions on dissolution enhancement.  With 
other systematic studies performed on a wider range of drug–polymer systems, a clearer 
picture is likely to emerge about the relevance of the nature and the strength of interactions 
on the dissolution enhancement of amorphous solid dispersions.   





Figure 3.6.  In vitro powder dissolution profiles of amorphous solid dispersions, each at 
33 %w/w drug loading.  (a) KTZ-PAA ASD and KTZ-Soluplus® ASD (b) CBZ-HPMCAS 




Table 3.3. Dissolution test results (±standard deviation, n=3). 

































































*Dissolution enhancement factor = (area under curve of sample)/ (area under curve 
of crystalline drug) 
 




















































































































We have presented a novel approach for characterizing drug–polymer interactions in 
aqueous solution, using sedimentation velocity analytical ultracentrifugation (AUC) with 
multi-wavelength UV detection.  The uniqueness and strength of the technique stem from 
the ability to track the sedimentation behavior of the drug, in the presence and absence of 
the polymer.  We analyzed drug–polymer pairs that were expected to present different 
types of interactions in aqueous solution, based on their physicochemical properties.  In 
each case, the sedimentation coefficient (𝑠-value) of the drug–polymer complex increased, 
compared to the sedimentation of the neat drug, suggesting drug–polymer interactions.   
 
The results reveal several advantages of using AUC to provide fundamental information 
on drug–polymer association patterns. Firstly, there is the possibility of teasing out and 
quantifying the free versus interacting fractions of drug, in the drug–polymer mixtures.  
Higher interacting-drug fractions are very likely to increase the duration of supersaturation.  
Secondly, for polymers with multi-modal sedimentation profiles, there is the possibility of 
quantifying the amount of drug that partitions into different polymer “populations”.  The 
latter will be particularly beneficial for characterizing functionalized polymers designed to 
interact with specific parts of drug molecules; an approach commonly used for controlled-
release purposes.  Thirdly, for poorly-soluble drugs which possess strong chromophores, 
the high sensitivity of ultraviolet absorption makes it possible to investigate interactions 
directly in aqueous buffers, without the need for organic cosolvents, or extrinsic tags and 
labels.  Finally, the sedimentation profiles of the neat polymers in this study were unique, 
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indicating that AUC protocols could be refined and adopted for routine quality control 
testing of pharmaceutical polymers.  With adequate scientific attention, analytical 
ultracentrifugation could be a versatile tool for physicochemical characterization of 
amorphous solid dispersions.   
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3.7 SUPPORTING INFORMATION 
Brief Theory of Analytical ultracentrifugation 
An analytical ultracentrifuge is simply a high-speed (up to 60,000 rev/min) centrifuge, with 
an appropriate detecting system for simultaneously recording solute migration.  In 
sedimentation velocity AUC experiments, high centrifugal forces (up to 250000 g) cause 
the solute to migrate from the meniscus to the base of the AUC cell.  The migration of 
molecules as a function of time is characterized by the sedimentation coefficient, expressed 
in the unit of seconds, and usually reported in Svedbergs (S), where 1 S = 10-13 seconds. 
The sedimentation coefficient (𝑠), is governed by the famous Svedberg equation,  
 
𝑠 =





where 𝑀 is the molar mass, 𝑣 the partial specific volume of the solute, 𝜌𝑠 the density of 
the solvent, 𝑓 is the friction coefficient and 𝑁 Avogadro’s number.  A hydrodynamic 
radius, 𝑟, can be derived from the diffusion coefficient, 𝐷, measured in a velocity 








where 𝑅 is the universal gas constant, 𝑇 is the temperature in Kelvin, and 𝜂 is the viscosity 










Additional details of the theory of Analytical Ultracentrifugation can be found in literature 
references83,164–166. 
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Figure S3.1.  Sedimentation velocity analytical ultracentrifugation raw data for neat 









Figure S3.2.  Sedimentation velocity analytical ultracentrifugation raw data for neat 












Figure S3.3. Sedimentation velocity analytical ultracentrifugation raw data for neat 
hydroxypropylmethylcellulose acetate succinate (HPMCAS). Top: Experimental data.  











Figure S3.4. Sedimentation velocity analytical ultracentrifugation raw data for neat 











Figure S3.5. Sedimentation velocity analytical ultracentrifugation raw data for neat 
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Figure S3.6.  Sedimentation velocity analytical ultracentrifugation raw data for 










Figure S3.7.  Sedimentation velocity analytical ultracentrifugation raw data for 










Figure S3.8.  Sedimentation velocity analytical ultracentrifugation raw data for 






4 Effect of Glycerol on the Order of the Mesophase 






Itraconazole, an antifungal drug, is a thermotropic liquid crystal that exhibits nematic (N) 
and smectic A (SmA) phases, when cooled from the melt.  By means of high-resolution 
adiabatic scanning calorimetry (ASC), we have obtained the temperature dependence of 
the heat capacity as well as the enthalpy (including latent heats) of the nematic to smectic 
A (N-SmA) and the isotropic to nematic (I-N) phase transitions.  The N-SmA transition is 
weakly first-order, with substantial pretransitional heat capacity increases. The critical 
exponent 𝛼 obtained from power law fits to the heat capacity data, is 0.50 ± 0.05, 
suggesting that the N-SmA transition must be very close to a tricritical point.  Indeed, with 
this character, the small molecule dopant glycerol (in binary mixtures with ITZ), causes 
interesting changes to the mesomorphic phase sequence and to the order of the phase 
transitions.  With increasing glycerol content, the temperature width of the nematic phase 
systematically reduces, until a critical concentration, at which the nematic phase 
disappears, leading to a direct isotropic-smectic A (I-SmA) transition.  The I-SmA 
transitions of the ITZ-glycerol mixtures show stronger first-order character with substantial 
latent heats and wide two-phase regions, when compared to the (N-SmA and I-N) 
transitions of neat itraconazole.  The ability of glycerol to drive the ITZ transitions to 
stronger first-order character indicates a possible coupling of the additive concentration to 
the smectic order parameter, which leads to the development of highly ordered, stable 





Liquid crystals (LCs), have properties intermediate between crystalline solids and isotropic 
liquids.  The rich variety of intermediate phases make LCs excellent model systems for 
testing general concepts of phase transitions and critical phenomena.  In particular, the 
first-order (discontinuous) or second-order (continuous) character of the transitions, and 
the universality class of critical exponents have been, and are being, the object of 
investigations. 
 
Two of the most common mesophases are the nematic (N) and the smectic-A (SmA) 
phases167.  In the nematic phase, rod-like molecules align parallel to each other, with their 
long axes all pointing approximately in the same direction. In the smectic phase, the 
molecules maintain the orientational order and are further organized into layers.   
 
The nematic to smectic A (N-SmA) transition is one of the most extensively studied. Since 
the order in the SmA phase can be described in terms of a two-component complex order 
parameter, the N-SmA transition can be expected to be in the 3D–XY universality class36,37. 
Experiments have however shown non-universal critical behavior in some systems.  
According to the molecular field theory of McMillan and Kobayashi31,38, as well as by  de 
Gennes36,37, the N-SmA transition could be either first- or second-order in nature, 
depending on the nematic range (i.e. the temperature width of the nematic phase).  A 
narrow nematic range indicates a strong coupling between the N and SmA order 
parameters, resulting in a first-order N-SmA transition. Conversely, a wide nematic range 
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(weak coupling) gives a continuous transition.  Halperin, Lubensky and Ma, via their HLM 
theory, however suggested that the coupling between the director fluctuations and the 
smectic order parameter makes the N-SmA transition always weakly first-order168.  The 
isotropic-nematic  (I-N) transition, usually described in terms of the Landau-de Gennes 
mean-field theory, or based on the Maier-Saupe theory, should be weakly first order36,37.   
  
Due to the wide range of complex phases that can be encountered within LC systems, as 
well as the different theoretical predictions about the nature of the mesomorphic transitions, 
experimental determination of the order of phase transitions, provides a pathway to 
understand the behavior of these systems.  To establish the order of a phase transition, the 
true latent heat (or absence of latent heat) must be measured.  With differential scanning 
calorimetry (DSC), the most popular calorimetric technique, it is possible to locate the 
different LC phases with sufficiently wide temperature ranges, and to qualitatively 
characterize the magnitude of the thermal features associated with the transitions. DSC is 
however not ideally suited for confirming the order of phase transitions. This is because 
the latent heat and the pretransitional increase in the specific heat near a phase transition 
are lumped together into one thermal event (peak)33.  Distinguishing between true latent 
heats and pretransitional (fluctuation induced) enthalpy variations is almost impossible, 
thereby making it difficult to distinguish between first- and second-order transitions33.   
 
Adiabatic Scanning Calorimetry (ASC), by maintaining thermal equilibrium, continuously 
measures the enthalpy (𝐻) and the heat capacity (𝐶𝑝) as a function of temperature.  
133 
 
Continuous determination of 𝐻(𝑇), serves as a unique approach for confirming the order 
of phase transitions. An enthalpy ‘jump’, indicative of latent heat (∆𝐻𝐿), is a characteristic 
feature of a first-order (discontinuous) transition.  Second-order (continuous) transitions 
show no discontinuities in the enthalpy (∆𝐻𝐿 = 0)
20,33.  However, the heat capacity, which 
is the temperature derivative of the enthalpy [(𝐶𝑝 = (𝜕𝐻/𝜕𝑇)𝑃], exhibits a discontinuous 
jump (mean-field behavior), or a divergence (critical fluctuation behavior).  Information 
on the pre-transitional heat capacity is also needed to analyze relevant thermal aspects of 
critical fluctuations33.  With ASC, the critical behavior of different LC classes, have been 
studied.  
 
Compounds (having or lacking liquid crystalline order) are added to LCs, forming binary 
mixtures, as a means of either (i) extending the working ranges of the mesophase transitions 
or (ii) exploring unusual phase sequences.  It has been observed that non-mesogenic solutes 
broaden the I-N transition temperature leading to the subsequent formation of two-phase 
regions34.  As an example, the I-N transition temperature of 5CB (a compound of the 
alkylcyanobiphenyl homologous series) increases, when doped with molecularly rigid 
carboxylic acids, but decreases when the carboxylic acid dopants have flexible aliphatic 
chains169.  The transition temperatures shift without any effects on the magnitude of the 
total enthalpy change of the I-N transition169.  In the case of N-SmA transitions, non-
mesogenic solutes can cause a change in the order of the transition (from second- to first-
order), by coupling to the order paramters170.  Conversely, nanoparticles dispersed in liquid 
crystals can induce a decoupling mechanism of the order parameters, leading to a change 
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in the critical behavior of the bulk material171.  The unusual phase sequences that result 
from LC mixtures, find practical use in LC devices for display and telecommunication 
applications172–174.   
 
Itraconazole (ITZ), a pharmaceutical compound indicated for treatment of fungal 
infections, is a known thermotropic LC175. ITZ exhibits nematic and smectic phases, when 
cooled from the isotropic melt, with a nematic range of ~16 °C. Itraconazole is a rather 
unusual glassy LC, being one of the few compounds for which the smectic order can be 
eliminated by cooling from the isotropic phase with an appropriate rate176.  Also, effects of 
addition of polymers on the smectic order of ITZ have been reported, for three different 
classes of polymers177.  The polymer either disrupts the smectic order, resulting in a 
uniform isotropic mixture, or remains separated from the smectic domains177. The critical 
behavior of the mesophase transitions in ITZ, however, has not been studied.  There is also 
a general interest, to know how other pharmaceutical additives affect the mesophase 
transitions in ITZ.  
   
The goal of this work is therefore, to investigate the effect of glycerol, a small-molecule 
plasticizer72, on the phase transitions of itraconazole. In the pharmaceutical sciences, 
glycerol is of interest, because it is sometimes incorporated into amorphous formulations, 
to aid processing51. Meanwhile, in the liquid crystal literature, glycerol is a typical protic 
solvent, used to supply mobility to amphiphilic molecules, in lyotropic LC systems178,179.  
Furthermore, when thermotropic mesogens were functionalized with glycerol (propane-
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2,3-diol attachments to the mesogen’s aromatic core), novel thermotropic mesophases were 
obtained180.  Thus, glycerol has the potential to induce unusual effects in the mesomorphic 
sequence of ITZ.  We have investigated the thermal behavior in itraconazole, with the 
glycerol concentration ranging from 1 to 40% w/w.  DSC studies were conducted with the 
goal of generating the phase diagram. We have also performed a detailed analysis of the 
critical behavior of the N-SmA transition of ITZ and investigated the effect of glycerol on 
the order of the mesophase transitions, using adiabatic scanning calorimetry.  
 
4.3 EXPERIMENTAL METHODS 
4.3.1 Materials 
Itraconazole (Bepharm Limited, Shanghai, China; purity ~98%) and glycerol (Sigma 
Aldrich, USA, purity ≥99.5%) were used as received.  All other reagents and chemicals 
were of analytical grade and purchased from Sigma Aldrich. 
 
4.3.2 Sample preparation 
Amorphous itraconazole (glass without smectic order) was prepared by melting the 
crystalline drug at 180 °C and rapidly cooling by dipping the melt in liquid nitrogen. To 
prepare ITZ-glycerol mixtures, crystalline ITZ was dissolved in dichloromethane at 50 °C 
with sonication, glycerol was dissolved in methanol and the two solutions were mixed.  
The solvent was rapidly evaporated at 50 °C under reduced pressure, in a rotary evaporator 
(IKA-HB10 digital system, Werke GmbH and Co. Germany) at 250 rpm, and lightly 
ground using a mortar and pestle, to obtain a free-flowing powder.  The powder samples 
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were further dried at room temperature under vacuum for 24 hours, to remove any residual 
solvent, and kept in desiccators containing anhydrous calcium sulfate at -20 °C, until 
further use. 
 
4.3.3 Differential scanning calorimetry (DSC) 
A differential scanning calorimeter (Q2000, TA Instruments, New Castle, DE) equipped 
with a refrigerated cooling accessory unit was used. The instrument was calibrated 
(temperature, heat capacity and enthalpy) with tin, indium, and sapphire.  An accurately 
weighed sample was hermetically sealed in an aluminum pan (T-zero®, TA instruments) 
and subjected to a modulated temperature program, under dry nitrogen gas purge (50 
mL/min).  The temperature modulation used was ±0.212 °C every 40 s, with an underlying 
heating rate of 2 °C/min. 
   
The sample was heated from room temperature (~20 °C) to 180 °C, held for ~1 minute to 
ensure complete melting, cooled back to room temperature and reheated to the melting 
temperature. Both the heating and cooling rates were 2 °C/min. 
 
DSC data analysis was performed with Universal Analysis® software (TA Instruments). 
In the text, glass transition temperatures (𝑇𝑔) are reported as the midpoint of the baseline 
shift (step-change) in the reversing heat flow signals.  Phase transition temperatures are 
evaluated from the peak positions of the endothermic or exothermic reversing heat flow 
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signals. Enthalpy change values are the peak areas of the reversing heat flow endo or 
exotherms. 
 
4.3.4 Adiabatic scanning calorimetry (ASC) 
High-resolution enthalpy and heat capacity data were obtained with a novel Peltier-
element-based implementation of the adiabatic scanning calorimetry concept (pASC).  The 
modes of operation are described in detail elsewhere181,182. An accurately weighed sample 
(~50 mg) was placed in a 120 µl stainless steel medium-pressure DSC crucible (Mettler-
Toledo GmbH, Switzerland).  The sample was heated from room temperature to ~190 °C, 
held for ~1 minute to ensure complete melting, and rapidly cooled back to room 
temperature.  The resulting glass was again reheated rapidly to ~60 °C, after which a very 
slow average scan rate (on the order of 50 mK/min; details in the text) was imposed while 
the ASC data were collected in the 60-100 °C region.  This sequence was necessary (i) to 
ensure the samples did not crystallize during the run, and (ii) to ensure a standardized 
thermal history for the samples. 
 
4.4 BRIEF THEORY OF ADIABATIC SCANNING CALORIMETRY 
Adiabatic scanning calorimetry measures with high resolution, the heat capacity and 
enthalpy near critical points in soft matter systems (e.g. liquid mixtures and liquid 
crystals)167,183. A constant, known heating or cooling power is applied to the sample cell 
(differently from imposing a constant rate, as done in DSC-type calorimeters) with an 
adiabatic shield that follows the temperature evolution of the sample cell. During a run, the 
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sample temperature 𝑇(𝑡) is recorded as a function of time 𝑡, and the heat capacity  𝐶𝑝(𝑇) 
as a function of temperature is calculated via the ratio of the known constant power 𝑃 and 







This leads to a continuous heat capacity curve. The heat capacity of the addenda  𝐶𝑎𝑑𝑑(𝑇), 
obtained in a separate calibration experiment, is subtracted from 𝐶𝑝(𝑇) in order to obtain 
the heat capacity of the bare sample.  The result is divided by the sample mass to arrive at 
the specific heat capacity of the sample. The same 𝑇(𝑡) data and the known constant power 
𝑃 directly result in the continuous enthalpy curve 𝐻(𝑇), since 
 𝐻(𝑇) − 𝐻(𝑇0) = ∫ 𝑃𝑑𝑡
𝑡(𝑇)
𝑡0
= 𝑃(𝑡 − 𝑡0), 
(4.2) 
where 𝐻(𝑇0) is the enthalpy of the system at the starting time 𝑡0 of the experiment.  The 
constant power results in the simple solution of the integral. The enthalpy of the sample is 
obtained after subtraction of the enthalpy of the addenda obtained from the calibration 
experiment. Further division by the sample mass results in the specific enthalpy.  
 
In an ASC run, the power 𝑃 is kept constant in equation (4.1) and the resulting changing 
rate ?̇? is measured.  This is exactly the opposite of what is done in DSC; in DSC, a 
predetermined constant rate (usually large for resolution reasons) is applied, and the 
changing power P(t) is measured (differentially).  Also, in ASC, at a transition, the rate 
reduces almost effectively to zero, which ensures thermal and thermodynamic equilibrium.  
In DSC however, it becomes more and more challenging to deliver (at the right 
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temperature) the strongly increasing power needed to maintain the imposed temperature 
rate. This results in rounding off and overshooting phenomena. 
 
An essential requirement of high-resolution ASC operating in a (slow) heating mode is the 
equality (mK or better) of the temperatures of the adiabatic shield and of the sample holder 
in very weak thermal contact with this adiabatic shield. The temperature of the adiabatic 
shield is maintained at the temperature of the sample holder by means of a proportional-
integrating feedback loop that controls electrical heating of the shield.  In cooling mode, a 
constant (preset) temperature difference between sample and shield must be maintained 
within the same stability limits. To achieve this, highly sensitive thermistors (placed on the 
sample holder and shield), requiring careful and extensive calibrations, have been used in 
the past. However, differences in the temperature coefficients of the thermistors, made 
measurements over large temperature ranges very complicated.  In the recent Peltier-
element-based implementation, pASC, these problems are completely eliminated181,182. 
This is achieved by inserting a highly sensitive semi-conductor-material-based Peltier 
element, to detect (and next nullify) the temperature difference between sample and shield.  
 
4.5 RESULTS AND DISCUSSION 
4.5.1 General information on itraconazole 
Itraconazole (ITZ) is a crystalline powder, that melts at 168 °C175,177.  When cooled from 
the melt, the isotropic (I) liquid transforms, first to a nematic (N) phase, and then to a 
smectic A (SmA) phase, before vitrifying.  The LC transitions are reversible upon 
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reheating.  The isotropic melt is light yellow and transparent. However, a visible color-
change (white, opaque) occurs at the I-N transition temperature, which is retained upon 
vitrification.  Phase assignments based on differential scanning calorimetry and X-ray 
diffractometry, have been reported in the literature175,177,184,185.  
 
4.5.2 Effect of glycerol on the mesophase transitions  
Glycerol was incorporated into itraconazole, via the solvent evaporation technique, 
commonly used to make amorphous solid dispersions. Homogeneous itraconazole-glycerol 
mixtures were prepared up to a glycerol content of 40% w/w, beyond which the material 
became sticky and visibly phase-separated. The binary mixtures with glycerol content 
<30% w/w were free-flowing powders.  
 
To systematically characterize the phase transitions, under a “standardized” thermal 
history, each solvent-evaporated formulation was first melted in situ, in the DSC pan, 
cooled to room temperature at ~2 °C/min, and reheated at the same rate.  Representative 
reheating scans of select compositions are shown in Figure 4.1, with the corresponding 
transition temperatures and enthalpies listed in Table 4.1. A phase diagram constructed 
based on the DSC results, is presented in Figure 4.2.   
 
The mesophase transition temperatures for neat itraconazole, are pointed out in the topmost 
scan of Figure 4.1a.  The glass (𝑇𝑔), nematic-to-smectic A (𝑇𝑁−𝑆𝑚𝐴), and isotropic-to-
nematic (𝑇𝐼−𝑁) transitions, occur at ~ 59, 74 and 90 °C respectively.  These transition 
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temperature and enthalpy change values (Table 4.1, 0% glycerol) are in agreement with 
the literature values175,184,185.   
 
As the glycerol content increases from 0 to 2% w/w, the temperature of the nematic-to-
smectic A transition (𝑇𝑁−𝑆𝑚𝐴 ≈74 °C, for neat itraconazole) does not change appreciably, 
indicating that the smectic state is not destabilized by the additive.  The isotropic-to-
nematic transition temperature (𝑇𝐼−𝑁 ≈90 °C, in neat itraconazole) however, systematically 
shifts to lower values. At glycerol concentrations ≥ 5% w/w, the nematic phase completely 
disappears, indicating a direct isotropic → smectic A (I-SmA) transition.  The I-SmA 
transition is also temperature-invariant, with increasing glycerol concentration (Figure 
4.1b; Table 4.1, 5-40% glycerol). 
 
The enthalpy changes of the mesophase transitions are also affected by the additive.  As 
the glycerol content increases from 0% to 2% w/w, the enthalpy change of the nematic-to-
smectic transition (∆𝐻𝑁−𝑆𝑚𝐴) increases, whilst that of the nematic-to-isotropic transition 
(∆𝐻𝐼−𝑁) decreases (Table 4.1).  The I-SmA transition endotherms (observed in 
compositions with ≥ 5% w/w glycerol), are however noticeably pronounced. Of note, the 
∆𝐻𝐼−𝑆𝑚𝐴 at any composition, is much higher, than the sum of ∆𝐻𝐼−𝑁 and ∆𝐻𝑁−𝑆𝑚𝐴 
(observed at glycerol concentrations ≤ 2% w/w).  
 
Generally, condensation from the isotropic to the nematic phase (I-N) requires calamitic 
molecules to reorient with their molecular axes approximately parallel to the nematic 
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director.  This typically manifests as a larger change in enthalpy, than transition from the 
nematic to the smectic A phase (N-SmA), which only requires longitudinal displacement 
of the molecules to form layers (in fact only weak density modulations along the 
director)20,33. Direct transition from the isotropic to the smectic A phase (I-SmA), on the 
other hand, typically goes along with a pronounced enthalpy change33,39. This is because, 
in order to complete the I-SmA transition, a significant increase in orientational as well as 
translational order must occur almost simultaneously.  
 
Often, when a mesogenic material possesses intermediate phases, the individual enthalpy 
changes of the low-ordered phases sum up to the total enthalpy change for the higher 
ordered phase39. Thus, the enthalpy change of the I-N and N-SmA phases are expected to 
sum up to the total enthalpy change of the I-SmA transition.  However, as shown in Table 
4.1, the ∆𝐻𝐼−𝑆𝑚𝐴 values are substantially higher. This unusual finding indicates that the 
ITZ molecules become exceptionally well-ordered, with 5-10% glycerol being the most 
favorable composition.  
 
 
4.5.3 Effect of glycerol on the glass transition temperature 
The glass transition temperature (𝑇𝑔) decreases only slightly, as the glycerol content 
increases (Figure 4.1; Figure 4.2; Table 4.1).  Glycerol, due to its low 𝑇𝑔 (~ -83 °C), is 
usually a potent plasticizer of amorphous pharmaceuticals.  To assess the extent of 
plasticization, the experimentally determined 𝑇𝑔 values, are compared with the values 
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predicted by the Gordon-Taylor (GT) additivity rule for binary mixtures64,74,186,187 







The subscripts 1 and 2 represent the components itraconazole and glycerol respectively, 








where 𝜌1 and 𝜌2 are the densities of itraconazole (1.4 g/cm
3) and glycerol (1.26 g/cm3) 
respectively. 
 
The GT relation assumes perfect volume additivity at 𝑇𝑔 and no interactions between the 
two components187.  As shown in Figure 4.3, a consistent positive deviation from the trend 
predicted by the GT equation, is observed for mixtures, indicating a reduction in the net 









Figure 4.1. DSC heating curves of itraconazole-glycerol binary mixtures of different 
compositions. The glycerol content (w/w) is given above each curve.  (a) 0 to 5% glycerol, 
and (b) 10 to 40% glycerol.  Each sample was heated from room temperature (~20 °C) to 
180 °C, held for 1 minute, and cooled back to room temperature.  The sample was then 
reheated to 180 °C. Both the heating and cooling rates were 2 °C/min. Only the final 
heating curves over the temperature range of interest, are shown.  
 
 
























































Figure 4.2.  Phase diagram generated from the DSC results (Figure 4.1;Table 4.1).  Solid 




Figure 4.3. Experimental glass transition temperatures (𝑇𝑔) of itraconazole-glycerol binary 
mixtures, compared with the values predicted using the Gordon-Taylor equation. 
  
















































Table 4.1. Transition temperatures (𝑇, °C) and associated enthalpies (∆𝐻, J/g) determined 
from the reversible heat flow signals of modulated DSC reheating scans (at 2 °C/min). 
Each value is an average of three replicate runs with standard deviations in parentheses. 

















𝑇, °C ∆𝐻, 
J/g 
𝑇, °C ∆𝐻, 
J/g 



































-- -- 55.6 
(0.8) 
0.980 











































4.5.4 The order of the transitions 
In the context of this investigation, three types of phase transitions are relevant: the 
isotropic-nematic (I-N), the nematic-smectic A (N-SmA) and the isotropic-smectic A (I-
SmA).  For purely geometrical reasons (regarding molecular orientation), the I-N transition 
must be first-order (with the possible exception at a single critical point induced by an 
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external parameter)37. On the same grounds (because orientational order is also present in 
the SmA phase), the I-SmA transition should be first-order.  
 
There are no obvious reasons, however, for the N-SmA transition to be first- or second-
order. Extensive calorimetric investigations of the N-SmA transition have been carried 
out33. It has been found that the temperature range of the nematic phase (i.e. the temperature 
width between the I-N and N-SmA transitions) plays an important role. Compounds with 
narrow nematic ranges are more likely to exhibit first-order N-SmA transitions, while 
second-order transitions are encountered for compounds with wide nematic ranges31,36–38.  
This behavior is often qualitatively characterized by the McMillan phenomenological 
parameter,  𝑟 = 𝑇𝑆𝑚𝐴−𝑁/𝑇𝑁−𝐼 (ratio of absolute temperatures)
31.  According to McMillan’s 
model the N-SmA transition is first-order for 𝑟 > 0.87, but second-order for values below 
0.87. Experimentally, first-order transitions have only been observed for McMillan ratios 
close to 1, typically above 0.9533,41. From the variation in McMillan parameter and 
differences in total transition enthalpies (𝛥𝐻 in Table 4.1), there is some indication for 
differences in the order of the transition for the itraconazole samples having different 
glycerol contents.  Therefore, in the following sections, we analyze Adiabatic Scanning 
Calorimetry (ASC) data to establish the nature of the N-SmA transition of the itraconazole 




4.5.5 ASC results for neat itraconazole 
Figure 4.4a shows an overview of the temperature dependence of the specific heat capacity 
𝐶𝑝 and the specific enthalpy 𝐻 from well below the smectic A (SmA) to well into the 
isotropic (I) phase. For the sake of clear contrast, a large, linearly temperature-dependent 
enthalpy background has been subtracted from the measured enthalpy values.  Indeed, for 
a constant heat capacity, the enthalpy increase is linearly dependent on temperature. 
Subtracting such (often irrelevant) contribution allows a more detailed study of fine phase 
transition effects.  Furthermore, a careful inspection of the enthalpy and heat capacity, as 
well as higher order derivatives, allows the temperature width of the (impurity induced) 
two-phase region to be located, and the true latent heats to be separated from (often 
substantial) pretransitional effects. This treatment was applied to all the samples, and the 
transition temperatures and latent heats are summarized in Table 4.2.  The transition 
temperatures and total enthalpy changes (𝛥𝐻) measured by adiabatic scanning calorimetry, 
for all the samples (Table 4.2) are in agreement with the corresponding values obtained 
via DSC (Table 4.1). 
 
We first describe the N-SmA transition for neat itraconazole.  In Figure 4.4b, the 
temperature scale of the 𝐻(𝑇) data is expanded (within 2 °C temperature range), to show 
the detailed behavior very close to the N-SmA transition.  A linear change in enthalpy with 
an almost constant effective heat capacity (constant slope) can be identified between the 
two dashed vertical lines, over a temperature interval of 0.15 ± 0.03 °C.  This allows a 
small but finite latent heat of 0.095 ± 0.010 J/g, to be identified, indicating that the N-SmA 
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transition is weakly first-order.  Similar analyses of the 𝐻(𝑇) data were performed around 
the isotropic-to-nematic (I-N) transition. A larger latent heat of 0.27 ± 0.02 J/g can be 
separated from the total enthalpy change (see Table 4.2), confirming a stronger first-order 
nature, for the I-N transition.  It is clear (from the profiles in Figure 4.4), that for both 
transitions (N-SmA and I-N), there are large pretransitional contributions to the total 







Figure 4.4. (a) ASC data for neat itraconazole, covering the N-SmA and the I-N transitions.  
The upper panel displays the specific heat capacity and the bottom panel the specific 
enthalpy as a function of temperature.  Dashed lines are the mesophase transition 
temperatures. A linear temperature-dependent background, 2.3(𝑇 − 𝑇𝑟𝑒𝑓), with 𝑇𝑟𝑒𝑓 an 
arbitrary reference temperature, has been subtracted from the direct enthalpy results. (b) A 
blow-up of the small square in the bottom panel of Figure 4.4a.  The vertical dashed lines 













































Table 4.2.  Adiabatic scanning calorimetry results for itraconazole with different glycerol 
contents. The transition temperature (𝑇, °C), total enthalpy change over the transition (𝛥𝐻, 
J/g), and true latent heat (𝛥𝐻𝐿, J/g) are measured during a heating run with constant power, 
resulting in slow average scanning rate, on the order of 50 mK/min for full measuring 
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4.5.6 ASC results for the ITZ-glycerol mixtures 
Figure 4.5a (similar to Figure 4.4) gives an overview of the temperature dependence of 
the specific heat capacity 𝐶𝑝 and the specific enthalpy 𝐻 from well below the smectic A 
(SmA) to well in the isotropic phase, for the ITZ + 2% glycerol mixture.  Compared to neat 
ITZ, the I-N transition occurs at a lower temperature (80.4 °C), whilst the N-SmA transition 
temperature (72.7 °C) remains almost unaffected, resulting in a much narrower nematic 
range (i.e. 𝑇𝐼−𝑁 – 𝑇𝑁−𝑆𝑚𝐴  = 7.7 °C).  Both transitions are clearly first-order, with 
substantial (true) latent heats (see Table 4.2; 2% glycerol). Additionally, some 
pretransitional specific heat capacity increases and minor supercooling are observed.   
 
When the glycerol content is increased to 5% w/w, however, only one strongly first-order 
transition, with substantial total enthalpy increase and a large true latent heat over a wide 
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two-phase region, is observed (see Figure 4.5b and Table 4.2). The I-SmA transition also 
shows some pretransitional heat capacity increase in the SmA phase. 
 
(a) ITZ + 2% Glycerol (b) ITZ + 5% Glycerol 
  
Figure 4.5.  ASC results for ITZ-glycerol mixtures from the smectic A to the isotropic 
phase. The upper panel shows the specific heat capacity and the bottom panel the specific 
enthalpy as a function of temperature. For the sake of clarity, a linear temperature-
dependent background has been subtracted from the direct enthalpy results. (a) ITZ + 2% 
w/w glycerol; background 2.7(𝑇 − 𝑇𝑟𝑒𝑓). (b) ITZ + 5% w/w glycerol; background 2.2(𝑇 −


































































4.5.7 Critical exponent analysis of the N-SmA transition 
Second-order (continuous) phase transitions are characterized by large fluctuations, which, 
for a properly defined order-parameter, diverge in size to infinity. This size divergence can 
be described by a power law, with a characteristic critical exponent depending on the 
universality class of the phase transition189. The limiting behavior of the specific heat 
capacity at a second-order transition, can also be described by means of a power law of the 
form: 
 𝐶𝑝 = 𝐴|𝜏|
−𝛼 + 𝐵 (4.5) 
 
with 𝜏 =  (𝑇 – 𝑇𝑐)/𝑇𝑐. The parameter 𝐴 is the critical amplitude, 𝛼 is the critical exponent, 
𝑇𝑐  is the critical temperature (𝑇 and 𝑇𝑐 in kelvin) and 𝐵 is the background term. The 
different coefficients in equation (4.5) must be derived from (non-linear) least-squares 
fitting of experimental data. However, the fact that ASC scans result directly in an enthalpy 









which corresponds to the slope of the chord connecting 𝐻(𝑇) at 𝑇, with 𝐻𝑐  at 𝑇𝑐. It can 
easily be shown, that 𝐶 has a power law behavior of the form33,167: 
 
𝐶 =  
𝐴
1 − 𝛼





Both 𝐶𝑝 and 𝐶 have the same critical exponent, and either equation (4.5) or (4.7) can be 
used in fitting data to arrive at important values for the critical exponent 𝛼 and amplitude 
𝐴. However, by considering the difference (𝐶– 𝐶𝑝), above or below 𝑇𝑐, the (unimportant) 
background term drops out, resulting in:   
 






Taking the logarithm on both sides of equation (4.8) gives: 
 log(𝐶 − 𝐶𝑝) = log (
𝛼𝐴
1−𝛼
) − 𝛼 log|𝜏|                                                                                                                             (4.9) 
 
As a result, one obtains a straight line with a negative slope immediately giving the critical 
exponent 𝛼. 
 
In Figure 4.6, data for the two quantities 𝐶 and 𝐶𝑝 are given for the N-SmA transition of 
neat itraconazole. The corresponding logarithmic plot [see equation (4.9)] is given in 
Figure 4.7. From the detailed analysis of the enthalpy and heat capacity curves, and their 
higher derivatives, we arrived at a two-phase region of 150 ± 30 mK and a small latent heat 
of 0.095 ± 0.010 J/g. Since the power law description breaks down in the two-phase region, 
only data outside that region are used in Figure 4.6 and Figure 4.7.  From the limiting 
slope of the data (for log│τ│<-2.5) in Figure 4.7, a value for 𝛼 of 0.50 ± 0.05 can be 
estimated above and below the transition.  The deviations from the straight line observed 
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for log│τ│> -2.5, can be ascribed to higher order correction terms, relevant away from the 
transition, which have been neglected in equations (4.5) and (4.7).  
 
  
Figure 4.6.  Adiabatic scanning calorimetry results above and below the N-SmA transition 
of neat itraconazole. The lower (blue) curves are the specific heat capacity 𝐶𝑝 values, a 
blow up of the square in the top panel of Figure 4.4a.  The upper (orange) curves are results 
for the quantity 𝐶 defined in equation (4.6). 
 
 























Figure 4.7.  Adiabatic scanning calorimetry results for the N-SmA transition of neat 
itraconazole. Double logarithmic plot of the difference (𝐶 − 𝐶𝑝) expressed in J/gK, as a 
function of the reduced temperature difference │𝜏│. Red triangles are for 𝑇 < 𝑇𝑐 and green 
circles for 𝑇 > 𝑇𝑐. The average limiting slope of the black solid line, is consistent with 
𝛼=0.50 ± 0.05.  
 
Although the N-SmA transition in neat itraconazole is weakly first-order, the small value 
of the latent heat and the consistency of the obtained value of critical exponent 𝛼 with the 
tricritical value 𝛼 = 0.5, indicates the N-SmA transition is close to a tricritical point. 
 
For the mixture of itraconazole with 2% of glycerol, although a N-SmA transition (with a 
much smaller nematic range) is observed, a substantial true latent heat (0.61 ± 0.03 J/g), in 
addition to pretransitional contributions, is also present for this transition. Moreover, the 
transition is broadened over several tenths of a degree, not allowing a similar critical 
exponent analysis as for neat itraconazole. Nevertheless, the substantial latent heat, the 




















are fully consistent with the overall picture of the nature of the nematic-to-smectic A 
transitions. 
 
For the isotropic-to-nematic (I-N) transitions observed for neat itraconazole and 
itraconazole + 2% glycerol, as well as for the isotropic-to-smectic A (I-SmA) transition for 
itraconazole + 5% glycerol, sizeable true latent heats (with wide two-phase regions) and 
pretransitional contributions are observed (see Table 4.2). Unfortunately, the widths of the 
two-phase regions do not allow a reliable analysis of the pretransitional contributions.   
 
4.5.8 Implications of the critical behavior 
The critical exponent analysis and the extracted magnitudes of the latent heats confirm the 
general picture concerning the three transitions investigated.  The N-SmA transition in ITZ, 
being close to a tricritical point, is easily driven from a weakly first-order transition, to a 
(strongly) first-order transition, most likely due to a coupling of the concentration of 
glycerol to the nematic and smectic order parameters. The invariance of the resulting I-
SmA transition temperature to increasing glycerol concentration, the exceptionally large 
total enthalpy change, and the large latent heats of the I-SmA transition, all point to ITZ-
glycerol mixtures having highly ordered, rigid smectic layers.  Structural, molecular 
orientation, and molecular interaction studies from scattering and spectroscopy 
experiments, will be needed to provide additional insight into the smectic ordering process 
of the binary mixtures, and to arrive at the most likely packing arrangement.  This will be 





Glassy liquid crystals are versatile materials, with wide range of applications from displays, 
to organic electronics.  This study demonstrates that glycerol (and by extension, other 
similar small-molecule plasticizers, such as water or ethylene glycol) can be incorporated 
at very low concentrations to modulate the thermotropic phase sequence and to increase 
the stability of the smectic-A layers.  In the model compound studied, this wide range of 
tunability is linked to the fact that the N-SmA transition is close to a tricritical point.  A 
coupling of the concentration of glycerol to the smectic order parameter, drives the N-SmA 
transition from a weak to a strong first-order character. Beyond a critical additive 
concentration, the nematic phase can be eliminated. This relatively simple approach of 
incorporating a small molecule plasticizer via solvent evaporation, into a glassy 
thermotropic LC, presents an opportunity to systematically modulate phase behavior in 
smectic phases.  Since the smectic phase possesses a lower free energy level than the 
amorphous phase, pharmaceutical thermotropic LCs with stabilized smectic phases may be 
more resistant to crystallization, while offering adequate dissolution enhancement, when 
compared to the corresponding crystalline drug.  The stabilized smectic phase therefore 
presents an alternate formulation approach for improving the bioavailability of 





We have investigated the effects of glycerol, a small molecule dopant, on the phase 
behavior of the thermotropic liquid crystal, itraconazole.  A phase diagram was constructed 
from DSC heating curves, by varying the concentration of glycerol from 1 to 40% w/w.  
When cooled from the melt, the isotropic liquid of neat itraconazole transitions to the 
nematic (N) state, and then to the smectic A (SmA) state, before vitrifying.  
 
With increasing glycerol content, the I-N transition shifts to lower temperatures without 
substantial modification of the N-SmA transition temperature.  At glycerol contents ≥5% 
w/w, however, the nematic phase disappears, indicating a direct I-SmA transition. The I-
SmA transition enthalpy is significantly larger than the individual I-N and N-SmA 
transition enthalpies.   
 
We also performed heat capacity and enthalpy measurements around the phase transitions, 
with high resolution adiabatic scanning calorimetry.  The N-SmA transition in neat 
itraconazole shows the characteristics of a weakly first-order transition, with a small latent 
heat of 0.095 ± 0.010 J/g. From a detailed analysis of the critical pretransitional behavior, 
an effective heat capacity critical exponent of 0.50 ± 0.05 is obtained, in agreement with 
predictions of the Landau-de Gennes mean-field theory for tricritical behavior.  
 
As expected, the I-N transition in ITZ is found to be first-order with a larger latent heat.  
The transitions observed in the ITZ-glycerol binary mixtures, however, show stronger first-
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order character (when compared to those in neat ITZ), with sizeable true latent heats, and 
pre-transitional contributions.   
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5 Stabilization of the Smectic Phase of Itraconazole: 










Itraconazole (ITZ) is an antifungal compound with thermotropic liquid crystalline 
properties.  Upon cooling from the melt, neat itraconazole transitions from the isotropic 
liquid (I) to the nematic (N) and then to the smectic A (SmA) phase, before being vitrified. 
The objective of this study was to investigate the effects of low concentrations of glycerol, 
a small molecule additive, on the mesophase sequence and structural packing of ITZ. With 
increasing glycerol content, the temperature range of the nematic phase systematically 
decreased, with little destabilization of the N-SmA phase transition temperature. At 
glycerol contents ≥ 5% w/w, the nematic phase disappeared, and the ITZ-glycerol samples 
transitioned directly from the isotropic liquid to the smectic A state. The I-SmA transitions 
exhibited strong first-order character, marked by unusually large enthalpy change values. 
There was a rapid rise in smectic order as determined by variable temperature synchrotron 
X-ray diffractometry, a sharp discontinuity in lateral correlation lengths, and a hysteresis 
upon thermal cycling. The smectic order parameter, which characterizes the quality of 
smectic layering, was tunable within a considerable range, with near-perfect smectic layers 
formed for glycerol contents ≥ 5% w/w. Alpha relaxation times of unaligned samples, 
measured with dielectric spectroscopy, progressively increased with increasing glycerol 
content in the isotropic, but not in the smectic phase, indicating that glycerol did not 
accelerate mobility in the smectic phase. Interestingly, drug crystallization was not 
observed in the ITZ-glycerol samples for up to 2 years, at pharmaceutically relevant storage 
temperatures (25-45 °C). Further, the dissolution performance of the ITZ-glycerol sample 
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was better than that of neat amorphous itraconazole (lacking smectic order), but 
comparable to the performance of an amorphous solid dispersion. The results suggest that 
the stabilized smectic state, can offer the dual advantage of good physical stability with 
adequate dissolution and possibly bioavailability.  
 
Keywords: phase transition; itraconazole; dielectric spectroscopy; thermotropic liquid 





As the number of poorly water-soluble pharmaceutical compounds under development 
increases, formulation strategies that can enhance the apparent aqueous solubility of the 
drugs, with adequate physical stability, become increasingly important.  Attention has been 
given to amorphous solid dispersions, which are homogeneous, molecular-level drug-
polymer mixtures: the disordered (isotropic) state can result in apparent drug solubility, 
much higher than the solubility of the corresponding, fully ordered crystalline form8.  
Liquid crystals (LCs) are partially ordered materials, with properties intermediate between 
the properties of crystalline solids and isotropic liquids.  The intermediate mesomorphic 
states are thermodynamically stable at defined temperatures and pressures28, and can cause 
mechanical, structural, electrical and optical responses, useful in diverse fields such as 
organic electronics, thermal sensors and agriculture.29  The pharmaceutical benefits of this 
class of compounds have, however, not been adequately explored42.  
 
LCs can be divided into two broad classes based on their structure, composition and method 
of preparation as (i) thermotropic liquid crystals, whose mesophases are formed by heating 
the crystalline solid or cooling the isotropic melt, and (ii) lyotropic liquid crystals, formed 
when amphiphilic compounds are dissolved in protic solvents, under appropriate 
conditions of solvent concentration and temperature28.  The majority of pharmaceutical 
LCs form lyotropic phases, and, because of their ability to interact with phospholipids, 
typically find use as topical preparations22.  Thermotropic LC drugs are relatively less 
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common22,42.  Nonetheless, because they possess positional and/or orientational order, 
thermotropic LC drugs could be more stable physically, than the corresponding fully 
disordered amorphous forms.  Additionally, the higher Gibbs free energy of mesophases, 
compared with the crystalline solid, should in principle lead to higher apparent solubility 
of mesophases. From the drug-delivery viewpoint, thermotropic LCs can therefore provide 
a good balance of physical stability and increased bioavailability. 
 
Itraconazole (ITZ; Figure 5.1a), indicated in the treatment of fungal infections, is a 
thermotropic LC that forms nematic (N) and smectic-A (SmA) mesomorphic phases, upon 
cooling from the isotropic (I) melt175. In the nematic phase, the rod-like ITZ molecules 
align parallel to each other, with their long axes all pointing approximately in the same 
direction.  In the smectic phase, the molecules maintain the orientational order and are 
further organized into layers167.  Depending on the cooling rate from the melt, ITZ glasses 
of varying molecular order can be produced: with quench-cooling, smectic ordering can be 
arrested, resulting in nearly isotropic glasses, whilst slow cooling leads to glasses with 
organized smectic layers176,190.  The degree of smectic order can alternatively be varied 
with compression pressure191, and the depth of smectic layer spacings can be modulated 
based on substrate temperature during vapor deposition192.   
 
Apart from the different degrees of molecular order that can be induced by different 
preparation methods, some unexpected effects of water (a ubiquitous plasticizer) on the 
physical stability of itraconazole have been documented.  Su190 reported the appearance of 
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a sharp peak in the small angle region (𝑞 = 0.4 Å-1) of the X-ray diffraction pattern of 
itraconazole, upon storage at 40 °C/75% RH.  The peak persisted for up to two months, 
without subsequent drug recrystallization190.  Mugheirbi et al193 investigated further, and 
confirmed that the sharp low-angle peak, indicative of smectic ordering, developed with 
sorption of 2.5% w/w water (1:1 drug:water mole ratio).  The glass transition temperature 
(𝑇𝑔) of ITZ was, however, not substantially depressed with increasing water content
193.  
Our preliminary studies also revealed a similar effect with glycerol (Figure 5.1b) as 
additive24.  With up to 10% w/w glycerol content, drug crystallization was not observed in 
the ITZ-glycerol binary mixtures stored at 40 °C/0% RH, for more than two months, in 
agreement with Su’s observations.  Neat ITZ is known to be a slow-crystallizing, stable 
glass former194.  Nonetheless, since very low levels of plasticizers invariably cause rapid 
crystallization in many stable glass formers57,187,195, the physical stability of ITZ with such 
high plasticizer contents, is an unusual property, warranting detailed investigations of the 
underlying mechanisms.   
 
Because the low angle X-ray diffraction peak of ITZ denotes the layered structure of the 
smectic phase176,193,196, we hypothesized that additives with fast dynamics (such as water 
or glycerol), even at very low concentrations, accelerate the development of smectic order 
in amorphized ITZ.  The smectic phase, being at a higher free energy level than the fully 
ordered 3D crystalline state, would offer higher drug solubility and thereby better 
dissolution, than the crystalline form.  To test this hypothesis, we first investigated the 
phase behavior of ITZ-glycerol mixtures.  Glycerol offered one main advantage over water, 
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in that, having a lower vapor pressure and higher boiling point than water, the ITZ-glycerol 
systems could be easily melt-quenched and characterized, with precise control over the 
plasticizer content.  Furthermore, to aid processing, glycerol and other small-molecule 
plasticizers are included in amorphous formulations51.  The current investigations could 
therefore shed light on some of the mechanisms of additive-induced phase transitions that 
may be encountered in rod-like pharmaceutical compounds.  
 
The first part of our study was recently reported, where we determined the critical behavior 
of the N-SmA transition of ITZ, as well as the effect of glycerol on the order of the 
mesophase transitions, using high-resolution adiabatic scanning calorimetry (ASC)24.  
Here, to understand the mechanisms by which glycerol modulates the mesophase sequence, 
we have characterized the structural features and molecular mobility of the ITZ-glycerol 
binary mixtures with synchrotron X-ray diffractometry (s-XRD) and dielectric 
spectroscopy (DES), respectively.  Long-term stability studies in the glassy state, as well 





Figure 5.1.  Structures of the model compounds.   (a) Itraconazole; molecular length, ~30 
Å.  (b) Glycerol; ~6.4 Å.  Molecular lengths were determined from the most extended 




5.3 EXPERIMENTAL METHODS 
5.3.1 Materials 
Itraconazole (Bepharm Limited, Shanghai, China), glycerol (Sigma Aldrich, USA), and 
polyacrylic acid (PAA, 1800 g/mol, Sigma Aldrich, USA) were used as received.  All other 
reagents and chemicals were of analytical grade and purchased from Sigma Aldrich. 
 
5.3.2 Sample Preparation 
Amorphous itraconazole, considered to be without smectic order, was prepared by melting 
the crystalline drug at 180°C and quenching, by dipping the melt in liquid nitrogen. The 
ITZ-glycerol, and ITZ-PAA samples were prepared by solvent-evaporation, followed by 
melt-quenching.  Crystalline ITZ was dissolved in dichloromethane (at 50°C with 
sonication), glycerol or PAA was dissolved in methanol, and the two solutions were mixed.  
The solvent was rapidly evaporated under reduced pressure at 50°C, 250 rpm, in a rotary 
evaporator (IKA-HB10 digital system, Werke GmbH and Co. Germany). The resulting 
mass was ground in a mortar and pestle, to obtain a free-flowing powder.  The powder 
samples were further dried under vacuum and at room temperature for 24 hours, to remove 
residual solvent, and kept in desiccators containing anhydrous calcium sulfate at -20°C, 




5.3.3 Differential Scanning Calorimetry (DSC) 
A differential scanning calorimeter (Q2000, TA Instruments, New Castle, DE) equipped 
with a refrigerated cooling accessory unit was used. Temperature, heat capacity and 
enthalpy calibrations were performed with tin, indium, and sapphire respectively.  An 
accurately weighed sample (~15 mg) was hermetically sealed in an aluminum pan (T-
zero®, TA instruments) and subjected to a temperature program, under dry nitrogen gas 
purge (50 mL/min).  A heating rate of 2 °C/min was used with a temperature modulation 
of ±0.212 °C every 40 s. 
   
Each sample was heated from room temperature (~20 °C) to 180 °C, held for ~1 minute to 
ensure complete melting, and cooled back to room temperature.  The sample was then 
reheated to the melting temperature. Both the heating and cooling rates were 2 °C/min. 
 
DSC data analyses were performed with the Universal Analysis® software (TA 
Instruments). Glass transition temperatures (𝑇𝑔) are reported as the midpoint of the step-
change (baseline shift) in the reversing heat flow signal.  Phase transition temperatures 
were evaluated from the peak positions of the exothermic or endothermic reversing heat 





5.3.4 Variable Temperature Synchrotron X-ray diffractometry 
High resolution, rapid acquisition powder diffraction experiments were carried out at 
beamline 17-BM-B of the Advanced Photon Source, Argonne National Laboratory, IL, 
USA. A monochromatic X-ray beam (incident beam energy 27.3 keV; wavelength 0.45390 
Å; beam diameter 300 μm) was used in transmission mode, with a two-dimensional area 
detector (PaxScan 4343, Varex Imaging). The scattering wavevector (𝑞) scale was 
calibrated with LaB6 (SRM 660c; NIST) and silver behenate.   
 
An accurately weighed quantity of each sample (~10–30 mg, depending on density) was 
tightly packed and hermetically sealed in an aluminum pan generally used for DSC analysis 
(T-zero, TA Instruments®).  The pan was mounted vertically on a custom-made polyether 
ether ketone (PEEK) holder, at a sample-to-detector distance of 1200 mm. The path length 
of the X-ray beam through the sample in the pan was 3 mm.  Temperature was controlled 
with a stream of nitrogen gas (Cryostream 800 plus®, Oxford Cryosystems, with precision 
better than 0.1 K) pointed to the top of the aluminum pan. A fine-wire thermocouple was 
placed in direct contact with the bottom of the sample pan to record the actual sample 
temperature, via a temperature input device (USB-TC01, National Instruments).  The 
accuracy of the temperature readings was verified by monitoring the crystal-to-melt 
transition temperatures (𝑇𝑚, indicated by the disappearance of all characteristic XRD 
peaks) of crystalline ibuprofen (𝑇𝑚~76°C) and crystalline itraconazole (𝑇𝑚~168°C) in the 
same sample configuration.  A nominal ramp rate of 2° C/min set on the Cryostream 
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corresponded to an actual steady-state rate of 1.67 °C/min measured by the thermocouple 
attached to the sample pan.  
 
Two-dimensional (2D) diffraction images were recorded in 30 second intervals. Ten 
frames were summed up to make up each scan, with an exposure time of 1 second per scan.   
The 2D raw images were azimuthally integrated to obtain one-dimensional scattering 
intensity (𝐼) versus scattering wavevector (𝑞 = 4𝜋𝑠𝑖𝑛 𝜃/𝜆;  𝜃 is the angle of incidence and 
𝜆 is the wavelength) plots, using the GSAS II software197. Unless otherwise stated in the 
text, each low-angle liquid crystalline peak (at 𝑞 ≈ 0.2, 0.4 and 0.6 Å-1) from the 1D 
patterns, was fitted with a single Pseudo-Voigt (the sum of a Gaussian and Lorentzian peak, 
weighted by a fourth parameter) function on a linear background, using Jade® software 
(Materials Data Inc, CA), to obtain peak areas, full width at half maximum (𝑓𝑤ℎ𝑚) values, 
and layer spacings (𝑑 = 2𝜋/𝑞).  Wide angle peaks (discussed in the text) were 
deconvoluted by fitting two pseudo-Voigt profiles, each centered at 𝑞 ≈ (1.3 and 1.6) Å-1, 
respectively.  The skew of the two sub-peaks was unified, whilst the peak positions, widths, 
𝑓𝑤ℎ𝑚, and heights were left as free parameters.  Diffraction patterns of the empty DSC 
pan and silver behenate packed in the DSC pan, were used for background correction and 
beam intensity normalization, respectively. 
 
5.3.5 Dielectric Spectroscopy 
Approximately 50 mg of each sample was placed on a gold-plated stainless-steel electrode 
(20 mm diameter) and heated on a hotplate until complete melting was achieved.  The melt 
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was spread evenly as a thin film, separated with three 50 µm glass fiber spacers, covered 
with a second electrode, and rapidly quenched on a cold metal block (pre-cooled at -20°C).  
 
Measurements at ambient pressure were performed with a broadband dielectric 
spectrometer (Alpha-AK high performance frequency analyzer, Novocontrol 
Technologies, Germany), which uses a Quatro system liquid nitrogen cryostat to maintain 
the sample temperature with stability better than 0.1 K. The complex dielectric permittivity 
( ∗), consisting of real ( ′) and imaginary (ε”) components, was measured at multiple fixed 
temperatures within the frequency (𝑓) range of 10-2 to 106 Hz.  Dielectric spectra obtained 
in the supercooled region (at 𝑇 > 𝑇𝑔) were analyzed with the Havriliak-Negami (HN) 
function198 (equation (5.1)) with an additional term describing the dc conductivity (𝜎):  









In the HN function, 𝜏𝐻𝑁 is the characteristic relaxation time, 𝛼𝐻𝑁 and 𝛽𝐻𝑁 are the shape 
parameters accounting for symmetric and asymmetric broadening of the spectrum 
respectively, 𝜔 is the angular frequency (𝜔 = 2𝜋𝑓) and ∆  is the dielectric strength given 
by ∆ = 0 − ∞ where 0 is the low frequency limit (𝜔 → 0) of 
′(𝜔) and ∞ is the high 
frequency limit (𝜔 → ∞) of ′(𝜔).   
For neat itraconazole, the temperature dependence of 𝛼 relaxation times (𝜏𝛼) at 𝑇 > 𝑇𝑔 was 
modeled with the Vogel-Fulcher-Tamman (VFT) equation45: 








where 𝜏0, 𝑇0 and 𝐷 are fitting parameters: 𝜏0 is the relaxation time of the unrestricted 
material, 𝐷 is the strength parameter, an indicator of the kinetic fragility of the material, 
and 𝑇0 is the temperature of zero mobility (theoretical Kauzmann temperature). 
The temperature dependence of 𝜏𝛼 for samples with >2% glycerol content (details 
discussed in text), was fitted to the Arrhenius equation45: 






where 𝜏∞ is the pre-exponetial factor representing the high temperature limit of the 
relaxation rate, 𝐸𝑎  is the energy barrier (activation energy) for the relaxation process, and 
𝑘𝐵  is the Boltzmann constant.   
 
5.3.6 Infrared Spectroscopy 
Infra-red spectra of the dry powder samples were obtained with a spectrometer (Vertex 70, 
Bruker, Ettlingen, Germany; equipped with a globar mid-IR source) using an attenuated 
total reflectance (ATR) accessory (single reflection germanium crystal) and a DLaTGS 
detector.  For each measurement, 64 scans were acquired in the 4000–400 cm−1 range, with 
a 4 cm−1 resolution. 
 
5.3.7 Nuclear Magnetic Resonance Spectroscopy 
Solid-state NMR spectra were acquired at the Minnesota NMR Center with a Bruker 
spectrometer operating at a 1H Larmor frequency of 700 MHz and equipped with 3.2 mm 
MAS probe. All spectra were acquired at 25 °C using the Hartmann-Hahn cross 
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polarization (CP) experiment at 12 kHz MAS rate. The CP contact time was set to 3 ms, 
the recycle delay was set to 3 s, and 15N acquisition time was set to 10 ms with 100 kHz 
spectral width. During CP, 15N and 1H RF amplitudes were set to 35 and 59 kHz 
respectively. SPINAL decoupling was used during acquisition with 83.33 kHz 1H RF 
amplitude. A total of 15,000 to 35,000 scans were used for acquiring each sample. 
 
5.3.8 Powder Dissolution 
Dissolution tests were performed with a USP Apparatus II (Varian 705 DS, Agilent 
Technologies, Santa Clara, CA).  Each sample, containing 100 mg of drug (powdered and 
sifted through a 250 µm pore-size sieve) was dispersed in 250 mL of dissolution medium 
(0.1 N HCl) at 37 °C and stirred at a paddle speed of 100 rpm.  Aliquots (3 mL) were 
withdrawn at each time point, filtered (0.45 µm pore size, Whatman® GHP), and diluted 
appropriately with 0.1 N HCl.  The drug concentration in the filtrate was determined via 
UV spectroscopy (Cary 100 Bio, Agilent Technologies) at the wavelength of maximum 
absorption (~254 nm), using a calibration curve of crystalline itraconazole dissolved in 




5.4 RESULTS AND DISCUSSION 









Figure 5.2.  DSC curves obtained from the second heating of (a) Neat ITZ, (b) ITZ + 2% 
glycerol and (c) ITZ + 5% glycerol.  Mesophase transition temperatures are indicated by 
the dashed lines.  Each sample was cooled from the melt to -20 °C and reheated to 180 °C. 
Both the heating and cooling rates were 2 °C/min. Only the final heating curves over the 
temperature range of interest, are shown. Figure (d) shows the phase diagram, constructed 
from the mesophase transition temperatures.  Data replotted from reference24. 
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Figure 5.2a shows the DSC heating scan of neat itraconazole that has been cooled from 
the melt, and reheated. The isotropic (I), nematic (N), smectic (SmA) and vitrified smectic 
(V-Sm) phases have been labeled. The mesophase transition temperatures (indicated with 
dashed lines) and enthalpies (not given), agreed with the values reported in the 
literature175,177,184,185. The mesophase transitions are reversible. The transition names 
adopted in this text will therefore reflect mesophase sequences encountered upon cooling 
from the melt.   
 
Glycerol was incorporated into ITZ via solvent evaporation, followed by melt-quenching.  
Of note, the resulting free-flowing powders are thermotropic, not lyotropic, LC systems.  
With 2% glycerol content (Figure 5.2b), the isotropic to nematic (I-N) transition shifted to 
a lower temperature, even though the nematic to smectic A (N-SmA) transition temperature 
remained relatively unaffected, resulting in a much narrower nematic range.  With 5% 
glycerol, however, the nematic phase completely disappeared, resulting in a direct 
isotropic-to-smectic A (I-SmA) transition (Figure 5.2c).  Other ITZ-glycerol mixtures with 
higher glycerol contents (>5%) also exhibited the direct I-SmA transition, as shown in the 
phase diagram (Figure 5.2d). The glass transition temperature, also plotted on the phase 
diagram, was not substantially depressed (when compared to predictions from the free 




An extensive discussion of the thermal behavior of the ITZ-glycerol samples, has been 
presented earlier24, with two major conclusions.  First, the systematic decrease in the I-N 
transition temperature of ITZ (due to incorporation of glycerol), can be partly explained by 
the critical behavior of the N-SmA transition of neat ITZ. A heat capacity critical exponent 
of 0.5 was obtained by ASC, indicating that the N-SmA transition of neat ITZ is close to a 
tricritical point.  Thus, the impurity (i.e. glycerol) concentration, could be easily coupled 
to the order parameter of the mesogen (ITZ), driving the transition from a weak first-order 
N-SmA to a much stronger first-order I-SmA transition.  Second, since the enthalpy change 
of the I-SmA transition for the samples containing ≥5% w/w of glycerol is much larger 
than the sum of the enthalpy changes of the I-N and the N-SmA transitions of neat ITZ, it 
can be reasonably inferred that the resulting smectic structures for the ITZ-glycerol 
mixtures will be highly ordered, and consequently, very stable.  
 
5.4.2 Structural Analysis by Synchrotron X-Ray Diffractometry 
The structural features associated with the changes in the mesophase transitions were 
investigated in detail using high resolution synchrotron powder X-ray diffractometry.  The 
samples were unaligned, evidenced by the uniform rings in the 2D scattering images (see 
Figure S5.1).  
 
Neat itraconazole 
The one-dimensional (1D) pattern of neat itraconazole, quenched (with liquid nitrogen) 
from the melt, shows a major diffuse maximum at 𝑞 = 1.3 Å-1, commonly referred to as the 
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amorphous halo, as well as three minor diffuse maxima (small “humps”) equally spaced in 
the small angle region  (Figure 5.3a). The lack of Bragg peaks at small angles, confirms 
that neat itraconazole melted and rapidly quenched, lacks smectic order.  When slowly 
cooled from the melt, however, the diffraction pattern (Figure 5.3b), has two sharp Bragg 
peaks at 𝑞 = 0.21 and 0.42 Å-1, in addition to the wide-angle peak centered at 𝑞 ~ 1.34 Å-
1.  The appearance of the small angle Bragg peaks is classic evidence of a lamellar 
structure28.  The fundamental scattering peak (𝑞 = 0.21 Å-1) indicates a layer spacing (𝑑 =
2𝜋/𝑞) of ~30 Å.  The layer spacing agrees with the molecular length of itraconazole (~30 
Å), suggesting a smectic A structure. This result confirms earlier reports, that smectic 
ordering in itraconazole develops at slow cooling rates176,192.   
 
Itraconazole-Glycerol Samples 
The XRD patterns of the itraconazole-glycerol mixtures, however, have three sharp, well-
defined Bragg peaks at 𝑞 ≈ 0.21, 0.42 and 0.63 Å-1 (Figure 5.3c and d).  No other peaks in 
the 𝑞 < 0.1 Å-1 region were observed, when we investigated with a diffractometer having 
a wider 𝑞-range (data not shown).  The 𝑞 ≈ 0.6 Å-1 peak (absent in the neat ITZ samples) 
being equidistant to the first two, is likely an additional higher-order peak28.  The intensities 
of all the Bragg peaks increase significantly with increasing glycerol content.   
 
An important observation from the XRD patterns is that, while very slow cooling from the 
melt was required to induce the small angle LC peaks in neat itraconazole, all three LC 
peaks appeared in the glycerol-containing samples right after solvent evaporation, and 
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persisted upon melt-quenching. Intense low-angle peaks indicate well-ordered layers, with 
large coherence lengths, and a narrow distribution of directors28.   The sharpness of the 
peaks is related to the extent to which the smectic layer structure extends periodically over 
large distances28.  It is qualitatively very clear, therefore, that glycerol, in a concentration-
dependent manner, remarkably increases both the orientational and translational order of 
ITZ. Two key parameters that characterize the structure of smectic liquid crystals – the 
translational order parameter and the smectic layer spacings28 – will be discussed in the 
next section.    
 
Figure 5.3.  1D synchrotron powder diffraction patterns of unaligned samples, at ambient 
temperature (𝑇 ≈ 30 °C). (a) Neat itraconazole, rapidly cooled from the melt (melt-
quenched). (b) Neat itraconazole, slowly cooled from the melt. (c) ITZ + 1% glycerol. (d) 
ITZ + 2% glycerol. Each pattern has been offset on the vertical axis for clarity.   















(a) Neat ITZ, melt-quenched
(b) Neat ITZ, slow-cooled
(c) ITZ+1% Glycerol
(d) ITZ+2% Glycerol










5.4.2.1 Temperature variation of the small angle peaks (Evolution of smectic order) 
The translational order parameter Σ, introduced by McMillan30–32, is defined as the 
amplitude of a density wave that originates from the one-dimensional periodic layers, and 
may take values between 0 (for a system with no layer structure) and 1 (for a system with 
perfect layering, in the absence of thermal fluctuations).  From X-ray scattering 
experiments, Σ can be obtained by comparing the fundamental (001) smectic layer peak 
intensity observed at a certain temperature, 𝐼(𝑇), with the theoretical 001-peak intensity 





=  Σ2 
(5.4) 
 
Kapernaum and Giesselmann30, assuming a power-law dependence of Σ on reduced 
temperature, proposed a procedure to obtain 𝐼0 from the temperature-dependence of 𝐼.  








Equation (5.5) is fitted to the temperature-dependent experimental integrated peak 
intensities (peak areas), with three adjustable parameters – 𝐼0 defined above,  𝑇𝑐 the 
transition temperature in kelvin (or in the case of first-order transitions, the superheating 
limit of the smectic phase) and 𝛽, the order parameter exponent.  We applied this method 
to probe Σ, using synchrotron radiation. Diffraction patterns were acquired, without field 
alignment, as each sample was cooled (at ~ 2 °C/min) from the melt.  For selected 




Figure 5.4a shows the area of the 𝑞 ~ 0.2 Å−1 peak, as a function of temperature, for neat 
itraconazole.  As the sample was cooled from the melt, the peak appeared at ~75 °C, 
increased gradually until ~55 °C, and decreased from 55 °C to 30 °C.  The peak area stops 
increasing when the material falls out of equilibrium, as the smectic order becomes frozen 
in the glassy state.  The slight decrease in smectic order below 55 °C, may be due to tension 
caused by the larger thermal expansion of ITZ relative to the container176.  The rise in 
smectic order up to the temperature at which the maximum peak intensity occurred, was 
well-described by the empirical power-law expression (equation (5.5)).  The exponent of 
the fit (2𝛽=0.51) and the transition temperature (~76 °C) were in reasonable agreement 
with the literature values176,196.  The itraconazole sample with 1% glycerol content (Figure 
5.4b) also exhibited a similar behavior, with a steady rise in smectic order. The exponent 
of the power-law fit (2𝛽=0.45) was however lower than the exponent obtained for neat 
itraconazole, indicating that smectic order rises more rapidly in the ITZ+1% glycerol 
sample.  The heating curve retraced the cooling curve at the high temperature region, 








Figure 5.4.  Temperature dependence of the integrated intensity (peak area) of the 𝑞 ≈ 0.2 
Å−1 peak for (a) neat itraconazole, (b) ITZ + 1% glycerol.  The curves are fits of equation 
(5.5) to the high-temperature (>50 °C) data. Fit parameters are listed in Table 5.1.   
 
The samples with higher glycerol contents (from 2 to 20%) however, showed very rapid 
increases in the intensities of all the three low angle peaks (𝑞 =0.21, 0.42, and 0.63 Å−1), 
at the transition points.  Figure 5.5 is a representative example at 5% glycerol content. 
Additionally, a hysteresis (~3 °C gap) developed around the mesophase transition 
temperature upon thermal cycling, even though the heating and cooling curves perfectly 
overlapped at low temperatures (𝑇 < 65 °C).  The hysteresis was reproducible with 
multiple thermal cycles (data not shown) and therefore not due to macroscopic phase 
separation39,200.  The sharp discontinuity in peak intensities is a characteristic feature of 
strong first-order phase transitions30,34.  As shown earlier from the DSC curves, 
itraconazole containing 5% w/w glycerol (Figure 5.2c) transitions directly from the 
isotropic to the smectic A phase (I-SmA).  The I-SmA transition is expected to be a first-
order transition, based on the Landau-de Gennes theory and other molecular models35.  











































Indeed, from our earlier investigation, we obtained a latent heat of 4.8 ± 0.2 J/g, using 
adiabatic scanning calorimetry (ASC)24, in perfect agreement with the prevailing theories.  
A wide “impurity-induced” two-phase region was also identified with ASC24 which, 
together with the effect of minor supercooling, explains the hysteresis loop observed in the 
variable-temperature X-ray diffraction experiments200. To compare, a much smaller latent 
heat (0.095 ± 0.010 J/g) was measured for the N-SmA transition of neat itraconazole, 
indicating its weaker first-order nature and explaining the relatively gradual rise in smectic 
order.   The temperature variation of the area of the fundamental (001) peak, for all samples, 
upon cooling from the melt, are overlaid in Figure 5.6.  
 
Figure 5.5.  Temperature dependence of the integrated intensities (peak areas) of the three 
low angle Bragg peaks (𝑞 ≈ 0.2, 0.4, 0.6 Å-1) of the itraconazole sample containing 5% 
glycerol.   The red, black, and blue symbols are data points obtained upon cooling the 
isotropic melt; the violet, green and yellow symbols are data taken from the subsequent 
reheating cycle.  Data points are connected with solid lines, to assist in visualizing the 
trends. 
  
















q = 0.6 Å-1







Figure 5.6.  Integrated intensity (peak area, 𝐼) of the 𝑞 ≈ 0.2 Å−1 peak as a function of 
temperature during cooling, for neat ITZ (labelled as ITZ crystalline) and itraconazole 
formulations with different glycerol contents.  Solid lines are drawn to assist in visualizing 
the trends.   
 
The translational order parameter (Σ) values calculated from equation (5.4) are plotted in 
Figure 5.6b, as a function of reduced temperature.  Fitted curves for the samples with 
higher glycerol contents are presented in the supplementary information (Figure S5.3), and 
the corresponding fit parameters are given in Table 5.1.  The maximum order achieved for 
neat ITZ, and the sample containing 1% glycerol, were 0.47 and 0.52 respectively, both 
within the typical range of Σ values, for other smectic A materials30,201.  The samples 
containing ≥2% glycerol however had order parameters greater than 0.8, significantly 
higher than values reported for many compounds30,202. By simply varying the concentration 













ITZ + 1% Glycerol
ITZ + 2% Glycerol
ITZ + 5% Glycerol
ITZ + 10% Glycerol
ITZ + 20% Glycerol
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smectic layers formed at glycerol contents ≥5% w/w.  The high Σ values independently 
confirm that the smectic layers form spontaneously30,201,202.  More importantly, such high 
translational order parameter values, together with the large latent heat and enthalpy change 
values (obtained from ASC and DSC respectively) further indicate that the highly-ordered 





Figure 5.7.  (a) Translational order parameter Σ, calculated from equation (5.4), as a 
function of reduced temperature, for ITZ samples with different glycerol contents. Values 
of parameters returned from the fits, are listed in Table 5.1. (b) Maximum translational 
order parameter, Σ𝑚𝑎𝑥, as a function of glycerol content. Data points are connected to assist 
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Table 5.1.  Values of the parameters 𝐼0, 𝛽 and 𝑇𝑐 obtained from fits of equation (5.5) to the 
peak areas for the itraconazole samples with different glycerol contents. Errors of the fit 



























328-348 328 64 0.48 






331-346 331 87 0.51 






326-346 326 90 0.62 






323-339 323 122 0.85 








324-339 324 75 0.92 








327-339 327 94 0.92 
For all samples, 𝐼0, 𝛽 and 𝑇𝑐 were left as free (adjustable) parameters.  For the samples 
with ≥5% glycerol content, wide two-phase regions were observed, resulting in the first-
order transition temperature 𝑇0 being separated from 𝑇𝑐 by a few degrees. *Based on latent 
heats extracted from ASC24. **Temperature range of data that was fitted. *** Temperature 
at which the maximum peak area 𝐼𝑚𝑎𝑥, and thus the maximum smectic order, Σ𝑚𝑎𝑥, occurs. 
 
5.4.2.2 Temperature variation of the smectic layer spacings 
For all samples, (i.e. neat itraconazole, or itraconazole/glycerol binary mixtures), the layer 
spacings (𝑑 = 2𝜋/𝑞), and the corresponding full width at half maximum (𝑓𝑤ℎ𝑚) values 
for all three low angle peaks (𝑞 ≈ 0.2, 0.4, 0.6 Å−1) remained unchanged with increasing 
glycerol content; the peak positions did not vary with temperature, either.  The temperature 
invariance (or glycerol-concentration invariance) of the smectic layer spacing, gives two 
main indications.  First, the molecule director does not become tilted, with respect to the 
layer normal, as would have been the case if the smectic A phase were to switch to a 
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different smectic phase.  As an example, in the SmC phase, the layer spacing reduces due 
to the tilting of the molecules within the layers.  Second, glycerol does not exclusively 
occupy the tail ends of the ITZ molecules; the layers are thus not separated.  
 
5.4.2.3 The Wide Angle Peak 
The diffuse wide-angle peak (the “amorphous” halo) was at the same position (𝑞 ≈ 1.3 Å-
1), in neat itraconazole samples, having or lacking liquid crystalline order (Figure 5.3). 
Thus, the 1D diffraction patterns of the nematic phase are not easily distinguished from the 
patterns of the isotropic phase28.  It is also evident from Figure 5.3, that the wide-angle 
peak is not perfectly symmetrical.  Rather, apart from the main halo centered at 𝑞 ~ 1.3 Å-
1 (𝑑-spacing of ~4.8 Å) there is a “shoulder” that suggests a weaker second halo centered 
at about 𝑞 ~1.7 Å-1 (𝑑 ~ 3.7 Å).  An example of the wide-angle peak deconvolution is 
shown in Figure S5.2.  The origin of the wide-angle peaks have been the subject of earlier 
investigations196,203.  With pair distribution function analysis, it was shown that peaks in 
the 4-7 Å region, corresponded to second and higher atom-atom nearest neighbor 
distances196,203.  The sub-peak at 𝑞 ~ 1.3 Å-1 is therefore more likely related to the average 
side-to-side separation of the close-packed molecules (or the width, 𝑤0, of the itraconazole 
molecule, 𝑤0 = 2𝜋/𝑞)
28.  The peak is broad because the positional correlations extend 
over short distances28.  The positional correlation length, 𝜉, is inversely related to the width 
of the wide-angle peak (i.e., 𝜉 is related to the full width at half maximum, fwhm value; 




The wide-angle peaks of the ITZ-glycerol samples did not vary significantly (either in 
intensity or position) with increasing glycerol content, at room temperature. The 
implications of this observation will be discussed in subsequent sections.  
 
5.4.2.4 Temperature variation of the wide-angle peak 
The wide-angle peak (the “amorphous” halo) for each sample was deconvoluted into two 
sub-peaks, by fitting two pseudo-Voigt functions (see Figure S5.2 for a sample fit).  As 
we pointed out earlier, the sub-peak at 𝑞 ≈ 1.3 Å-1, is more likely related to the average 
side-to-side (lateral) separation of the close-packed ITZ molecules.  The lateral spacings 
(𝑑 =  2𝜋/𝑞) and the corresponding correlation lengths (𝜉 =  2𝜋/𝑓𝑤ℎ𝑚) for the different 
compositions, are plotted as a function of temperature, in Figure 5.8.   
 
Upon cooling from the melt, the average lateral separation of the molecules, for each 
sample (with or without glycerol), decreased from ~5.1 Å (at 140 °C) to ~4.6 Å (at 30 °C), 
as shown in Figure 5.8a.  The correlation lengths increased from ~11 Å in the isotropic 
phase, to ~19 Å in the smectic phase (Figure 5.8b).  Major differences were however 
observed at the mesophase transition temperatures.  For neat itraconazole, as well as 
itraconazole with 1% glycerol, there was a gradual change in the lateral spacing, as well as 
the correlation lengths, around the temperature of transition to the smectic phase. However, 
for the samples with glycerol content ≥ 2%, both parameters (𝑑 and 𝜉) changed abruptly at 
the mesophase transition temperatures.  The step change was more pronounced as the 
glycerol content increased.   The abrupt discontinuity in 𝑑 and 𝜉 at the transition point for 
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samples with higher glycerol contents, provides independent confirmation that the 
mesophase transitions become strongly first-order.  
 
Another observation that provides information on the structural packing arrangement is 
that, at 𝑇 < 50°C, the position of the main wide-angle peak (corresponding lateral spacing 
4.8 Å) remained the same for all samples, regardless of the glycerol content (see Figure 
5.8a; the 𝑑 values between 40 and 50 °C are all ~4.65 Å).  This indicates that glycerol did 
not disrupt the lateral separation of the close packed ITZ molecules. The positional 
correlation lengths, on the other hand, systematically increased with increasing glycerol 
content.  For example, in Figure 5.8b, at 40°C, the correlation length increased from ~17 
Å (neat ITZ) to ~20 Å (ITZ + 10% glycerol), in a glycerol concentration-dependent 
manner.  This shows that as the glycerol content increases, the smectic clusters become 








Figure 5.8.  Temperature dependence of the (a) average lateral separation (𝑑 =  2𝜋/𝑞) 
and (b) average bulk correlation length (𝑑 =  2𝜋/𝑓𝑤ℎ𝑚), of the wide-angle peak (sub 
peak at 𝑞~1.3 Å-1) of ITZ with different glycerol contents.  Data were obtained as each 
sample was cooled from the melt.   
 
5.4.3 Drug-plasticizer interactions 
The formation of a periodic smectic structure, is driven by interactions between the highly 
polarizable aromatic cores of mesogens (core-core interactions)30–32.  An additive that has 
a high affinity for the host molecule can, in principle, weaken the core-core interactions, 
thereby disrupting the smectic layers.  Itraconazole has electronegative atoms distributed 
along the rigid molecular core. With glycerol being a ubiquitous hydrogen bond donor, 
multiple avenues exist for establishment of itraconazole-glycerol hydrogen bonds in the 
lateral direction, with at least two possible consequences. On the one hand, glycerol, via 
weak H-bonding, could act as a molecular cross-link that “glues” the itraconazole 






















































































hand, strong ITZ-glycerol interactions could disrupt the core-core (ITZ-ITZ) hydrogen 
bonding interactions, leading to disruption of the smectic arrangement. We assessed the 
hydrogen bonding between itraconazole and glycerol using FTIR and NMR spectroscopy.  
 
Figure 5.9 shows the FTIR spectra of itraconazole with and without glycerol.  The sharp 
peak at 1700 cm-1 is attributed to the stretching vibration of the carbonyl group of 
itraconazole. Peaks at 1614 and 1451 cm-1 correspond to C-N and C=N stretching 
vibrations respectively, and peaks at 1230 and 1040 cm-1 are most likely from the C-O 
stretching vibrations.  When hydrogen-bonded to glycerol, the C=O, C=N, or C-O 
stretching peaks of itraconazole would be expected to broaden or to be down-shifted.  As 
shown in Figure 5.9, the addition of glycerol did not bring about any significant changes.  
N-H stretch vibrations, indicative of hydrogen bonding, are typically observed in the 3000-
3500 cm-1 region.  However, O-H stretching vibrations (from glycerol) which also occur 
in the same region, interfere with the weak N-H absorption band.  The possibility of N-H 
hydrogen bonding was thus investigated using 15N solid-state NMR.  As shown in Figure 
5.10, the NMR spectra of ITZ with and without glycerol are similar, suggesting the absence 
of hydrogen bonding between ITZ and glycerol.   
 
The NMR and FTIR data indicate that hydrogen bonding, if any, between ITZ and glycerol, 
will not be strong enough to disrupt the “core-core” (ITZ-ITZ) intermolecular attractive 
forces that stabilize the smectic layers in the lateral direction.  Thus, any glycerol molecules 
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wedged between the ITZ molecules laterally will more likely strengthen the link between 
the drug molecules, leading to more rigid smectic layers.   
 
Figure 5.9.  FTIR spectrum of neat ITZ, overlaid with spectra of ITZ-glycerol mixtures.   
Absorbance values of each spectrum have been normalized with the peak maximum at 




Figure 5.10.  Overlay of 15N solid-state NMR spectra.  Intensities for each spectrum are 
normalized to the maximum intensity value (~212 ppm).  An overlay of 13C spectra is 
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5.4.4 Molecular Mobility 
Dielectric spectroscopy provides a direct indication of molecular mobility through the 
measurement of relaxation times (𝜏).  In rod-like liquid crystals possessing large dipole 
moments, two main relaxation mechanisms are generally expected that can be related to 
reorientation about the long and short molecular axes45,204.  Molecular rotations about the 
long axes are faster, and result in a broad prominent loss peak, commonly referred to as the 
𝛼-relaxation peak.  The 𝛼-relaxation process, an effect of the cooperative motions of the 
molecules, is considered to be responsible for the glass transition.  The relaxation mode at 
the lower frequency (termed the 𝛼′-relaxation185 or the 𝛿-mode45,204) can be assigned to 
rotational fluctuations of the molecule about its short axis (end-over-end rotation).  Above 
the clearing temperature, the two processes may collapse into one broad loss peak. 
 
Figure 5.11(a-c) shows the dielectric loss curves as a function of frequency, measured at 
multiple temperatures above 𝑇𝑔.  The 𝛼-relaxation peak is observed within the frequency 
window.  The slow relaxation mode (the 𝛼′-peak), though prominent in neat ITZ, was 
absent in the ITZ-glycerol mixtures (data not shown).  Thus, only the faster motions, which 














Figure 5.11.  Panels a-c show the dielectric loss ( ″) vs frequency (𝑓) data, measured at 
multiple temperatures above the glass transition temperature, on unaligned samples. (a) 
Neat ITZ (b) ITZ + 2% glycerol, and (c) ITZ + 5% glycerol.   For clarity, the DC 
conductivity contribution has been subtracted. In panel d, the dielectric strength (∆ ) is 
plotted as a function of temperature, for the three samples. The data points are connected 
by lines, to assist in visualizing the trends.  The dashed vertical lines are mesophase 
transition temperatures observed by DSC, for each composition. 
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For each sample, the 𝛼-peak shifts to higher frequencies with increasing temperature, 
reflecting an increase in molecular mobility. It is also very clear in Figure 5.11a, that the 
maximum dielectric response, the 𝑚𝑎𝑥 value, changes abruptly at ~76 °C.  This 
temperature is within the vicinity of the smectic-nematic (SmA-N) phase transition of neat 
ITZ.  The 𝑚𝑎𝑥 gives an indication of the dielectric strength (∆ = 0 − ∞; terms defined 
in the experimental section). The temperature dependence of ∆  is thus shown in Figure 
5.11d.  The dielectric strength is generally considered an indicator of the total number of 
dipoles participating in the reorientation process.  It is clear from  Figure 5.11b and c, that 
in the smectic phase, the 𝑚𝑎𝑥 values for the samples containing glycerol, are substantially 
reduced, when compared to neat ITZ. The suppression of the dielectric strength in the ITZ-
glycerol samples, shows that molecular movements in the smectic phase are restricted by 
the presence of glycerol.  
 
Each dielectric loss spectrum was fitted with the Havriliak Negami function to obtain the 
characteristic relaxation time, 𝜏.  The temperature-dependence of the relaxation times, for 
each sample, are presented in Figure 5.12.  The behavior of neat itraconazole (black 
circles) is well described by the Vogel-Fulcher-Tamman (VFT) function, the fit parameters 
(𝜏0= 1.8×10
-11 s, 𝐸𝑎=0.08272 eV, 𝑇0=295.2 K) being in agreement with the literature 
values184,185,205.  The ITZ-glycerol mixtures however exhibited a different behavior.  For 
each composition, two linear trends in relaxation times with differing slopes can be 
identified, suggesting two separate activated processes.  The two activated processes can 
be attributed mainly to dipole reorientation in the smectic and the isotropic phases, since 
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from the DSC analysis, samples with >2%w/w glycerol lacked the nematic phase.  
Activation energies for the smectic phase are higher, indicating a greater barrier to dipole 
reorientation, a high degree of order, as well as an increase in local viscosity45.  The sharp 
discontinuity in 𝛼 relaxation times for samples with >2% w/w glycerol, is another clear 
indication of the strongly first-order character of the I/SmA transition, in agreement with 
the general observations from the X-ray diffraction and calorimetry data.   
 
Figure 5.12.  Temperature-dependence of α relaxation times for unaligned samples of 
itraconazole, containing different concentrations of glycerol.  The vertical line is the DSC 
𝑇𝑔 of neat ITZ.   
 
The effect of glycerol on the molecular mobility is evident from Figure 5.12.  At high 
temperatures (𝑇 > ~72 °C), with increasing glycerol content, there is a systematic decrease 
in 𝛼-relaxation times (increase in mobility).  The decrease in 𝛼-relaxation times in the 





























phase (at 𝑇 < 72 °C), however, the 𝛼-relaxation times for all samples overlap, indicating 
that the glycerol content does not appreciably influence molecular mobility.  As indicated 
earlier, for rod-like molecules, 𝜏𝛼 signifies rotation about the molecule’s long axes.  Thus, 
in the smectic phase, glycerol does not accelerate the rotational movements about the long 
molecular axis.   
 
5.4.5 Most probable molecular packing model 
To understand, at least qualitatively, the structural packing, we consider information from 
the molecular mobility, synchrotron x-ray diffraction and spectroscopy experiments, 
together.  Because the smectic layer spacing does not change with increasing glycerol 
content (indicated by the invariance of fundamental (001) X-ray diffraction peak position), 
it is unlikely that glycerol exclusively occupies the tail ends of the rod-like ITZ molecules. 
On the other hand, the average lateral spacing of the close-packed molecules (indicated by 
the wide-angle peak position) does not change significantly with increasing glycerol 
content either, indicating that glycerol does not separate the ITZ molecules laterally.  The 
invariance of the dielectric spectroscopy alpha relaxation times in the smectic temperature 
range as the glycerol content increases, show that glycerol does not lubricate the interstitial 
spaces of the ITZ molecules, but rather strengthens the ITZ-ITZ “core-core” interactions.  
The most likely scenario, therefore, is that glycerol – possibly via a mechanism similar to 
the hydrophobic effect – drives the formation of very long, highly-ordered, rigid smectic-
A clusters having near-perfect periodicity over several layers, similar to the well-known 




5.4.6 Effect of smectic layer stabilization on the crystallization tendency below 𝑻𝒈 
To evaluate their long-term physical stability, neat itraconazole, as well as the binary 
mixtures with 2% and 5% glycerol, melt-quenched and pulverized, were filled into DSC 
pans under dry conditions (0% RH), hermetically sealed, and stored at different 
temperatures below 𝑇𝑔 (25 to 45 °C).  Crystallization was monitored periodically with 
synchrotron radiation.   
 
The 1D X-ray pattern of freshly melt-quenched neat itraconazole did not have liquid 
crystalline Bragg peaks in the low-angle region (see Figure 5.3a).  However, with time, 
the peaks at 𝑞 ≈ 0.2 and 0.4 A-1 started to appear (see Figure S5.5 for a representative 
example at 45 °C).  The intensities and sharpness of the peaks increased with storage time, 
indicating a gradual increase in the degree of smectic order.  The positions of the two low 
angle peaks, however, did not change with time, indicating that the smectic A state 
persisted at all temperatures for the entire storage duration. Also, characteristic crystalline 
ITZ peaks did not develop when freshly melt-quenched neat amorphous ITZ was stored at 
different temperatures below 45 °C, for up to 2 years (Figure 5.13a).  Itraconazole is a 
stable glass former and has been classified as a slow crystallizer194.  The gradual molecular 
rearrangement from the isotropic, towards the smectic state, under isothermal storage 
conditions, strongly indicates, that the partially ordered smectic phase is a 
thermodynamically-stable, equilibrium state.  In the glassy region, it is likely that the 
198 
 
smectic phase represents a “local minimum” in the free energy landscape, when compared 
to the “global minimum” of the three-dimensional crystalline phase207,208.  
 
The sharp small-angle liquid crystalline peaks (𝑞 ≈ 0.2, 0.4 and 0.6 A-1) were present in the 
XRD patterns of the freshly prepared binary mixtures containing 2 and 5% w/w glycerol 
(see Figure 5.3d).  The positions and intensities of the low angle peaks did not change with 
time, under isothermal storage conditions (for a representative example, see Figure S5.6; 
ITZ + 5% glycerol, stored at 45 °C).  The samples with 2 and 5% w/w glycerol content, 
also did not crystallize when stored below 45 °C, for up to 2 years (Figure 5.13b).  The 
remarkable physical stability of the ITZ-glycerol samples is somewhat counterintuitive, 
since plasticizers, even at very low concentrations, reduce the glass transition temperature, 
and invariably accelerate crystallization in amorphous pharmaceuticals.  For example, 
ketoconazole is classified as a slow crystallizer just like itraconazole194.  However, when 
prepared with 2% glycerol, the KTZ-glycerol binary mixture crystallized rapidly within 2 
days, at 20 °C57 (the 𝑇𝑔 of KTZ decreased from 45 to 30°C).  The most likely explanation 
for the itraconazole situation is that, once the plasticizer accelerates the development of 
smectic order, the ITZ-glycerol mixtures become more resistant to crystallization because 









Figure 5.13.  Synchrotron XRD patterns obtained after each sample had been stored for 2 
years, at the different temperatures indicated.  (a) Neat amorphous ITZ, freshly melt-
quenched; the two LC peaks at 0.21 and 0.42 Å-1, that developed by 2 years, have been 
pointed out. Minor peaks between 1.5 and 2.0 Å-1 are from the aluminum pan. (b) ITZ+2% 
glycerol. 
 
5.4.7 Effect of smectic layer stabilization on dissolution performance 
Finally, to assess the potential impact of the stabilized smectic layers on drug release from 
a solid oral dosage form, in vitro powder dissolution tests were performed.  As earlier 
indicated, amorphous ITZ prepared by rapidly cooling the neat drug from the melt (i.e. 
melt-quenching), is considered to be free of smectic order.  On the other hand, the 
ITZ+10% glycerol sample, with a translational order parameter >0.9 at room temperature 
(see Figure 5.7b), has the drug molecules existing as highly-ordered smectic layers.  The 
dissolution behaviors of the two samples, were compared to that of an amorphous solid 
dispersion (ASD) of ITZ prepared with the polymer, polyacrylic acid (PAA).  The 










































ITZ+10% PAA ASD was also considered to be free of smectic order since there was no 
endotherm associated with the N-SmA transition, in the DSC scan of the ASD177.   
 
As shown in Figure 5.14, drug release from the ITZ+10% glycerol sample was rapid, with 
the supersaturation level, sustained for the entire duration of the experiment (4 h).  It is also 
clear, that the dissolution performance of the glycerol-containing sample is better than that 
of neat amorphous ITZ.  The smectic phase is the most solid-like mesophase of ITZ.  Thus, 
the substantially high content of smectic layers in the glycerol-containing sample should, 
in principle, confer a Gibb’s free energy level, lower than the energy level of the isotropic 
phase, but higher than the energy level of the crystalline phase. The rapid drug dissolution 
rate and sustained supersaturation of the glycerol-containing sample can therefore be 
attributed to the combined effects of the hydrophilic nature of glycerol and the high free 
energy of the smectic state.  More importantly, since the dissolution performance of the 
ITZ-glycerol sample is comparable to – or perhaps, marginally better than – the 
performance of the ASD containing an equal amount of a hydrophilic polymeric additive 
(Figure 5.14, ITZ+10% PAA ASD), the results strongly suggest that the stabilized smectic 





Figure 5.14.  In vitro dissolution profiles of powder samples in 0.1 N HCl, at 37 °C. (1) 
Itraconazole + 10% glycerol, possessing highly ordered smectic layers, Σ > 0.9. (2) 
Itraconazole + 10% polyacrylic acid amorphous solid dispersion, mostly free of smectic 
order, and (3) Neat amorphous itraconazole, melt-quenched, and mostly free of smectic 
order. The horizontal dashed line represents the solubility of crystalline itraconazole, 




It is well known that plasticizers generally accelerate molecular mobility and thereby 
crystallization (i.e. to the 3D crystalline structure) of amorphous compounds209. In this 
work, we have shown the unusual effect of glycerol, selectively accelerating the 
development of smectic order in thermotropic liquid crystal itraconazole, and consequently 
stabilizing the mesophase.  The highly ordered smectic arrangement may offer the two-
pronged advantage of good physical stability with increased dissolution performance.  As 
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more mesogenic APIs are identified, other additive-induced unusual phase sequences 
might be reported, with a clearer picture emerging about the pharmaceutical relevance of 
these partially ordered states.  It may very well turn out that plasticizers, at low 
concentrations, are stabilizers for a wide range of mesogenic APIs. 
 
5.6 CONCLUSIONS 
In our earlier work, we investigated the effects of glycerol on the phase behavior of 
itraconazole (ITZ), a thermotropic liquid crystal.  A phase diagram was constructed, based 
on differential scanning calorimetry transition temperatures.  Detailed investigations on the 
critical behavior (and the order) of the transitions were also performed with adiabatic 
scanning calorimetry24. With increasing glycerol content, the nematic temperature range of 
neat ITZ was systematically reduced, and eventually eliminated, resulting in direct I-SmA 
transition.  
 
In this report, we investigated the structural packing arrangement, molecular mobility, 
physical stability and dissolution performance of the ITZ-glycerol mixtures. Consistent 
with the observations from calorimetry, synchrotron X-ray diffraction experiments 
revealed that the ITZ-glycerol mixtures had exceptionally well-ordered smectic A layers. 
The smectic order parameter, which characterizes the quality of smectic layering, could be 
systematically varied from 0.47 (neat ITZ) to as high as 0.92 (ITZ+5% glycerol), without 
a change in the type of smectic arrangement (i.e. the smectic A state persisted).  Information 
from a range of complementary techniques (dielectric, infrared and NMR spectroscopy, as 
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well as synchrotron X-ray diffractometry) confirmed that the ITZ-glycerol binary mixtures 
formed rigid smectic clusters in the vitrified state, which were stable when the samples 
were stored, for up to 2 years, at pharmaceutically relevant temperatures.  The binary 
mixtures also achieved and sustained much higher drug concentration levels than the neat 
drug, when powder dissolution tests were performed.   
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5.8 SUPPORTING INFORMATION 
 
Figure S5.1.  Representative 2D synchrotron diffraction image of an ITZ + 5% glycerol 
sample, collected at ~30°C. The sample was unaligned, resulting in uniform diffraction 
rings.  The three inner rings are characteristic of the smectic layers. The diffuse ring, 
commonly referred to as the amorphous halo, indicates the lateral spacing of the close-








Figure S5.2.  Representative fit, showing the deconvolution of the diffuse wide-angle peak 
(𝑞 from 0.7 to 2.3 Å-1) of itraconazole containing glycerol (5% w/w), into two sub-peaks.  
The red curve is the experimental data profile.  The blue and green shaded areas are the 
sub-peaks.   The pink trace is the combined fitted profile, with the corresponding fitting 
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Figure S5.3.  Temperature dependence of the area of the 𝑞 ≈ 0.2 Å−1 peak for (a) ITZ+2% 
glycerol, (b) ITZ+5% glycerol, and (c) ITZ+10% glycerol.  The red curves are fits of 
equation (5.5) to the data in the high-temperature region (>50 °C).  The range of data 
included in the fitting is indicated by solid vertical lines.  𝑇𝑐 , indicated by the dashed 
vertical line, is separated by a few degrees from 𝑇0, the first-order transition temperature, 
which is a characteristic behavior of strong first-order transitions30. Fit parameters are 
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Figure S5.4.  Overlay of one-dimensional 13C NMR spectra for neat ITZ (blue) and ITZ + 
20% glycerol (red).  No significant differences are observed between the spectra.   
 
 
Figure S5.5  Synchrotron XRD patterns of neat amorphous itraconazole (rapidly quenched 
from the melt), held isothermally at 45 °C for various storage durations, 𝑡. The gradual 
development of smectic order, is indicated by the appearance and sharpening of the liquid 
crystalline peak at q=0.4 Å-1 (pointed out). The peak at q=0.2 Å-1 was not captured in its 
entirety. The bottom blue pattern is that of an empty pan, showing the pan peaks. 
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Figure S5.6  Synchrotron XRD patterns of ITZ+5% glycerol samples, held isothermally at 
45 °C for various storage durations, 𝑡. The characteristic LC peaks remain at their original 
positions, indicating that  smectic A state persists. The peak at q=0.2 Å-1 was not captured 
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6 CONCLUSIONS AND RECOMMENDATIONS FOR 
FUTURE RESEARCH  
 
In Chapter 2, we investigated the influence of drug–polymer interactions on the dissolution 
performance of amorphous solid dispersions, using ketoconazole (KTZ) and three 
polymers, PAA, PVP and PHEMA, as model compounds.  With three techniques – 
NOESY, DOSY, and ITC – we identified, confirmed and quantified KTZ–PAA 
interactions in the aqueous medium. The interaction was linked to an increased duration of 
supersaturation.  
 
This study can be extended to a wider variety of drug–polymer systems, in order to draw a 
more generalized conclusion.  Drug–polymer interactions have been characterized in the 
solid state in many model systems. For example, nifedipine interacts with PVP via strong 
hydrogen bonding, but not with PAA63.  Indomethacin (weakly acidic), also interacts with 
PVP, but not with PAA or poly(ethylene glycol)58,61.  In our preliminary studies, we 
determined the crystallization propensities of the nifedipine and indomethacin ASDs 
mentioned above, in aqueous buffers.  Consistent with our working hypothesis, the 
crystallization trends reported in the solid state, were also observed in aqueous media.  
Dissolution profiles of these and other systems can be determined, and the interactions 
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monitored using either analytical ultracentrifugation, or high-resolution NMR. The next 
step would be to assess the in vivo behavior of the ASDs. 
 
In Chapter 3, we explored the use of analytical ultracentrifugation (AUC) for 
characterizing drug–polymer interactions in aqueous solution.  We showed how 
differences in UV absorbance profiles of drugs and polymers can enable the sedimentation 
behavior of the drug to be monitored, within the polymer matrix.  The UV detection method 
was able to address the problem of poor signal sensitivity, generally encountered when the 
model drugs are dissolved in water.  Also, consistent with our expectations, shifts in 
sedimentation coefficient values (𝑠-values) of the drug–polymer mixtures were observed, 
indicative of interactions.  The major problem, however, was that the 𝑠-value shifts were 
not very strong, reflecting the weak nature of the interactions, and thereby limiting the 
utility of AUC in this regard.  We expect the AUC technique to be more suitable for 
characterizing drug–polymer interactions that are much stronger than the interactions 
probed in the current study.  This study can thus be repeated, with a focus on polymers 
designed to have substantial hydrophobic content which will very likely interact more 
strongly with the typical small molecule drugs, in water.  
 
When suitable drug–polymer pairs have been identified, it would be worthwhile comparing 
interactions probed by the AUC technique, to interactions probed by diffusion ordered 
spectroscopy (DOSY).  Both techniques measure diffusion coefficients, and it would be 
helpful to know the extent of agreement between the two techniques.  While the diffusion 
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data from AUC are easier to interpret, compared to the complex NMR peak assignments 
that are a prerequisite for DOSY analyses, NMR spectrometers are more readily 
available/accessible than analytical ultracentrifuges. 
 
In spite of the limitations in characterizing drug–polymer interactions, the AUC technique 
can be very useful for routine characterization of the hydrodynamic behavior of 
pharmaceutical polymers.  This was evident from the unique sedimentation profiles that 
were obtained for the different polymers.  The model-free physical parameters that can be 
obtained simultaneously from AUC analyses, are often important input parameters for 
mathematical models that describe the dissolution behavior of ASDs83,210,211.  Such 
parameters can be obtained in a single experiment, when viscosity and partial specific 
volume measurements are available. 
 
In Chapters 4 and 5, we investigated the mechanism by which glycerol modified the 
mesogenic properties of itraconazole (ITZ).  The temperature range of the nematic phase 
of ITZ systematically reduced, until a critical glycerol concentration, where the ITZ-
glycerol binary mixtures transitioned directly from the Isotropic liquid (I) to the smectic A 
(SmA) state.  The I-SmA transition was confirmed to be a strong first-order transition, in 
agreement with standard liquid crystalline (LC) theories and the ITZ-glycerol mixtures 




It will be useful to investigate if glycerol can similarly accelerate the development of 
smectic order in a wider variety of LCs (both pharmaceutical and non-pharmaceutical 
compounds).  Unusual phase sequences may be observed, which may result in other useful 
material properties.   Posaconazole, saperconazole, pramiconazole, and terconazole are 
structurally similar to itraconazole.  It has already been suggested that posaconazole does 
not have smectic phases, even though it does have nematic-like characteristics212.  
Saperconazole on the other hand does have the same mesomorphic sequence as 
itraconazole, albeit with different temperature ranges213.  It will be interesting to know if 
glycerol can induce smectic order in posaconazole, or stabilize the smectic phase of 
saperconazole.  
 
Apart from glycerol, other additives may similarly modulate the phase behavior of 
pharmaceutical LCs.  Preliminary experiments conducted using polyalcohols with different 
lengths of carbon chains – ethylene glycol (2C), erythritol (4C), xylitol (5C), and sorbitol 
(6C) – showed that the smectic state was similarly potentiated by these additives, even 
though the phase sequences were different.  The effect of the molecular length – and 
thereby the flexibility – of the additive on the LC phase transition sequences, as well as the 
translational and orientational order parameters, can be investigated using the protocols 
applied in this thesis.   
 
When additives are used to induce (and possibly isolate) intermediate LC phases, the 
physical stability and the dissolution of the LC phases can be less ambiguously 
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investigated.  This would strengthen the hypothesis that mesomorphic phases provide an 
alternative route for physical stability enhancement, with improved dissolution 
performance.   
 
Co-amorphous systems are emerging as an alternative way of delivering two or more BCS 
Class II active pharmaceutical ingredients (APIs).  When either of the APIs is mesogenic, 
attempts at co-amorphization could easily result in liquid crystalline host-guest effects.  
The effects of the other small-molecule drugs (having or lacking mesogenic properties), on 
thermotropic LCs can be investigated.  This will help formulation scientists understand 
how any unique packing arrangements that result from such binary mixtures+, affect the 
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